<SEC-DOCUMENT>0001047469-17-003056.txt : 20170428
<SEC-HEADER>0001047469-17-003056.hdr.sgml : 20170428
<ACCEPTANCE-DATETIME>20170428161130
ACCESSION NUMBER:		0001047469-17-003056
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170615
FILED AS OF DATE:		20170428
DATE AS OF CHANGE:		20170428
EFFECTIVENESS DATE:		20170428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-15006
		FILM NUMBER:		17795652

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2231947zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAE16401_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Celldex Therapeutics, Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration
statement number, or the Form or Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=923822,FOLIO='blank',FILE='DISK105:[17ZAE1.17ZAE16401]BA16401A.;5',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>Perryville III Building<BR>
53 Frontage Road, Suite&nbsp;220<BR>
Hampton, NJ 08827<BR>
NOTICE OF ANNUAL MEETING OF STOCKHOLDERS<BR>
To be held on June&nbsp;15, 2017  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>To the Stockholders of<BR>
Celldex Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>NOTICE IS HEREBY GIVEN</B></FONT><FONT SIZE=2> that the Annual Meeting of Stockholders of Celldex Therapeutics,&nbsp;Inc. (the "Company" or "we" or "us") will
be held at the Olde Mill Inn, 225 Route 202, Basking Ridge, New Jersey 07920, on June&nbsp;15, 2017 beginning at 9:00&nbsp;a.m. local time. At the meeting, stockholders will act on the following
matters to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> elect eight directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected
and qualified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the year ending
December&nbsp;31, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve, in accordance with the applicable rules of the NASDAQ Stock Market, the issuance of shares of our common stock in connection with
Milestone Payments that may become payable in the future to former securityholders of Kolltan Pharmaceuticals,&nbsp;Inc. under the terms of the Merger Agreement we entered into in November 2016; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve an amendment to our 2008 Stock Option and Incentive Plan to increase the shares reserved for issuance thereunder by 5,650,000 shares to
20,000,000 shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder by 200,000 shares to
400,000 shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive
Officers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> address any other matters that may properly come before the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only
stockholders of record at the close of business on April&nbsp;20, 2017 are entitled to receive notice of and to vote at the Annual Meeting or any postponement or adjournment
thereof. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important. Whether you plan to attend the meeting or not, you may vote your shares by marking, signing, dating and mailing the enclosed proxy card in the envelope provided.
If you attend the meeting and prefer to vote in person, you may do so even if you have already voted your shares. You may revoke your proxy in the manner described in the proxy statement at any time
before it has been voted at the meeting. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Avery W. Catlin<BR></FONT> <FONT SIZE=2><I>Chief Financial Officer and Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>May&nbsp;3,
2017<BR>
Hampton, NJ </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=7150,FOLIO='blank',FILE='DISK105:[17ZAE1.17ZAE16401]BE16401A.;4',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="page_dc16401_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  </B></FONT><FONT SIZE=2><B>Perryville III Building<BR>
53 Frontage Road, Suite&nbsp;220<BR>
Hampton, NJ 08827  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This proxy statement contains information related to the Annual Meeting of Stockholders to be held on June&nbsp;15, 2017 at 9:00&nbsp;a.m.
local time, at the Olde Mill Inn, 225 Route 202, Basking Ridge, New Jersey 07920, or at such other time and place to which the Annual Meeting may be adjourned or postponed. The enclosed proxy is
solicited by the Board of Directors of Celldex Therapeutics,&nbsp;Inc. The proxy materials relating to the Annual Meeting are being mailed to stockholders entitled to vote at the meeting on or about
May&nbsp;3, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Important Notice of Availability of Proxy Materials for the Annual Meeting of Stockholders to be held on June&nbsp;15, 2017.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Our proxy materials, including our Proxy Statement for the 2017 Annual Meeting, 2016 Annual Report to Stockholders (which contains our Annual Report on
Form&nbsp;10-K) and proxy card, are available on the Internet at www.proxyvote.com.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc16401_about_the_meeting"> </A>
<A NAME="toc_dc16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THE MEETING    <BR>    </B></FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why are we calling this Annual Meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are calling the Annual Meeting to seek the approval of our stockholders to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> elect eight directors to serve until the next Annual Meeting of Stockholders and until their respective successors shall have been duly elected
and qualified; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ratify the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm for the year ending
December&nbsp;31, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve, in accordance with the applicable rules of the NASDAQ Stock Market, the issuance of shares of our common stock in connection with
Milestone Payments that may become payable in the future to former securityholders of Kolltan Pharmaceuticals,&nbsp;Inc. under the terms of the Merger Agreement we entered into in November 2016; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve an amendment to our 2008 Stock Option and Incentive Plan to increase the shares reserved for issuance thereunder by 5,650,000 shares to
20,000,000 shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder by 200,000 shares to
400,000 shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this proxy statement; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> indicate, on an advisory basis, the preferred frequency of stockholder advisory votes on the compensation of the Company's Named Executive
Officers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> address any other matters that may properly come before the meeting. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=900077,FOLIO='1',FILE='DISK105:[17ZAE1.17ZAE16401]DC16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dc16401_1_2"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are the Board's recommendations?  </I></B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors recommends that you vote:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the election of each of the eight director nominees; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the ratification of the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent
registered public accounting firm for the year ending December&nbsp;31, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the approval, in accordance with the applicable rules of the NASDAQ Stock Market, of the
issuance of shares of our common stock in connection with Milestone Payments that may become payable in the future to former securityholders of Kolltan Pharmaceuticals,&nbsp;Inc. under the terms of
the Merger Agreement we entered into in November 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the approval of an amendment to our 2008 Stock Option and Incentive Plan to increase the
shares reserved for issuance thereunder by 5,650,000 shares to 20,000,000 shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> the approval of an amendment to our 2004 Employee Stock Purchase Plan to increase the
shares reserved for issuance thereunder by 200,000 shares to 400,000 shares; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> an advisory vote on the compensation of the Named Executive Officers as described in this
proxy statement; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B><I>FOR</I></B></FONT><FONT SIZE=2> an advisory vote on our executive compensation to be held on an annual frequency. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who is entitled to vote at the meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on the record date, April&nbsp;20, 2017, are entitled to receive notice of the Annual
Meeting and to vote the shares of common stock that they held on that date at the meeting, or any postponement or adjournment of the meeting. Holders of our common stock are entitled to one vote per
share on each matter to be voted upon. As of the record date, we had 125,104,714 outstanding shares of common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who can attend the meeting?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All stockholders as of the record date, or their duly appointed proxies, may attend the Annual Meeting. Please note that if you hold your shares
in "street name" (that is, through a broker or other nominee), you will need to bring a copy of your proxy card delivered to you by your broker or a legal proxy given to you by your broker and check
in at the registration desk at the meeting. For security reasons, you must comply with our pre-registration requirements, you must present a form of government issued photograph identification on the
day of the Annual Meeting, and you must arrive at least thirty minutes prior to the meeting in order to attend the Annual Meeting. If you are a stockholder of record and plan to attend the Annual
Meeting, please contact Kathy Reamer by email at kreamer@celldex.com or by phone at 908-200-7500 ext. 7508 to register to attend the Annual Meeting. If you hold shares through an intermediary, such as
a bank or broker, and you plan to attend, you must send a written request to attend either by regular mail or email, along with proof of
share ownership, such as a bank or brokerage firm account statement, confirming ownership to: Celldex Therapeutics,&nbsp;Inc., Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton,
NJ 08827, Attn:&nbsp;Kathy Reamer or kreamer@celldex.com. Attendance at the Annual Meeting will be limited to persons who pre-registered on or before June&nbsp;8, 2017, who present a form of
government-issued photograph identification on the day of the Annual Meeting and who arrive by 8:30&nbsp;a.m. local time. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What constitutes a quorum?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The presence at the Annual Meeting, in person or by proxy, of the holders of a majority of our common stock outstanding on the record date will
constitute a quorum for our meeting. Signed proxies </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=498002,FOLIO='2',FILE='DISK105:[17ZAE1.17ZAE16401]DC16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dc16401_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>received
but not voted and broker non-votes will be included in the calculation of the number of shares considered to be present at the meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How do I vote?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You can vote on matters that come before the Annual Meeting by completing, dating and signing the enclosed proxy card and returning it in the
enclosed postage-paid envelope. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
shares will be voted as you indicate on your proxy card. If you vote the enclosed proxy but you do not indicate your voting preferences, and with respect to any other matter that
properly comes before the meeting, the individuals named on the proxy card will vote your shares FOR the matters submitted at the meeting, or if no recommendation is given, in their own discretion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you are a stockholder of record, to submit your proxy by telephone or via the Internet, follow the instructions on the proxy card. If you hold your shares in street name, you may vote
by telephone or via the Internet as instructed by your broker, bank or other nominee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
you attend the Annual Meeting and prefer to vote in person, you may do so even if you have already voted your shares by proxy. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I vote and then change my mind?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may revoke your proxy at any time before it is exercised by:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> filing with the Secretary of the Company a notice of revocation; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> sending in another duly executed proxy bearing a later date; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> attending the meeting and casting your vote in person. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
latest vote will be the vote that is counted. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What is the difference between holding shares as a stockholder of record and as a beneficial owner?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Many of our stockholders hold their shares through a stockbroker, bank or other nominee rather than directly in their own name. As summarized
below, there are some distinctions between shares held of record and those owned beneficially. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder of Record  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered directly in your name with our transfer agent, Computershare Trust Company, N.A., you are considered, with respect
to those shares, the stockholder of record. As the stockholder of record, you have the right to grant your voting proxy directly to us or to vote in person at the Annual Meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Beneficial Owner  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in a stock brokerage account or by a bank or other nominee, you are considered the beneficial owner of shares held in
street name, and these proxy materials are being forwarded to you by your broker, bank or nominee which is considered, with respect to those shares, the stockholder of record. As the beneficial owner,
you have the right to direct your broker as to how to vote and are also invited to attend the Annual Meeting. However, because you are not the stockholder of record, you may not vote these shares in
person at the Annual Meeting unless you obtain a signed proxy from the record holder giving you the right to vote the shares. If you do not vote your shares or otherwise provide the stockholder of
record with voting instructions, your shares may constitute broker non-votes. The effect of broker non-votes is more specifically described in "What vote is required to approve each proposal?" below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=834220,FOLIO='3',FILE='DISK105:[17ZAE1.17ZAE16401]DC16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dc16401_1_4"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What are "broker non-votes"?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Broker non-votes occur when nominees, such as banks and brokers holding shares on behalf of beneficial owners, do not receive voting
instructions from the beneficial holders at least ten days before the meeting. If that happens, the nominees may vote those shares only on matters
deemed "routine", such as the ratification of auditors. Nominees cannot vote on non-routine matters unless they receive voting instructions from beneficial holders, resulting in so-called "broker
non-votes." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
election of directors (Proposal No.&nbsp;1), the approval, in accordance with the applicable rules of the NASDAQ Stock Market, of the issuance of shares of our common stock in
connection with Milestone Payments that may become payable in the future to former securityholders of Kolltan Pharmaceuticals,&nbsp;Inc. under the terms of the Merger Agreement we entered into in
November 2016 (Proposal No.&nbsp;3), the approval of an amendment to our 2008 Stock Option and Incentive Plan to increase the shares reserved for issuance thereunder by 5,650,000 shares to
20,000,000 shares (Proposal No.&nbsp;4), the approval of an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder by 200,000 shares to 400,000
shares (Proposal No.&nbsp;5), the advisory vote on the compensation of our Named Executive Officers (Proposal No.&nbsp;6) and the advisory vote on the frequency of stockholder advisory votes on
the compensation of our Named Executive Officers (Proposal No.&nbsp;7) are not considered to be "routine" matters, and brokers are not permitted to vote on those matters if the broker has not
received instructions from the beneficial owner. Accordingly, it is particularly important that beneficial owners instruct their brokers how they wish to vote their shares. The ratification of our
independent registered public accounting firm (Proposal No.&nbsp;2) is considered to be a "routine" matter, and hence your brokerage firm will be able to vote on Proposal No.&nbsp;2 even if it
does not receive instructions from you, so long as it holds your shares in its name. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What vote is required to approve each proposal?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of a majority of the outstanding shares entitled to vote must be present, in person or by proxy, at the Annual Meeting in order to have
the required quorum for the transaction of business. Pursuant to Delaware corporate law, abstentions and broker non-votes will be counted for the purpose of determining whether a quorum is present.
Abstentions and broker non-votes are not counted for the purpose of determining the number of votes cast and will therefore not have any effect with respect to any of the proposals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
that a quorum is present, the following votes will be required:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the election of directors (Proposal No.&nbsp;1), each nominee presented in Proposal 1 must be elected by a majority of the
votes cast in person or by proxy at the Annual Meeting. Nominees are elected by a majority vote for non-contested director elections. Because the number of nominees properly nominated for the Annual
Meeting is the same as the number of directors to be elected, the election of directors at this Annual Meeting is non-contested. If the number of votes "For" a nominee exceeds the number of votes
"Withheld" (among votes properly cast in person or by proxy), then the nominee will be elected. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the ratification of the appointment of PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm
(Proposal No.&nbsp;2), approval will require the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the Annual Meeting. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the approval, in accordance with the applicable rules of the NASDAQ Stock Market, of the issuance of shares of our common stock
in connection with Milestone Payments that may become payable in the future to former securityholders of Kolltan Pharmaceuticals,&nbsp;Inc. under the terms of the Merger Agreement we entered into in
November </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=6,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=63080,FOLIO='4',FILE='DISK105:[17ZAE1.17ZAE16401]DC16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dc16401_1_5"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>2016
(Proposal No.&nbsp;3), approval will require the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the Annual Meeting. </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the approval of an amendment to our 2008 Stock Option and Incentive Plan to increase the shares reserved for issuance
thereunder by 5,650,000 shares to 20,000,000 shares (Proposal No.&nbsp;4), approval will require the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at
the Annual Meeting. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the approval of an amendment to our 2004 Employee Stock Purchase Plan to increase the shares reserved for issuance thereunder
by 200,000 shares to 400,000 shares (Proposal No.&nbsp;5), approval will require the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the Annual
Meeting. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the advisory vote on the compensation of our Named Executive Officers as disclosed in this proxy statement (Proposal
No.&nbsp;6), approval will require the affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the Annual Meeting. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> With respect to the advisory vote on the frequency of stockholder advisory votes on the compensation of our Named Executive Officers (Proposal
No.&nbsp;7), the frequency receiving the highest number of votes cast in person or by proxy at the Annual Meeting will be considered the frequency preferred by our stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders
of the common stock will not have any dissenters' rights of appraisal in connection with any of the matters to be voted on at the meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Where can I find more information about the terms of the Kolltan Acquisition?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are including in this Proxy Statement a summary of the material terms of the Kolltan Acquisition because we believe an understanding of the
Kolltan Acquisition is necessary in order to make an informed voting decision with respect to the potential issuance of our securities in connection with Milestone Payments that may become due in the
future under the terms of the Merger Agreement we entered into in November 2016. We are not seeking stockholder approval or ratification of the Kolltan Acquisition because the transaction has been
consummated and the issuance of the consideration paid at closing did not require stockholder approval. There are no "dissenters" or "appraisal" rights available to our stockholders in connection with
Proposal 3. Your vote will determine whether we will have the ability to elect to pay any Milestone Payments that are earned in the future in common stock (or will instead be required to make all
Milestone Payments in cash). A summary of the terms of the Kolltan Acquisition is set forth below:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> We consummated the Kolltan Acquisition on November&nbsp;29, 2016 pursuant to an agreement and plan of merger, dated November&nbsp;1, 2016,
(the "Merger Agreement") by and among us, Kolltan, two wholly-owned subsidiaries of ours formed for the purpose of the acquisition, and Shareholder Representative Services&nbsp;LLC, solely in its
capacity as the Stockholders Representative. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The consideration paid at closing to the former securityholders of Kolltan consisted of 18,257,996 shares of our common stock (the "Closing
Merger Consideration"). In addition, we agreed to issue an aggregate of 437,901 shares of our common stock to certain officers of Kolltan in lieu of cash severance obligations. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> In addition, we will be required to pay to the former securityholders of Kolltan, if earned after the closing, Milestone Payments in an amount
of up to $172.5&nbsp;million in the aggregate, in the event of the successful completion of certain specified milestone events. The Merger Agreement provides that Milestone Payments may be made in
cash or in stock, at our option; provided, however we are required to maintain a certain percentage of the overall consideration paid in </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=7,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=361921,FOLIO='5',FILE='DISK105:[17ZAE1.17ZAE16401]DC16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dc16401_1_6"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>shares
of our common stock to satisfy certain tax requirements under the Merger Agreement and we will pay cash to any non-accredited former securityholders of Kolltan. For a description of the
milestone events, the respective Milestone Payment payable upon achievement thereof, and the manner in which the Milestone Payments are to be paid, see the chart and related discussion appearing in
Proposal 3 under the caption </FONT><FONT SIZE=2><I>"Mechanics of Milestone Payments."</I></FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
better understand Proposal 3 and the Kolltan Acquisition, you should carefully read this entire document and the other documents to which we refer. For a more detailed discussion of
the Kolltan Acquisition, please see the section entitled </FONT><FONT SIZE=2><I>"Proposal 3&#151;Approval, In Accordance With The Applicable Rules Of The NASDAQ Stock Market, Of The Issuance
Of Shares Of Our Common Stock In Connection With Milestone Payments That May Become Payable In The Future To Former Securityholders Of Kolltan Pharmaceuticals,&nbsp;Inc."</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why is stockholder approval necessary in order to pay Milestone Payments in stock?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the NASDAQ Global Market, and we are subject to the NASDAQ listing standards set forth in its Marketplace Rules.
Although we were not required to
obtain stockholder approval in connection with the issuance of the Closing Merger Consideration because the shares of our common stock issued at Closing constituted less than 20% of our outstanding
shares, we are required under Marketplace Rule&nbsp;5635(a) to seek stockholder approval for the issuance of shares of common stock in connection with the Milestone Payments as further described
below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ
Marketplace Rule&nbsp;5635(a) requires stockholder approval prior to the issuance of securities in connection with the acquisition of the stock or assets of another company,
including pursuant to an "earn-out" or similar provision, where due to the present or potential issuance of common stock (or securities convertible into or exercisable for common stock), other than a
public offering for cash, the common stock to be issued (a)&nbsp;constitutes voting power in excess of 20% of the outstanding voting power prior to the issuance or (b)&nbsp;is or will be in excess
of 20% of the outstanding common stock prior to the issuance. The Closing Merger Consideration that we have already issued to former Kolltan securityholders (including shares deposited for their
benefit into escrow) did not constitute more than 20% of our total shares of common stock outstanding, so we were not required to obtain stockholder approval for the issuance of these shares. The
Closing Merger Consideration constituted an amount of our common stock equivalent to approximately 18.5% of our outstanding common stock as of the November&nbsp;1, 2016 execution date of the Merger
Agreement. The issuance of additional shares of common stock to former Kolltan securityholders in connection with the Milestone Payments would be aggregated with the shares we issued as Closing Merger
Consideration for purposes of NASDAQ Marketplace Rule&nbsp;5635(a). Accordingly, issuing additional shares of common stock as Milestone Payments to the former Kolltan securityholders may result in
the aggregate number of shares issued by us in connection with the Kolltan Acquisition exceeding 20% of our total shares outstanding prior to the Kolltan Acquisition. Therefore, we are requesting
stockholder approval for Proposal 3 under this NASDAQ listing standard to ensure that we have stockholder approval to issue shares of common stock as Milestone Payments to the extent that any such
shares issued, when aggregated with shares previously issued in connection with the Kolltan Acquisition, exceed 20% of our common stock outstanding prior to the Kolltan Acquisition. To the extent a
Milestone is achieved and we elect to pay the corresponding Milestone Payment in shares of our common stock, the shares would be valued pursuant to a formula based on the then-market price of our
common stock, as described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Merger Agreement, we agreed to seek stockholder approval at our next stockholders meeting following the execution of the Merger Agreement for the possible issuance of
shares of our common stock pursuant to the Merger Agreement in excess of 19.99% of our outstanding shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=8,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1005589,FOLIO='6',FILE='DISK105:[17ZAE1.17ZAE16401]DC16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dc16401_1_7"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What will happen if stockholder approval is not obtained to issue shares of common stock in connection
with Milestone Payments?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we do not obtain stockholder approval to issue common stock in connection with Milestone Payments, pursuant to the Merger Agreement, we would
not be able to make Milestone Payments in shares of common stock to the extent Milestones are achieved resulting in stock payments aggregating to a 20% issuance in connection with the Kolltan
Acquisition. In the event we do not have stockholder authorization to pay the Milestone Payments in common stock, and we instead elected to make Milestone Payments in cash we expect we would have to
raise additional financing to pay such Milestone Payments in cash. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
in the event this proposal is not approved, we intend to solicit such approval at next year's annual meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What will happen if stockholder approval is obtained and we issue additional shares of common stock in
connection with Milestone Payments?  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If stockholder authorization is obtained to issue in connection with the Kolltan Acquisition common stock in excess of 20% of our outstanding
shares, and (i)&nbsp;assuming all $172.5&nbsp;million of Milestone Payments were to become payable and we elected to pay all such Milestone Payments in shares of our common stock, and
(ii)&nbsp;further assuming a market price of $3.30, based on the closing price of our common stock on April&nbsp;10, 2017, then, we would issue to the former securityholders of Kolltan (except
with respect to non-accredited former shareholders of Kolltan to whom we will pay cash) in connection with such Milestone Payments an aggregate of 52,272,727 shares of our common stock, or
approximately 42% of our outstanding shares as of April&nbsp;10, 2017. The actual number of shares that may become issuable as Milestone Payments will depend on multiple factors including the
Milestones that are actually achieved, the amount of the corresponding Milestone Payments that we elect to pay in shares of our common stock, and the market price of our common stock at the time that
we pay the corresponding Milestone Payment in shares of our common stock. For purposes of the Milestone Payments, our common stock will be valued based on the average closing price per share of our
common stock for the five trading day period ending three calendar days prior to the achievement of the relevant Milestone. While we believe that having the ability to pay Milestone Payments in shares
of common stock offers benefits to the Company and its stockholders, including conservation of cash, the payment of Milestone Payments in shares of common stock may cause substantial dilution to the
equity interest of our current stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How are we soliciting this proxy</I></B></FONT><FONT SIZE=2>? </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are soliciting this proxy on behalf of our Board of Directors by mail and will pay all expenses associated therewith. Some of our officers and other employees also
may, but without compensation other than their regular compensation, solicit proxies by further mailing or personal conversations, or by telephone, facsimile or other electronic means. In addition, we
have retained Georgeson&nbsp;LLC to assist in the solicitation of proxies and to provide related corporate governance services and informational support. We expect to pay Georgeson approximately
$35,000 for their services and reimburse them for their out-of-pocket costs. We will also, upon request, reimburse brokers and other persons holding stock in their names, or in the names of nominees,
for their reasonable out-of-pocket expenses for forwarding proxy materials to the beneficial owners of the capital stock and to obtain proxies. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=9,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=286739,FOLIO='7',FILE='DISK105:[17ZAE1.17ZAE16401]DC16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_de16401_1_8"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de16401_proposal_1__to_elect_eight_dir__pro05580"> </A>
<A NAME="toc_de16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 1: TO ELECT EIGHT DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING<BR>  AND UNTIL THEIR SUCCESSORS HAVE BEEN DULY<BR>  ELECTED AND QUALIFIED    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de16401_(proposal_no._1)"> </A>
<A NAME="toc_de16401_2"> </A></FONT> <FONT SIZE=2><B>  (Proposal No.&nbsp;1)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the Annual Meeting, eight directors are to be elected. All directors of the Company hold office until the next Annual Meeting of Stockholders
or until their respective successors are duly elected and qualified or their earlier resignation or removal. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It
is the intention of the persons named in the proxies for the holders of common stock to vote the proxies for the election of the nominees named below, unless otherwise specified in
any particular proxy. Our management does not contemplate that the nominees will become unavailable for any reason, but if that should occur before the meeting, proxies will be voted for another
nominee, or other nominees, to be selected by our Board of Directors. In accordance with our by-laws and Delaware law, a stockholder entitled to vote for the election of directors may withhold
authority to vote for certain nominees for directors or may withhold authority to vote for all nominees for directors. Each director
nominee must be elected by a majority of the votes cast in person or by proxy at the Annual Meeting. Nominees are elected by a majority vote for non-contested director elections. Because the number of
nominees properly nominated for the Annual Meeting is the same as the number of directors to be elected, the election of directors at this Annual Meeting is non-contested. Broker non-votes will not be
treated as a vote for or against any particular director nominee and will not affect the outcome of the election. Stockholders may not vote, or submit a proxy, for a greater number of nominees than
the eight nominees named below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominees for Election  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The persons listed below are our current directors and have been nominated for re-election or nominated for election at the Annual Meeting (the
"Director Nominees") to fill the eight director positions to be elected by the holders of the common stock. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Directors

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Year First<BR>
Became<BR>
Director </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Larry Ellberger (Chairman of the Board)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2003</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci (Chief Executive Officer)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith L. Brownlie</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>64</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Nominee</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>84</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2008</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James J. Marino</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gerald McMahon</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>71</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>63</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2001</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following biographical descriptions set forth certain information with respect to the Director Nominees, based on information furnished to Celldex by each Director Nominee. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Nominees  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Larry Ellberger</B></FONT><FONT SIZE=2> was appointed Chairman of the Board of Directors in September 2009 and has been
a director of Celldex since August 2003. Mr.&nbsp;Ellberger was formerly Chairman of the Board of Omrix BioPharmaceuticals,&nbsp;Inc. until its acquisition by Johnson&nbsp;&amp; Johnson in 2008.
From 2003 to July 2012, Mr.&nbsp;Ellberger was Founding Partner of HVA,&nbsp;Inc., a consulting firm specializing in business development, product acquisition and licensing, and mergers and
acquisitions for pharmaceutical, biotechnology, drug delivery and medical device companies. From October 2005 to May 2006, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=495742,FOLIO='8',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Ellberger
was Interim Chief Executive Officer of PDI,&nbsp;Inc., a provider of sales and marketing services to the biopharmaceutical industry. Previously, he was a member of the Board of
Directors of PDI and Chairman of the Audit Committee. From 2000 to 2003, Mr.&nbsp;Ellberger was Senior Vice President and a member of the Board of Directors of Powderject&nbsp;PLC, a U.K. vaccine
company. From 1995 to 1999, Mr.&nbsp;Ellberger held several senior executive positions at W.R. Grace&nbsp;&amp;&nbsp;Co. including Interim Chief Executive Officer, Chief Financial Officer and Senior
Vice President, Strategic Planning and Development. From 1975 to 1995, Mr.&nbsp;Ellberger held numerous senior executive positions at American Cyanamid Company, serving the last four years as Vice
President, Corporate Development. Mr.&nbsp;Ellberger currently serves on the Board of Directors and is a member of the Audit and Nominating Committees of NeuroDerm,&nbsp;Ltd., a NASDAQ-listed
Israeli biotech company. He is also a Director of The Jewish Children's Museum. Mr.&nbsp;Ellberger received a B.A. in Economics from Columbia College and a B.Sc. in Chemical Engineering from
Columbia School of Engineering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Anthony S. Marucci</B></FONT><FONT SIZE=2> was appointed as permanent President and Chief Executive Officer of Celldex in September 2008 and as a director of
Celldex in December 2008. Since May 2003, Mr.&nbsp;Marucci has held a number of roles with Celldex, including as a founder, Vice President, Chief Financial Officer, Treasurer and Secretary. In
addition, he was Treasurer of Medarex,&nbsp;Inc. (now a part of Bristol Myers Squibb&nbsp;Co.) from December 1998 to March 2004. Mr.&nbsp;Marucci held a series of senior financial positions at
Medarex from December 1998 to May 2003. Mr.&nbsp;Marucci is a member of the Board of Trustees of BioNJ&nbsp;Inc. and also served as its Treasurer through 2010. Mr.&nbsp;Marucci is a member of
the Board of the College of Business and Public Management at Kean University. Mr.&nbsp;Marucci received his M.B.A. from Columbia University and his Executive Master of Healthcare Leadership from
Brown University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Keith L. Brownlie</B></FONT><FONT SIZE=2> was nominated for election to our Board of Directors in March 2017. Mr.&nbsp;Brownlie was employed by the accounting
firm Ernst&nbsp;&amp; Young&nbsp;LLP from 1974 to 2010. At Ernst&nbsp;&amp; Young, he served as audit partner for numerous public companies and was the Life Sciences Industry Leader for the New York
Metro Area. Since his retirement from Ernst&nbsp;&amp; Young in 2010, Mr.&nbsp;Brownlie has served as a member of the board of directors and chairman of the audit committee of Soligenix,&nbsp;Inc.,
a
publicly-held biopharmaceutical company. Since 2012, Mr.&nbsp;Brownlie has served as a member of the board of directors and served as the chairman of the audit committee of
RXi&nbsp;Pharmaceuticals Corporation, a publicly-held biopharmaceutical company. From 2011 to 2013, Mr.&nbsp;Brownlie also served as a member of the board of directors and served as the chairman
of the audit committee of EpiCept Corporation, a publicly-held biopharmaceutical company. From 2013 to 2014, Mr.&nbsp;Brownlie was a member of the board of directors and served as the chairman of
the audit committee of Cancer Genetics,&nbsp;Inc., a publicly-held biopharmaceutical company. Mr.&nbsp;Brownlie received a B.S. in Accounting from Lehigh University and is a Certified Public
Accountant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Herbert J. Conrad</B></FONT><FONT SIZE=2> became a director of Celldex in March 2008 upon consummation of the AVANT Merger. Mr.&nbsp;Conrad had been a director
of Celldex Research since March 2004. Mr.&nbsp;Conrad was President of the U.S. Pharmaceuticals Division of Hoffmann-La Roche,&nbsp;Inc., a pharmaceutical company, from 1982 until his retirement
in 1993. Mr.&nbsp;Conrad currently serves as Chairman of the Board of Matinas BioPharma Holdings,&nbsp;Inc., a publicly-held biopharmaceutical company and a director of Arbutus Biopharma
Corporation, a publicly-held biopharmaceutical company. Mr.&nbsp;Conrad serves as an Advisor to the Seaver Autism Center at Mount Sinai Hospital. In addition to serving on the board of directors of
privately held biotechnology companies, Mr.&nbsp;Conrad has served as Chairman of the Board of Directors of Pharmasset,&nbsp;Inc., GenVec,&nbsp;Inc. and Bone Care International,&nbsp;Inc.
Mr.&nbsp;Conrad has also served as director of Savient Pharmaceuticals,&nbsp;Inc. and was a director and co-founder of Reliant Pharmaceuticals,&nbsp;Inc. He received B.S. and M.S. degrees from
the Brooklyn College of Pharmacy and an honorary Doctorate in Humane Letters from Long Island University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>James J. Marino</B></FONT><FONT SIZE=2> became a director of Celldex in March 2017. Mr.&nbsp;Marino has served as a member of the board of directors of Onconova
Therapeutics,&nbsp;Inc., a publicly-held biopharmaceutical company, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=111441,FOLIO='9',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2>since
July 2015. Prior to July 2015, Mr.&nbsp;Marino was a Partner at the global law firm of Dechert&nbsp;LLP for 28&nbsp;years, where he served as Managing Partner of the Princeton Office.
Previously, he served on the board of directors of Pharmacopeia&nbsp;Inc. and has worked in advisory capacities and on the boards of multiple non-profit organizations, including Robert Wood Johnson
University Hospital. He currently serves on the Board of Trustees of Wake Forest University and Wake Forest University Baptist Medical Center. Mr.&nbsp;Marino received his B.A., M.B.A., and J.D.
from Rutgers University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Gerald McMahon</B></FONT><FONT SIZE=2> became a director of Celldex in December 2016. Since December 2016, Dr.&nbsp;McMahon has been President and Chief
Executive Officer of Harpoon Therapeutics,&nbsp;Inc., a private biopharmaceutical company. Prior to Celldex's acquisition of Kolltan, Dr.&nbsp;McMahon served as President and Chief Executive
Officer and a member of the board of directors of Kolltan, a private biopharmaceutical company. Prior to joining Kolltan, Dr.&nbsp;McMahon served as Senior Vice President of Oncology at
MedImmune&nbsp;LLC, a wholly owned subsidiary of the healthcare company AstraZeneca AB, or AstraZeneca, from October 2010 to May 2012. From 2006 to 2008, Dr.&nbsp;McMahon served as the Chairman
and Chief Executive Officer of the pharmaceutical company NeoRx Corp. From 2008 to
2011, Dr.&nbsp;McMahon served as the Chairman and Chief Executive Officer of Poniard Pharmaceuticals,&nbsp;Inc. Previously, Dr.&nbsp;McMahon served as a business executive in the healthcare and
biotechnology industries at companies such as Pfizer&nbsp;Inc., Pharmacia Corporation, and Sandoz,&nbsp;Inc. Dr.&nbsp;McMahon also previously served as President of Sugen&nbsp;Inc., a
pharmaceutical company. Dr.&nbsp;McMahon holds a B.S. in biology and a Ph.D. in biochemistry from Rensselaer Polytechnic Institute. In addition, Dr.&nbsp;McMahon has served as a member of the
board of directors of Mateon Therapeutics,&nbsp;Inc., a publicly-held biopharmaceutical company, formerly known as OXiGENE,&nbsp;Inc. since September 2011. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Harry H. Penner, Jr.</B></FONT><FONT SIZE=2> has been a director of Celldex since January 1997 and was Chairman of AVANT prior to the consummation of the AVANT
Merger. Mr.&nbsp;Penner has served as Chairman and Chief Executive Officer of Nascent BioScience,&nbsp;LLC, a firm engaged in the creation and development of new biotechnology companies since
2001. From 1993 to 2001, Mr.&nbsp;Penner was President, Chief Executive Officer and Vice Chairman of Neurogen Corporation. From 1985 to 1993, Mr.&nbsp;Penner was an Executive Vice President of
Novo Nordisk A/S, serving from 1988 to 1993 as Executive Vice President for North America and President, Novo Nordisk of North America, and from 1985 to 1988 as the company's Executive Vice President
and General Counsel in Denmark. He has served as BioScience Advisor to the Governor and the State of Connecticut, as Co-Chairman of Connecticut United for Research Excellence, and as Chairman of the
Connecticut Board of Governors of Higher Education and the Connecticut Technology Council. In addition to having served on the board of directors of several public and privately held life science
companies, Mr.&nbsp;Penner is currently on the Board of Directors of Prevention Pharmaceuticals,&nbsp;Inc., Affinimark Technologies,&nbsp;Inc., Neurovail,&nbsp;Inc. and Aria
Neurosciences,&nbsp;Inc., all of which he is a founder. Mr.&nbsp;Penner received a B.A. from the University of Virginia, a J.D. from Fordham University, and an L.L.M. in International Law from New
York University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Karen L. Shoos</B></FONT><FONT SIZE=2> has been a director of Celldex since May 2001. Ms.&nbsp;Shoos is currently a consultant in AABB's Division of Global
Services. From May 2013 to September 2016, Ms.&nbsp;Shoos was Principal Investigator, AABB International Technical Assistance. From October 1994 to May 2013, Ms.&nbsp;Shoos was Chief Executive
Officer of AABB. AABB is a professional standards setting and accrediting organization in the fields of blood and cellular therapies. Prior to AABB, from 1984 to 1994, Ms.&nbsp;Shoos held senior
positions at the American Red Cross, including Acting Senior Vice President, Biomedical Services (1993-1994) and Secretary and General Counsel (1990-1993). Prior to the American Red Cross,
Ms.&nbsp;Shoos was a lawyer in private practice. Ms.&nbsp;Shoos earned her B.A. from Yale University and her J.D. from Case Western Reserve University. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=437608,FOLIO='10',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_11"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Family Relationships  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are no family relationships among our Director Nominees, management and other key personnel. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board of Directors and Its Committees  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board of Directors  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are currently managed by an eight member Board of Directors, a majority of whom are "independent" as that term is defined in the applicable
NASDAQ listing standards. Other than Mr.&nbsp;Marucci and Dr.&nbsp;McMahon, each of our directors is deemed "independent" as that term is defined in the applicable NASDAQ listing standards. Our
Board of Directors met nine times in 2016. Each of the directors attended at least 75% of the aggregate of (i)&nbsp;the total number of meetings of our Board of Directors (held during the period for
which such directors served on the Board of Directors) and (ii)&nbsp;the total number of meetings of all committees of our Board of Directors on which the Director served (during the periods for
which the director served on such committee or committees). Our annual meeting of stockholders is generally held to coincide with one of the Board's regularly scheduled meetings. We do not have a
formal policy requiring members of the Board of Directors to attend our annual meetings, although our directors typically attend the annual meeting. Each of the then current directors attended the
2016 Annual Meeting of Stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established an Audit Committee currently consisting of George O. Elston, Chair, Larry Ellberger and Harry H. Penner,
Jr. Mr.&nbsp;Elston's term as director will expire at the 2017 Annual Meeting. Following the 2017 Annual Meeting, Mr.&nbsp;Brownlie is expected to be
appointed to the Audit Committee. The Audit Committee makes recommendations concerning the engagement of independent public accountants, reviews with the independent public accountants the scope and
results of the audit engagement, approves professional services provided by the independent public accountants, reviews the independence of the independent public accountants, considers the range of
audit and non-audit fees, and reviews the adequacy of our internal accounting controls. Each member of the Audit Committee is "independent" as that term is defined in the rules of the SEC and the
applicable NASDAQ listing standards. The Board has determined that each Audit Committee member has sufficient knowledge in financial and auditing matters to serve on the Committee. The Board has
designated George O. Elston as an "audit committee financial expert," as defined under the applicable rules of the SEC and the applicable NASDAQ listing standards. The Audit Committee met six times
during 2016. Our Board has adopted an Audit Committee Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldex.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established a Compensation Committee currently consisting of James&nbsp;J. Marino, Chair, Herbert J. Conrad and
Harry H. Penner, Jr. The primary function of the Compensation Committee is to assist the Board in the establishment of compensation for the Chief Executive Officer, to approve the compensation of
other officers and senior employees and to approve certain other personnel and employee benefit matters. Each member of the Compensation Committee is "independent" as that term is defined in the rules
of the SEC and the applicable NASDAQ listing standards. In 2016, the Compensation Committee engaged Radford, an Aon Hewitt Company, to provide guidance on various aspects of the company's board and
executive compensation programs. The Compensation Committee has assessed the independence of Radford and concluded that no conflict of interests exists under applicable SEC rules. The Compensation
Committee met ten times during 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=862355,FOLIO='11',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_12"> </A>


<P style="font-family:times;"><FONT SIZE=2>Our
Board has adopted a Compensation Committee Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldex.com.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominating and Corporate Governance Committee  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors has established a Nominating and Corporate Governance Committee currently consisting of Karen L. Shoos, Chair, Herbert J.
Conrad and Larry Ellberger. The primary function of the Nominating and Corporate Governance Committee is to assist the Board in reviewing, investigating and addressing issues regarding Board
composition, policy and structure; membership on Board committees; and other matters regarding our governance. Each member of the Nominating and Corporate Governance Committee is "independent" as that
term is defined in the rules of the SEC and the applicable NASDAQ listing standards. The Nominating and Corporate Governance Committee met five times during 2016. Our Board has adopted a Nominating
and Corporate Governance Committee Charter, which is available for viewing at </FONT><FONT SIZE=2><I>www.celldex.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director selection criteria  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Nominating and Corporate Governance Committee is responsible for reviewing, on an annual basis, the appropriate mix of professional
competencies, key attributes, skills and experiences required of board members to work together as a team to properly oversee our strategies and operations. The process followed by the Nominating and
Corporate Governance Committee to evaluate any candidates whether identified or recommended by board members, management, members of the Nominating and Corporate Governance Committee, stockholders or
other external sources, includes meetings from time to time to evaluate biographical information and background material relating to potential candidates to the Board and interviews of selected
candidates by members of the Committee and the Board. All nominees must have, at a minimum, high personal and professional integrity, exceptional ability and judgment, and be effective in collectively
serving the long-term interests of all stockholders, all as described above. Other qualifications that may be considered by the Committee are described in the Nominating and Corporate Governance
Committee Charter. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
board members are expected to possess certain key attributes necessary to creating a functional board: high personal and professional ethics, integrity and values; practical wisdom
and mature judgment; an inquisitive and objective perspective; professional experience at a policy-making level in business, government, education or medicine; time availability for in-person
participation at board and committee meetings; and a commitment to representing the long-term interests of our stockholders. We look for directors with professional competencies that include senior
management operational experience, accounting and finance capabilities, deep industry-related experience, biologic development and manufacturing expertise, business development leadership, medical and
scientific proficiencies, and government and public policy experience. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of our directors brings unique perspectives and experiences to the Board of Directors and contributes in guiding and directing our strategies to meet our business objectives and to
provide value to our stockholders. For example, Mr.&nbsp;Conrad, Mr.&nbsp;Ellberger, Mr.&nbsp;Marucci, Dr.&nbsp;McMahon, Mr.&nbsp;Penner and Ms.&nbsp;Shoos have all either currently or
formerly been chief executive officers of life sciences or healthcare-related companies and have experienced the challenges of such a position. Messrs.&nbsp;Ellberger and Marucci have formerly been
chief financial and chief corporate development officers at pharmaceutical and life sciences companies and have completed a significant number of financing and business development transactions.
Ms.&nbsp;Shoos has experience in the highly regulated blood supply and cellular therapies sectors, which are similar to our regulated biologics industry. Mr.&nbsp;Penner has been the chief legal
officer at a large public pharmaceutical company and for that company and for life sciences companies has completed a significant number of financing and business development transactions.
Mr.&nbsp;Marino, as partner at a large law firm, focused his practice on representing public and private life sciences companies and has extensive experience advising his clients in the full range
of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=14,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=296948,FOLIO='12',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2>corporate,
transactional, finance, compliance and governance matters. Mr.&nbsp;Brownlie, as partner at an international public accounting firm and leader of the firm's regional life sciences
industry practice, and as chairman of the audit committees of other publicly-traded biopharmaceutical companies, has developed a deep knowledge of the life sciences industry and the relevant public
company accounting standards and regulations and is deemed a "Financial Expert" under the Sarbanes-Oxley Act as that term is defined by the SEC. Messrs.&nbsp;Brownlie, Conrad and Ellberger have many
years of experience on the boards of directors of larger public pharmaceutical and life sciences companies. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Independence
also is an important selection criterion for nomination to our Board. Independent directors should be free of any relationship with us, our management, other directors or
other parties that may impair, or appear to impair, the director's ability to make independent judgments. Independent directors must satisfy the criteria for independence established by NASDAQ.
Currently all of our directors are independent except for our Chief Executive Officer, Mr.&nbsp;Marucci, and Dr.&nbsp;McMahon. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
all board members are expected to act in our best interests and the best interests of our stockholders and to avoid any conflicts of interest in accordance with our Code of
Business Conduct and Ethics. In selecting director nominees, the Nominating and Corporate Governance Committee seeks individuals who are free from conflicts of interest. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
candidates should be enthusiastic and excited about their service on our Board and working collaboratively with existing board members to create value for all of our
stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder nominations for directorships  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders may propose a potential director candidate for consideration by the Nominating and Corporate Governance Committee by submitting
their names and background to the Secretary of Celldex at Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, NJ 08827. All such recommendations will be forwarded to the Nominating
and Corporate Governance Committee, which will review and consider only such recommendations if appropriate biographical and other information is provided, as described below, on a timely basis. All
security holder recommendations for director candidates must be submitted to us not less than 120 calendar days prior to the date on which our proxy statement is released to stockholders in connection
with our annual meeting, and must include the following information:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name and address of record of the security holder; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a representation that the security holder is a record holder of our securities, or if the security holder is not a record holder, evidence of
ownership in accordance with Rule&nbsp;14a-8(b)(2) of the Securities Exchange Act of 1934; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name, age, business and residential address, educational background, current principal occupation or employment, and principal occupation
or employment for the preceding five&nbsp;(5)&nbsp;full fiscal years of the proposed director candidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a description of the qualifications and background of the proposed director candidate which addresses the minimum qualifications and other
criteria for Board membership approved by the Board from time to time and set forth in the Nominating and Corporate Governance Committee Charter; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a description of any arrangements or understandings between the security holder and the proposed director candidate; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the consent of the proposed director candidate to be named in the proxy statement relating to our annual meeting of stockholders and to serve
as a director if elected at such annual meeting. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=15,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=271374,FOLIO='13',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Assuming
that appropriate information is provided for candidates recommended by stockholders, the Nominating and Corporate Governance Committee will evaluate those candidates by
following substantially the same process, and applying substantially the same criteria, as for candidates submitted by Board members or other persons, as described above and as set forth in its
written charter. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board recognizes that one of its key responsibilities is to evaluate and determine its optimal leadership structure so as to provide
independent oversight of management. The Board understands that there is no single, generally accepted approach to providing Board leadership and that given the dynamic and competitive environment in
which we operate, the right Board leadership structure may vary as circumstances warrant. Consistent with this understanding, the Nominating and Corporate Governance Committee considers the Board's
leadership structure on an annual basis. This consideration includes the pros and cons of alternative leadership structures in light of the Company's operating and governance environment at the time,
with the goal of achieving the optimal model for effective oversight of management by the Board. Currently, the roles of Chief Executive Officer and Chairman of the Board are separate.
Mr.&nbsp;Marucci, our Chief Executive Officer, is a member of our Board. Mr.&nbsp;Ellberger, an independent director, serves as Chairman of the Board. The Board believes that its current
leadership structure provides independent board leadership, engagement and oversight. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, our independent committee chairs are responsible for leading committee meetings, determining committee meeting schedules, agenda and information flow, and reporting to the
full Board on the committee's actions and areas of responsibilities. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Oversight  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our management is responsible for assessing and managing risk and the Board of Directors oversees and reviews certain aspects of our risk
management processes. The Board of Directors is involved in risk oversight through direct decision-making authority with respect to significant matters and the oversight of management by the Board of
Directors and its committees. The Board is responsible for overseeing risks related to our overall operations and strategy, including, among others, product development, potential asset acquisitions,
financial reporting, business continuity (including succession planning) and reputational risks faced by us. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
committees of the Board execute their oversight responsibility for risk management as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Audit Committee is responsible for overseeing our internal financial and accounting controls and the work performed by the independent
registered public accounting firm. As part of its oversight function, the Audit Committee regularly discusses with management and the independent registered public accounting firm our major financial
and controls-related risk exposures and steps that management has taken to monitor and control such exposures. The Audit Committee also reviews our risk management insurance programs. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Compensation Committee is responsible for overseeing risks related to our cash and equity-based compensation programs and practices. As
part of its oversight function, the Compensation Committee periodically discusses with the President and Chief Executive Officer as well as the Board of Directors, as necessary, the compensation plan
for both executive officers and the independent directors, performance goals and objectives for the period and related achievement, peer group and other relevant compensation benchmarks and practices
and other matters to ensure our compensation practices are in our best interest and that of our shareholders. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The Nominating and Corporate Governance Committee is responsible for overseeing risks related to the composition and structure of the Board of
Directors and its committees and our corporate governance. In this regard, the Nominating and Corporate Governance Committee </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=16,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=806626,FOLIO='14',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_15"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>assesses
the qualifications and independence of members of the Board, makes annual recommendations regarding Board and committee membership, and reviews any transactions between us and our officers,
directors, affiliates of officers and directors or other related parties for conflicts of interest. </FONT></P>

</UL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Governance Matters  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon the recommendation of our Nominating and Corporate Governance Committee, we adopted amended and restated by-laws to among other things
replace with plurality voting standard with a majority voting standard for uncontested elections of directors and eliminate the mandatory retirement age for directors. Since it is an uncontested
election at this Annual Meeting, all director nominees are required to receive a number of "FOR" votes representing at least a majority of votes cast in the election. If such a director nominee fails
to receive "FOR" votes representing at least a majority of votes cast and is an incumbent director, the by-laws require the director to promptly tender his or her resignation to the Board, subject to
acceptance by the Board. The Nominating and Corporate Governance Committee of the Board would then be charged with making a recommendation to the Board as to whether to accept or reject the tendered
resignation, or whether other action should be taken. In contested elections, where the number of nominees exceeds the number of directors to be elected, the plurality voting standard would continue
to apply. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, upon the recommendation of our Nominating and Corporate Governance Committee, we adopted corporate governance guidelines which are posted to our corporate website. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Communications  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors will give appropriate attention to written communications that are submitted by stockholders, and will respond if and as
appropriate. Absent unusual
circumstances or as contemplated by committee charters, and subject to advice from legal counsel, the Secretary of Celldex is primarily responsible for monitoring communications from stockholders and
for providing copies or summaries of such communications to the Board of Directors as he considers appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Communications
from stockholders will be forwarded to all directors if they relate to important substantive matters or if they include suggestions or comments that the Secretary
considers to be important for the Board of Directors to know. Communication relating to corporate governance and corporate strategy are more likely to be forwarded to the Board of Directors than
communications regarding personal grievances, ordinary business matters and matters as to which Celldex tends to receive repetitive or duplicative communications. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders
who wish to send communications to the Board of Directors should address such communications to: The Board of Directors, Celldex Therapeutics,&nbsp;Inc., Perryville III
Building, 53&nbsp;Frontage Road, Suite&nbsp;220, Hampton, NJ 08827, Attention: Secretary. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Code of Business Conduct and Ethics  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a Code of Business Conduct and Ethics that applies to our directors, officers and employees. The purpose of the Code of Business
Conduct and Ethics is to deter wrongdoing and to promote, among other things, honest and ethical conduct and to ensure to the extent possible that our business is conducted in a consistently legal and
ethical manner. Our Code of Business Conduct and Ethics is publicly available on our website at www.celldex.com. If we make any substantive amendments to the Code of Business Conduct and Ethics or
grant any waiver, including any implicit waiver from a provision of the Code of Business Conduct and Ethics to our Directors or Executive Officers, we will disclose the nature of such amendments or
waiver on our website or in a current report on Form&nbsp;8-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=17,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=584540,FOLIO='15',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_16"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding our current executive officers: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="144pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Individual

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position and Office </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>55</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>President, Chief Executive Officer and Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Chief Financial Officer and Secretary</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Product Development Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Executive Vice President and Chief Medical Officer</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Executive Vice President and Chief Scientific Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Theresa LaVallee, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President, Regulatory and Precision Medicine</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Business Officer</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard Wright, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>53</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Senior Vice President and Chief Commercial Officer</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Anthony S. Marucci</B></FONT><FONT SIZE=2> was appointed as permanent President and Chief Executive Officer of Celldex in September 2008 and as a director of the
Company in December 2008. See Mr.&nbsp;Marucci's biography under </FONT><FONT SIZE=2><I>Director Nominees</I></FONT><FONT SIZE=2> above. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Avery W. Catlin</B></FONT><FONT SIZE=2> joined Celldex in January 2000. Mr.&nbsp;Catlin has more than 25&nbsp;years of financial and business expertise in the
biotechnology and medical device industries. Prior to joining Celldex, he served as Vice President, Operations and Finance, and Chief Financial Officer of Endogen,&nbsp;Inc., a public life science
research products company, from 1996 to 1999. From 1992 to 1996, Mr.&nbsp;Catlin held various financial positions at Repligen Corporation, a public biopharmaceutical company, serving the last two
years as Chief Financial Officer. Earlier in his career, Mr.&nbsp;Catlin held the position of Chief Financial Officer at MediSense,&nbsp;Inc., a Massachusetts-based medical device company.
Mr.&nbsp;Catlin currently serves on the Board of Directors of Corbus Pharmaceuticals Holdings&nbsp;Inc., a publicly-held biopharmaceuticals company, and is Chair of the Audit Committee.
Mr.&nbsp;Catlin received his B.A. degree from the University of Virginia and his M.B.A. from Babson College and is a Certified Public Accountant. As previously disclosed in March 2017,
Mr.&nbsp;Catlin has announced his intention to retire from Celldex on June&nbsp;30, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Elizabeth Crowley</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Product Development Officer in August 2016. Ms.&nbsp;Crowley served as Senior
Vice President, Product Development of Celldex from July 2014 to August 2016. Ms.&nbsp;Crowley joined Celldex in 2009 as Vice President, Clinical Development. Prior to that, she held several senior
level roles at CuraGen Corporation, most recently serving as the Vice President of Development Operations. Ms.&nbsp;Crowley started her career at Bayer Corporation in 1992, holding various positions
providing leadership of clinical research and project management prior to completing her tenure there as the Director of Global Study Audit Management. Ms.&nbsp;Crowley received her B.S. in
Chemistry with a concentration in Business from Boston College. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Thomas Davis, M.D.</B></FONT><FONT SIZE=2> became Executive Vice President and Chief Medical Officer of Celldex in July 2014. Dr.&nbsp;Davis served as Senior
Vice President and Chief Medical Officer of Celldex from March 2008 to July 2014 and as Vice President of Clinical Development and Chief Medical Officer of Celldex from April 2006 to March 2008. Prior
to Celldex, Dr.&nbsp;Davis served as Chief Medical Officer at GenVec from July 2005 to April 2006. Dr.&nbsp;Davis was also Senior Director of Clinical Science at Medarex. Dr.&nbsp;Davis has
supervised clinical efforts in adult hematologic malignancies and marrow transplantation and therapeutic antibodies at the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute
(NCI) and worked with Dr.&nbsp;Ron Levy on the development of rituximab and idiotype vaccines at Stanford University. Dr.&nbsp;Davis received his B.A. degree in Biophysics from Johns Hopkins </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=18,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=676314,FOLIO='16',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_de16401_1_17"> </A>

<P style="font-family:times;"><FONT SIZE=2>University,
his M.S. degree in Physiology from Georgetown University and his M.D. from Georgetown University School of Medicine. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Tibor Keler, Ph.D.</B></FONT><FONT SIZE=2> became Executive Vice President and Chief Scientific Officer of Celldex in July 2014. Since, May 2003, Dr.&nbsp;Keler
has held a number of positions with Celldex, including as a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and
Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March
2004. Dr.&nbsp;Keler received his Ph.D. in Microbiology from the University of Pennsylvania. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Theresa LaVallee, Ph.D.</B></FONT><FONT SIZE=2> became Senior Vice President, Regulatory and Precision Medicine in November 2016. From April 2013 to November
2016, Dr.&nbsp;LaVallee served as Kolltan's Senior Vice President, Translational Medicine. From April 2008 to April 2013, Dr.&nbsp;LaVallee served as Senior Director, Translational Medicine at
MedImmune&nbsp;LLC, a wholly owned subsidiary of the healthcare company AstraZeneca. From 1998 to 2008, Dr.&nbsp;LaVallee served in a number of positions in the healthcare industry, including
Senior Director, Cell Biology, at Casi Pharmaceuticals,&nbsp;Inc., formerly EntreMed&nbsp;Inc. Dr.&nbsp;LaVallee received a Ph.D. from the University of California, Los Angeles and a B.A. in
Biochemistry from the University of California, Santa Barbara. Dr.&nbsp;LaVallee completed postdoctoral research at the American Red Cross Holland Laboratory. Dr.&nbsp;LaVallee has informed
Celldex of her decision to relocate to the West Coast to be closer to family and, as such, has provided notice of her resignation which will be effective during the second quarter of 2017. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Ronald Pepin, Ph.D.</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Business Officer of Celldex in July 2011. From June 2010 to April 2011,
Dr.&nbsp;Pepin served as Vice President at Shire Pharmaceuticals. From August 2000 to December 2009, Dr.&nbsp;Pepin was Senior Vice President, Business Development at Medarex. Earlier in his
career, Dr.&nbsp;Pepin was Executive Director of External Science and Technology at Bristol-Myers Squibb Company. Dr.&nbsp;Pepin received his B.A. from Tufts University and his Ph.D. in Genetics
from Georgetown University. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Richard Wright, Ph.D.</B></FONT><FONT SIZE=2> became Senior Vice President and Chief Commercial Officer of Celldex in July 2015. Dr.&nbsp;Wright served as Vice
President of Commercial Operations of Celldex from April 2012 to July 2015. From November 2010 to April 2012, Dr.&nbsp;Wright was Managing Director of Navigant Consulting, a global life sciences
consulting practice. From September 2003 to October 2010, Dr.&nbsp;Wright held several senior leadership roles at Bristol-Myers Squibb including Senior Vice President of the U.S. ImmunoScience
Division. Dr.&nbsp;Wright currently serves on the Scientific Advisory Board for the Seaver Foundation, a nonprofit organization supporting the Center for Autism Treatment and Research at Mount Sinai
Hospital. Dr.&nbsp;Wright received his B.S. in Biological Sciences from Rutgers University and his M.S. and Ph.D. in Microbiology and Molecular Genetics from The University of Medicine and Dentistry
of New Jersey (Rutgers University). He received an M.B.A. in Marketing and Finance from Columbia University. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=19,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=674178,FOLIO='17',FILE='DISK105:[17ZAE1.17ZAE16401]DE16401A.;9',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dg16401_1_18"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


EXECUTIVE COMPENSATION  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dg16401_compensation_discussion_and_analysis"> </A>
<A NAME="toc_dg16401_1"> </A></FONT> <FONT SIZE=2><B>  Compensation Discussion and Analysis    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Introduction  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee oversees and administers our executive compensation programs. The Committee's complete roles and responsibilities are
set forth in the written charter of the Compensation Committee adopted by our Board of Directors, which can be found at our website, </FONT><FONT SIZE=2><I>www.celldex.com</I></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive compensation programs are designed to deliver compensation that is competitive with our peer group and that allows us to attract
and retain superior talent who can perform effectively and succeed in a demanding business environment. Our compensation programs are also designed to reward performance against pre-established goals
and align the interests of our executives with our stockholders. We believe that the compensation of our executive officers should focus executive behavior on the achievement of near-term corporate
targets as well as long-term business objectives and strategies. We believe that pay-for-performance compensation programs, which reward our executives when they achieve individual and/or corporate
goals, create stockholder value and thus have emphasized company and individual performance in setting compensation. We use a combination of base salary, annual cash incentive compensation programs, a
long-term equity incentive compensation program and a broad-based benefits program to create a competitive compensation package for our executive management team. We describe below our compensation
philosophy, policies and practices with respect to our Chief Executive Officer, Chief Financial Officer and our three most highly compensated executive officers, other than the Chief Executive Officer
and Chief Financial Officer, who were serving as executive officers as of December&nbsp;31, 2016, who are collectively referred to as our Named Executive Officers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a biopharmaceutical company focusing on the development of several immunotherapy technologies, we establish corporate goals that are designed to contribute to the development of our
lead programs and to ensure that we manage our cash effectively and have sufficient funding to complete near-term development activities for our lead drug candidates and, where appropriate, to pursue
partnerships and collaborations through which we can leverage the value of our drug candidates. We seek to link the financial interests of our Named Executive Officers to those of our stockholders by
tying compensation to the achievement of these strategic corporate goals, which we believe will drive long-term stockholder value. Each year we establish corporate goals, the achievement of which we
believe are essential to the long-term success of our business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee has adopted a compensation philosophy of targeting our executive compensation to the 50<SUP>th</SUP>&nbsp;percentile of executive compensation of our peer
group and the Radford Global Life Sciences Survey results. Executive compensation may be above or below the 50<SUP>th</SUP>&nbsp;percentile based on an executive's experience, scope of position,
individual performance and company constraints. The Compensation Committee increased the annual base salary for Mr.&nbsp;Marucci, Mr.&nbsp;Catlin, Dr.&nbsp;Davis and Dr.&nbsp;Keler by 2.0% to
3.5% in mid-2016, depending on the position. Ms.&nbsp;Crowley's annual base salary increased 6.0% upon her promotion to Senior Vice President and Chief Product Development Officer in August 2016. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
December 2016 and February 2017, our Compensation Committee reviewed our performance relative to our 2016 corporate goals and concluded that we had achieved at least 80% of our
pipeline development, business and financial operations goals, particularly with respect to progress in our lead clinical programs&#151;our glembatumumab vedotin (or glemba) and varlilumab (or
varli)
programs. Our Compensation Committee approved annual bonus payments for our Named Executive Officers, which </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=20,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=488288,FOLIO='18',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_19"> </A>

<P style="font-family:times;"><FONT SIZE=2>resulted
in a payout of 75.7% to 83.5% of our Named Executive Officers' 2016 bonus target, depending on the position. Further, stock options granted to our executive officers in 2016 have exercise
prices equal to 100% of the fair value on the date of grant and vest over four years, beginning with 25% vesting one year after the date of grant, then pro-rata vesting quarterly thereafter based on
continued service. We believe that stock options structured in this manner encourage our executive officers to focus on increasing stockholder value and stock price appreciation over the long term and
limit unnecessary risk taking behavior, while promoting retention. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2016, we (i)&nbsp;ended the year with cash, cash equivalents and marketable securities of $189.8&nbsp;million and (ii)&nbsp;accomplished the following significant clinical and
operational milestones during the year: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Kolltan Pharmaceuticals acquisition
completed:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;In late November, we completed the acquisition of Kolltan Pharmaceuticals,&nbsp;Inc., adding a unique platform of antibodies
targeting receptor tyrosine kinases (RTKs) to our pipeline. Clinical and preclinical data suggest these drug candidates can help overcome tumor resistance mechanisms associated with current tyrosine
kinase inhibitors and seen in patients who have failed other cancer therapies.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Considerable progress in METRIC
enrollment:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Enrollment in the Phase&nbsp;2b randomized study (METRIC) of glembatumumab vedotin in patients with metastatic triple negative
breast cancers that overexpress gpNMB has accelerated consistently over the last several months across the United States, Canada, Australia and the European Union. Assuming the current rate of
enrollment continues, we expect enrollment will be completed by the end of September 2017.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Third arm added to glembatumumab vedotin Phase&nbsp;2 study in metastatic
melanoma:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;Enrollment has initiated in a glembatumumab vedotin plus checkpoint inhibitor (Opdivo&reg; or Keytruda&reg;) arm in
patients who failed prior checkpoint therapy. Enrollment continued in the glembatumumab vedotin and varlilumab arm, with data from this portion of the study expected in the fall of 2017. Positive data
from the single-agent arm of this study in patients who had previously progressed on checkpoint therapy were presented at the European Society for Medical Oncology (ESMO) Congress in October 2016. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Continued progress in Phase&nbsp;2 varlilumab/Opdivo&reg;
study:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The Phase&nbsp;2 study of varlilumab and Opdivo continues to enroll patients across multiple indications (colorectal cancer, ovarian
cancer, head and neck squamous cell carcinoma, renal cell carcinoma and glioblastoma). We anticipate that data from the Phase&nbsp;1 study of varlilumab and Opdivo will be presented mid-year 2017.
We plan to complete enrollment across all cohorts in the Phase&nbsp;2 portion of the study in the first quarter of 2018 and will work with Bristol-Myers Squibb to present data from the study at a
future medical meeting.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2><B> Enrollment ongoing in Phase&nbsp;1 study of
CDX-014:</B></FONT><FONT SIZE=2>&nbsp;&nbsp;The study in advanced renal cell carcinoma (clear cell and papillary) is designed to determine the maximum tolerated dose and to
recommend a dose level for further study. We expect the Phase&nbsp;1 dose-escalation portion of the study will complete enrollment by year-end 2017. </FONT></DD></DL>
</UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Independent Compensation Consultants  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee believes that independent advice is important in developing Celldex's director and executive compensation programs
and in 2016, 2015 and 2014 engaged Radford as its independent compensation consultant. In 2016, Radford focused on both executive and director compensation. In 2015, Radford focused on director
compensation and in 2014, Radford focused on executive compensation. In 2015, Radford also provided advisory services in connection with the amendment and restatement of our 2008 Stock Option and
Incentive Plan, including an increase in the number of shares reserved for issuance under the Plan. Radford reports directly to the Committee and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=21,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=213225,FOLIO='19',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_20"> </A>

<P style="font-family:times;"><FONT SIZE=2>provides
guidance on trends in executive and non-employee director compensation, the development of specific executive compensation programs, the composition of the Company's compensation peer group
and other matters as directed by the Committee. The Company also participated in various Radford surveys in 2016, 2015 and 2014. During 2016, 2015 and 2014, the Company paid Radford approximately
$67,700, $35,300 and $52,300, respectively, in consulting fees directly related to these services. In 2016, 2015 and 2014, Radford did not provide any other services to Celldex. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Data Used to Make Compensation Determinations  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In making decisions regarding the compensation of our executive officers, the Compensation Committee generally considers compensation and survey
data for similarly situated executives at a comparison group of companies it considers our peer group. These comparison data are primarily used to gauge the reasonableness and competitiveness of
executive compensation decisions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
draw upon a pool of talent that is highly sought after by large and established pharmaceutical and biotechnology companies as well as by other development-stage life science
companies, both within and outside our geographic areas. We believe that the compensation practices of our industry in general and of our select peer group in particular provide useful information to
help us establish compensation practices that allow us to attract, retain, and motivate a highly talented executive team. We believe we must offer a compensation package to all of our officers and our
other employees that is competitive with our peer group, as well as larger pharmaceutical and biotechnology companies from whom we frequently recruit. In addition, the comparator companies should be
aligned with our current stage of development and have similar short and long-term growth objectives. In 2016, the Compensation Committee set the target level of total executive compensation, as well
as the key elements of compensation, at the 50<SUP>th</SUP>&nbsp;percentile of our peer group, but then adjusted each of the elements based on an individual's performance and contribution to our
strategic objectives. The Committee may need to adjust these levels in the future to attract or retain specific individuals. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
review the levels of cash, equity and total compensation for all comparable officers in our peer group relative to the elements of compensation paid to our officers. In considering
how these data relate to our existing compensation structure, we take into account our size, stage of development, performance and geographic location as compared to these peer companies, as well as
what we know about the comparable scope of responsibilities of our officers versus those of comparable executives at such peer group companies. With the assistance of our compensation consultant,
Radford, we used two primary market frames of reference (which we refer to as the "market") against which to compare our total executive compensation practices and levels and inform our decisions
regarding compensation of our officers as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Select Peer Group&#151;A select group of national biotechnology companies at a similar stage of development as our company with similar
headcount, R&amp;D expense, market capitalization and in most cases, similar therapeutic targets, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Radford Global Life Sciences Survey&#151;A national survey of executive compensation levels and practices that covers approximately
sixty executive positions in over 600 multinational life sciences organizations. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not apply a specific weighting to either data source when making compensation comparisons. Instead, we develop competitive market guidelines using these data sources. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
review our peer group each year to ensure continued relevance as we grow and develop, and the Compensation Committee approves our peer group prior to its adoption. The select peer
group as </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=22,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=751949,FOLIO='20',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_21"> </A>

<P style="font-family:times;"><FONT SIZE=2>of
May 2016 was analyzed and used to inform our decisions affecting executive compensation based on 2016 performance consisted of the following companies: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="39%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="39%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Achillion Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>MacroGenics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Agenus&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Merrimack Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>bluebird bio,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>NewLink Genetics Corporation</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Clovis Oncology,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>OncoMed Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Epizyme,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Progenics Pharmaceuticals,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Exelixis,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>PTC Therapeutics,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ImmunoGen,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Puma Biotechnology,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Infinity Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sangamo BioSciences,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Inovio Pharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Xencor,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>INSYS Therapeutics,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>ZIOPHARM Oncology,&nbsp;Inc.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Keryx Biopharmaceuticals,&nbsp;Inc.</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
peer group consisted of public companies in the biopharmaceutical industry with product candidates generally in late-stage development, with similar employee headcount (average of
184), R&amp;D expense less than $282&nbsp;million (average of $93&nbsp;million) and market capitalization in the range of $283&nbsp;million to $1.9&nbsp;billion (average of $727&nbsp;million).
We believe that, as of May 2016, this list was representative of the companies with whom we generally compete for talent. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Administration and Objectives of Our Executive Compensation Program  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee of the Board of Directors, which comprises independent, non-employee directors, is responsible for establishing and
administering the policies governing the compensation of our employees, including salary, bonus and stock option grants. The policy of the Compensation Committee is to compensate our employees with
competitive salaries based on their level of experience and job performance. All permanent employees, including executive officers, are eligible for annual bonus awards based on achievement of our
strategic corporate goals and participation in our stock option program. The stock option grants are made in accordance with our 2008 Stock Option and Incentive Plan, as amended (the "2008 Plan"). The
Compensation Committee is also responsible for the administration of our 2004 Employee Stock Purchase Plan, as amended (the "2004 Plan"), in which employees participate on a voluntary basis. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee has designed our overall executive compensation program to achieve the following objectives:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> attract and retain talented and experienced executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> motivate and reward executives whose knowledge, skills and performance are critical to our success; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> provide a competitive compensation package that aligns the interests of our executive officers and stockholders by including a significant
variable component which is weighted heavily towards performance-based rewards, based upon achievement of predetermined goals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> ensure fairness among the executive management team by recognizing the contributions each executive makes to our success; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> foster a shared commitment among executives by aligning our and their individual goals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> compensate our executives to manage our business to meet our near-term and long-term objectives. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
use a mix of short-term compensation (base salaries and cash incentive bonuses) and long-term compensation (equity incentive compensation) to provide a total compensation structure
that is </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=23,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=716927,FOLIO='21',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_22"> </A>

<P style="font-family:times;"><FONT SIZE=2>designed
to achieve these objectives. We determine the percentage mix of compensation structures that we think is appropriate for each of our executive officers. In general, the Compensation Committee
believes that a substantial percentage of the compensation of our executive officers should be performance based. The Compensation Committee uses its judgment, experience and the recommendations of
the chief executive officer (except for his own compensation) to determine the appropriate mix of compensation for each individual. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
determining whether to adjust the compensation of any of our Named Executive Officers, we annually take into account the changes, if any, in the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> market compensation levels; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the contributions made by each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the performance of each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the increases or decreases in responsibilities and roles of each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the business needs of the Company with respect to each executive officer; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the relevance of each executive officer's experience to other potential employers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the readiness of each executive officer to assume a more significant role within the organization. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, with respect to new executive officers, we take into account their prior base salary and annual cash incentives, their expected contribution and our business needs. We
believe that our executive officers should be fairly compensated each year relative to market pay levels within our industry. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation Components  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In order to both attract and retain experienced and qualified executives to manage us, the Compensation Committee's policy on executive
compensation is to (i)&nbsp;pay salaries which are competitive with the salaries of executives in comparable positions in the biotechnology industry, and (ii)&nbsp;allow for additional
incentive-based compensation through the payment of annual cash bonuses and the grant of stock-based incentive awards. This policy is designed to have a significant portion of each executive's total
compensation be tied to our progress in order to incentivize the executive to fully dedicate himself or herself to achievement of corporate goals, and to align the executive's interest with those of
our stockholders through equity incentive compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive compensation program is primarily composed of base salary, annual incentive cash compensation payable on an annual basis and equity compensation. In addition, we provide
our executives with benefits that are generally available to our salaried employees, including medical, dental, group life and accidental death and dismemberment insurance, short- and long-term
disability coverage and our 401(k) plan. Within the context of the overall objectives of our compensation programs, we determined the specific amounts of compensation to be paid to each of our
executives in 2016 based on a number of factors including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our understanding of the amount of compensation generally paid by similarly situated companies to their executives with similar roles and
responsibilities; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the roles and responsibilities of our executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the individual experience and skills of, and expected contributions from, our executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amounts of compensation being paid to our other executives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our executives' historical compensation. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=24,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=918918,FOLIO='22',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_23"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
discuss each of the primary elements of our executive compensation in detail below. While we have identified particular compensation objectives that each element of executive
compensation serves, our compensation programs complement each other and collectively serve all of our executive compensation objectives described above. Accordingly, whether or not specifically
mentioned below, we believe that, as a part of our overall executive compensation, each element to a greater or lesser extent serves each of our objectives. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salary  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each executive officer (except the chief executive officer whose performance is reviewed by the Compensation Committee) has an annual
performance review with the chief executive officer who makes recommendations on salary increases, promotions and stock option grants to the
Compensation Committee. We have historically established base salaries for each of our executives based on many factors, including average salary increases expected in the biotechnology industry in
the Boston, Massachusetts, New Haven, Connecticut and central New Jersey areas, competition in the marketplace to hire and retain executives, experiences of our Board members and leadership team with
respect to salaries and compensation of executives in similarly situated companies in our industry and other similar industries, as well as additional factors which we believe enable us to hire and
retain our leadership team in an extremely competitive environment. Our Compensation Committee annually reviews salary ranges and individual salaries for our executive officers. The Compensation
Committee increased the annual base salary for Mr.&nbsp;Marucci, Mr.&nbsp;Catlin, Dr.&nbsp;Davis and Dr.&nbsp;Keler by 2.0% to 3.5% in mid-2016, depending on the position. Ms.&nbsp;Crowley's
annual base salary increased 6.0% upon her promotion to Senior Vice President and Chief Product Development Officer in August 2016. For 2015, the Compensation Committee increased annual base salary
for our Named Executive Officers by 3.1% to 6.5%. For 2014, the Compensation Committee increased annual base salary by 3.0% to 6.5% for our Named Executive Officers. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Performance-Based Cash Bonus  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have designed our annual cash bonuses to reward our executive officers for their individual performance and their actual performance and
contributions to our corporate goals for each year, as approved in advance by our Compensation Committee and Board of Directors. The corporate goals are allocated between specific product and
financial performance targets. Achievement of our corporate goals was, in 2016, the primary factor considered by our Compensation Committee in determining the annual bonuses for our executive
officers. However, the Compensation Committee retains discretion to adjust any individual bonus based on assessment of such individual's performance. Our performance-based bonus plan emphasizes the
contributions of each of our executive officers to the achievement of our corporate goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the beginning of each calendar year, the Compensation Committee establishes annual corporate performance goals and target bonuses. In 2016 based on Radford's recommendation, the
Compensation Committee established target bonuses for each of our Named Executive Officers as follows: 60% of base salary for Mr.&nbsp;Marucci and 40% of base salary for Dr.&nbsp;Keler,
Mr.&nbsp;Catlin and Dr.&nbsp;Davis. Ms.&nbsp;Crowley became a Named Executive Officer in August 2016 and her target bonus of 35% is based on her employment agreement. Corporate goals are
proposed by management, reviewed and approved by the Compensation Committee and also approved by the Board of Directors on an annual basis. The Compensation Committee considers and assigns a relative
weight to appropriately focus efforts on corporate goals that are intended to enhance shareholder value. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee reviewed the 2016 corporate goals at meetings held in April, June and September 2016 to gauge our levels of achievement and to assess whether the corporate
goals approved earlier in the year remained relevant and complete. In December 2016 and February 2017, prior to approving 2016 incentive bonuses, the Compensation Committee evaluated our 2016 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=25,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=297125,FOLIO='23',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_24"> </A>

<P style="font-family:times;"><FONT SIZE=2>performance
by assessing if, and the extent to which, we achieved or failed to achieve the corporate goals approved by the Board of Directors for 2016. The Compensation Committee considered the
progress in our clinical programs, including our glembatumumab vedotin and varlilumab programs, and our corporate development activities. Based primarily on the discontinuation of our Phase&nbsp;3
study of Rintega&reg; in patients with newly diagnosed EGFRvIII-positive glioblastoma in March 2016 and our inability to raise sufficient financing, other than through our ATM facility with
Cantor, to provide cash runway into 2019, the Compensation Committee determined that we met 80% of our 2016 corporate goals for pipeline development and business and financial operations. Our
corporate goals for 2016 and the level at which the Compensation Committee determined they were achieved are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 Corporate Goal </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Relative<BR>
Weight </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016<BR>
Achievement </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Pipeline Development:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Rintega (Rindopepimut) Development Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Deliver savings of
&gt;$45M in 2016 associated with wind down activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Support continued access
to Rintega via compassionate use for appropriate patients as long as benefitting</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glembatumumab Vedotin (CDX-011) Development Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Activate
~50&nbsp;European sites to supplement METRIC enrollment</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Deliver top-line primary
study results in melanoma (ORR, duration of response and safety) and progress melanoma development strategy</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Develop commercial
strategy for key indications, markets and potential for partnerships</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Varlilumab (CDX-1127) Development Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2> Complete combination
Phase&nbsp;1 dosing studies to evaluate preliminary safety, select Phase&nbsp;2 dose and initiate Phase&nbsp;2 enrollment of combination studies to explore activity and further evaluate safety</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Develop commercial
strategy for key indications, markets and potential for partnerships</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1401/CDX-301 Development Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Initiate company
sponsored study in combination with a checkpoint inhibitor</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Support expanded clinical
development through external collaborations</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-014 Development Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2> Complete site activation
and initiate Phase&nbsp;1 study</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>CDX-1140 Development Activities</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Manage preclinical
development of agonist CD40 mAb towards IND filing in 2017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Business and Financial Operations:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2>Provide sufficient cash
through various mechanisms to achieve our corporate goals and extend our runway through 2018</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;text-align:left;"><p align=left style="font-family:times;margin-top:0pt;margin-bottom:-12pt;margin-left:20pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:left;" -->


</FONT> <FONT SIZE=2> </font> <font size=2> &#149;</font></p> <p align=left style="font-family:times;margin-top:0pt;margin-left:30pt;"><font size=2></FONT><FONT SIZE=2> Complete a substantial
collaboration or licensing transaction with respect to pipeline assets in 2016, if appropriate and acceptable</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Totals:</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>% </FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to the Compensation Committee's December 2016 and February 2017 meetings, Mr.&nbsp;Marucci reviewed in detail the performance of each executive officer, excluding himself, and
considered such individual's contributions to our success in 2016. Mr.&nbsp;Marucci's bonus recommendations were based on such individual performance assessments and the fact that the Company
achieved 80% of its predetermined corporate goals in 2016 and each employee, including the executive officers, contributed to our success in achieving the 2016 corporate goals. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=26,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=889430,FOLIO='24',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_25"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee discussed Mr.&nbsp;Marucci's recommendations for the Named Executive Officers and reviewed Mr.&nbsp;Marucci's performance for fiscal 2016. Based on
Mr.&nbsp;Marucci's recommendations for each of the Named Executive Officers, the Compensation Committee's review of Mr.&nbsp;Marucci's performance and the Compensation Committee's determination
that 80% achievement of the corporate goals for 2016, the Compensation Committee determined that the annual cash incentives approved for each Named Executive Officer (including Mr.&nbsp;Marucci)
should be set at 75.7% to 83.5% of the targets established for each Named Executive Officer, depending on the position. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee determined that annual incentive bonuses paid to the Named Executive Officers for 2016, were fair, reasonable and appropriate based on the factors described
above. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We also use stock options and equity-based incentive programs to attract, retain, motivate and reward our executive officers. Through our
equity-based grants, we seek to align the interests of our executive officers with our stockholders, reward and motivate both near-term and long-term executive performance and provide an incentive for
retention. Our decisions regarding the amount and type of equity incentive compensation and relative weighting of these awards among total executive compensation have been based on our understanding
of market practices of similarly situated companies and our negotiations with our executives in connection with their initial employment or promotion. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have adopted an equity grant policy that formalizes how we grant equity awards by setting a regular schedule for granting equity awards in connection with the hiring or promotion of
any of our employees, granting annual equity awards and granting equity awards to non-employee directors. Such policy also outlines grant approval requirements and specifies the vesting schedule and
exercise prices for restricted stock units and stock option awards. We believe that this policy will mitigate the risk that issues or concerns would be raised in the future regarding the timing of
grants of equity awards to our officers, directors and employees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
such grants to our Named Executive Officers are subject to prior approval by the Compensation Committee at a regularly scheduled meeting during the year. The date of grant and the
fair market value of the award are based upon the date of the Compensation Committee meeting approving such
grant. When granting equity-based awards, the Compensation Committee considers a number of factors in determining the amount of equity incentive awards, if any, to grant to our executives,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the existing levels of stock ownership among the executive officers relative to each other and to our employees as a whole; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> previous grants of stock options to such executive officers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> vesting schedules of previously granted options; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the performance of the executives and their contributions to our overall performance; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an outside survey of stock option grants and restricted common stock awards in the biotechnology industry; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> an internally prepared survey of similarly situated biotechnology companies' proxy statements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> personal knowledge of the Compensation Committee members regarding executive stock options and restricted common stock awards at comparable
companies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the financial statement impact of stock option awards on our results of operations; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount and percentage of our total equity on a diluted basis held by our executives. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=27,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=407337,FOLIO='25',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_26"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Equity
compensation awards to our Named Executive Officers primarily consist of stock option awards. Stock option awards provide our executive officers with the right to purchase shares
of our common stock at a fixed exercise price typically for a period of up to ten years, subject to continued employment with us. Stock options are earned on the basis of continued service to us and
generally vest over four years, beginning with 25% vesting one year after the date of grant, then pro-rata vesting quarterly thereafter. All historical option grants were made at what our Compensation
Committee and Board of Directors determined to be the fair market value of our shares of our common stock on the respective grant dates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June&nbsp;8, 2016, the Compensation Committee awarded stock options to all qualified employees, including stock options to purchase 475,000 shares, 162,000 shares, 157,000 shares,
135,000 shares and 81,000 shares of our common stock to each of Messrs.&nbsp;Marucci, Keler, Davis and Catlin and Ms.&nbsp;Crowley, respectively. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;1, 2017, the Board of Directors approved an amendment to the 2008 Plan, subject to approval at this Annual Meeting by our stockholders, to increase the number of shares
reserved for issuance thereunder by 5,650,000 to 20,000,000 shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors believes that the approval of the amendment to the 2008 Plan to increase in the number of shares reserved for issuance thereunder is essential to our continued
success. In particular, the Board of Directors believes that our employees are our most valuable assets and that the awards permitted under the 2008 Plan are vital to our ability to attract and retain
outstanding and highly skilled individuals in the extremely competitive labor markets in which we operate. Such awards also are important to our ability to motivate our employees to achieve our goals.
The proposed
increase in the number of shares authorized for issuance under the 2008 Plan is intended to provide sufficient shares to fund anticipated equity awards for new and existing employees and independent
contractors for up to three years. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Benefits  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that establishing competitive benefit packages for our employees is an important factor in attracting and retaining highly qualified
personnel. Executive officers are eligible to participate in all of our employee benefit plans, such as medical, dental, group life and accidental death and dismemberment insurance, short- and
long-term disability coverage and our 401(k) plan, in each case on the same basis as other employees. We provide a matching contribution under our 401(k) plan. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Employment Agreements and Post-Termination Compensation and Benefits  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We depend greatly on the intellectual capabilities and experience of our key executives. Our success is dependent on our ability to attract and
retain highly skilled executives with significant experience in the biotechnology industry, particularly as we expand our activities in clinical trials, the regulatory approval process and sales and
manufacturing. Therefore we enter into employment agreements with each of our Named Executive Officers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
general, each employment arrangement provides for cash severance, 100% acceleration of any unvested options, restricted stock and/or other equity awards and continuation of certain
employee benefits in the event that an executive's employment is terminated without cause or is terminated by the executive for good reason within a one year period immediately following a change of
control. The cash severance consists of a single lump sum payment equal to (i)&nbsp;twenty-four (24)&nbsp;times the executive's highest monthly base compensation paid hereunder during the
preceding twenty-four month period, plus (ii)&nbsp;150% (200%, in the case of Mr.&nbsp;Marucci) of the highest one-year annual bonus actually received by the executive during the preceding two
full fiscal years prior to the date of termination. We use a "double trigger" with respect to benefits that are to be provided in connection with a change of control. A change of control does not
itself trigger benefits; rather, benefits are paid only if the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=28,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=676079,FOLIO='26',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dg16401_1_27"> </A>

<P style="font-family:times;"><FONT SIZE=2>employment
of the executive is terminated by us other than for cause, death or disability or by the executive for good reason during the one year period immediately following the change of control. We
believe a "double trigger" benefit maximizes shareholder value because it prevents a windfall to executives in the event of a change of control in which the executive retains significant
responsibility as defined in his or her individual agreement, while still providing our executives appropriate incentives to cooperate in negotiating any change of control that may put their jobs at
risk. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition to the benefits that only accrue in connection with a change of control, our agreements with the Named Executive Officers provide for cash severance, 25% acceleration of
unvested options, restricted stock and/or other equity awards and continuation of certain employee benefits if we terminate their employment with us without cause or they terminate their employment
with us for good reason, as such terms are defined in the applicable agreement with the executive officer. The cash severance consists of a lump sum cash payment equal to 100% (200% in the case of
Mr.&nbsp;Marucci) of the executive's then existing base salary. A further discussion of the terms and projected payments under each of these agreements is set forth below under the heading </FONT> <FONT SIZE=2><I>Potential Payments upon Termination
of Employment or Change in Control.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committee Consideration of the Company's 2016 Shareholder Advisory Vote on Executive Compensation  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At our 2016 Annual Meeting of Shareholders, approximately 96% of the shares voted at the meeting approved, on an advisory basis, the
compensation of the Named Executive Officers. Given that a majority of the shares voted approved the 'say on pay' advisory proposal, the Committee did not implement specific changes and continued with
its performance-based compensation philosophy and its balanced approach to various components of its compensation program. However, the Compensation Committee does monitor the results of the annual
advisory 'say-on-pay' proposal and refers to such results as one of many factors considered in connection with the discharge of its responsibilities, although the Committee does not assign a
quantitative weighting to any such factors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board of Directors has determined that an advisory vote should be conducted on an annual basis and has recommended that our stockholders indicate their preference for an annual
advisory vote in Proposal No.&nbsp;7. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=29,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=288503,FOLIO='27',FILE='DISK105:[17ZAE1.17ZAE16401]DG16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_di16401_1_28"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_summary_compensation_table"> </A>
<A NAME="toc_di16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary compensation table reflects certain information concerning compensation for services in all capacities awarded to, earned
by or paid during the years ended December&nbsp;31, 2016, 2015 and 2014 to each person who served as our Chief Executive Officer and Chief Financial Officer at any time during the year ended
December&nbsp;31, 2016 and the three most highly compensated executive officers, other than the Chief Executive Officer and Chief Financial Officer, who were serving as executive officers as of
December&nbsp;31, 2016 (collectively, the "Named Executive Officers"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="26pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="35pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="34pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Years </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive<BR>
Plan<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value and<BR>
Nonqualified<BR>
Deferred<BR>
Compensation<BR>
Earnings<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>577,361</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>282,086</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,496,440</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,308</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,370,195</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>President and Chief</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>559,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>302,924</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,371,528</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>39,874</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,273,726</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Executive Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>520,879</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>293,234</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,431,856</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>64,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,310,906</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=1> Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>337,235</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>105,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>425,304</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>7,132</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>874,671</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>339,457</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>130,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,436,359</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6,024</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,911,840</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Chief Financial Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>317,017</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>102,097</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>799,038</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,717</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,223,869</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>438,057</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>134,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>494,613</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>9,361</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>1,076,031</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Executive Vice President</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>434,421</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>165,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,818,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9,297</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,427,586</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>and Chief Medical Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>407,453</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>148,960</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,011,826</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8,749</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,576,988</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=1> Tibor Keler., Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>414,445</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>134,324</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>510,365</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>3,937</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>1,063,071</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>Executive Vice President</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>409,996</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>159,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,818,868</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,391,664</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1><I>and Chief Scientific Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>384,517</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>158,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,011,826</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,763</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,558,606</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><BR><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Elizabeth Crowley(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>321,970</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>97,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>255,182</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>4,233</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><BR><FONT SIZE=1>678,385</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=1><I>Senior Vice President and</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1><I> </I></FONT><FONT SIZE=1><I>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Product Development</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:14pt;text-indent:-7pt;"><FONT SIZE=1><I> </I></FONT><FONT SIZE=1><I>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Officer</I></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts in the Bonus column include annual bonus amounts earned by each of our Named Executive Officers in 2016, 2015 and 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts in the Option Awards column reflect the dollar amounts for the aggregate grant date fair value in accordance with accounting principles generally
accepted in the United States of America (U.S.&nbsp;GAAP) of stock option awards made in fiscal years ended December&nbsp;31, 2016, 2015 and 2014 for annual awards pursuant to the 2008 Plan. For a
discussion regarding the valuation of our stock option awards for financial statement reporting purposes, please refer to Note&nbsp;2 in the Notes to the Financial Statements contained in our Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016. These amounts do not represent the actual amounts paid to the Named Executive Officers or the actual value that may be realized
by the Named Executive Officers upon exercise of such stock options.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>The
amounts listed in the All Other Compensation column includes our matching contribution to the 401(k) Savings Plan of each Named Executive Officer and premiums
paid for life insurance under our nondiscriminatory group plan for each Named Executive Officer. In addition, Mr.&nbsp;Marucci's compensation includes (i)&nbsp;the annual premium of $2,550 in
2016, 2015 and 2014 for a $1,000,000 term life insurance policy, (ii)&nbsp;$3,123, $3,948 and $4,747 for the personal use of a Company car in 2016, 2015 and 2014, and (iii)&nbsp;tuition
reimbursement of $24,634 and $49,266 in 2015 and 2014 related to an executive master of healthcare leadership program.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>On
August&nbsp;10, 2016, Elizabeth Crowley was promoted to Senior Vice President and Chief Product Development Officer. The amounts included above are for the full
year ended December&nbsp;31, 2016. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=30,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=187966,FOLIO='28',FILE='DISK105:[17ZAE1.17ZAE16401]DI16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_di16401_1_29"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_grants_of_plan-based_awards"> </A>
<A NAME="toc_di16401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Grants of Plan-Based Awards    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information on stock options and stock awards granted in 2016 to each of our Named Executive Officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=4 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=4 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Options<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Estimated Future<BR>
Payouts Under<BR>
Equity Incentive Plan Awards </B></FONT></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Stock<BR>
Awards:<BR>
Number of<BR>
Shares or<BR>
Units<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=3 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=3 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date<BR>
Fair Value of<BR>
Stock and<BR>
Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH ROWSPAN=2 style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ROWSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise or<BR>
Base Price of<BR>
Option<BR>
Awards<BR>
($/Sh)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Threshold<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Maximum<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/8/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>475,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,496,440</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/8/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>425,304</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/8/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>157,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>494,613</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/8/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>162,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>510,365</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/8/16</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4.72</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>255,182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
exercise prices reflect the closing price of our common stock on the grant date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
grant date fair values are generally the amount we would expense in our financial statements over the award's service period, but does not include a reduction
for forfeitures. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=31,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=672309,FOLIO='29',FILE='DISK105:[17ZAE1.17ZAE16401]DI16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_di16401_1_30"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_outstanding_equity_awards_at_fiscal_year-end"> </A>
<A NAME="toc_di16401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Outstanding Equity Awards at Fiscal Year-End    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the stock option grants and stock awards to our Named Executive Officers at
December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="4pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=14 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options (#)<BR>
Unexercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Unearned<BR>
Options (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Shares or<BR>
Units of<BR>
Stock<BR>
That<BR>
Have Not<BR>
Vested ($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Number of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity<BR>
Incentive<BR>
Plan<BR>
Awards:<BR>
Market or<BR>
Payout<BR>
Value of<BR>
Unearned<BR>
Shares,<BR>
Units or<BR>
Other<BR>
Rights<BR>
That<BR>
Have Not<BR>
Vested (#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>475,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>105,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>175,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>175,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>105,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>227,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>52,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>280,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>180,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>164,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>129,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Anthony S. Marucci</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>254,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/7/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>135,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>57,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>57,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>34,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>73,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>35,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>67,153</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Avery W. Catlin</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>157,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,687</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>72,813</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>72,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,688</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>93,437</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>21,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>115,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>104,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>95,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>76,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>148,825</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/7/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>162,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,687</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>72,813</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>72,812</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>43,688</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>93,437</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>21,563</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>115,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5.69</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/12/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>99,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>90,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>72,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.52</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/6/19</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>254,243</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8.16</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3/7/18</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>81,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.72</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/8/26</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>28,125</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>46,875</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>25.41</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/10/25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>19,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>11,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>13.45</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6/4/24</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>24,375</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>5,625</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>16.36</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>7/1/23</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>30,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>6.37</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>9/20/22</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2.80</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>8/5/21</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:7pt;text-indent:-7pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Elizabeth Crowley.&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>20,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4.50</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1/21/20</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=1>25%
of the options vest on the first anniversary of the grant date and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=32,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=518721,FOLIO='30',FILE='DISK105:[17ZAE1.17ZAE16401]DI16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_di16401_1_31"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_option_exercises_and_stock_vested"> </A>
<A NAME="toc_di16401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  Option Exercises and Stock Vested    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information regarding the number of option exercises in fiscal 2016 and the number of shares of stock
issued under the 2008 Plan that vested in fiscal 2016 and the corresponding amounts realized by our Named Executive Officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="98pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="93pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="69pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Acquired on Exercise<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value Realized<BR>
on Exercise<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of Shares<BR>
Acquired on Vesting<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value Realized<BR>
on Vesting<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,847</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>53,171</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Represents
the aggregate dollar amount realized by the Named Executive Officer upon exercise of the options, calculated by determining the difference between the
closing price on the date of exercise and the exercise price. These amounts do not correspond to the actual value received by the Named Executive Officers.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_employment_agreements"> </A>
<A NAME="toc_di16401_5"> </A>
<BR></FONT><FONT SIZE=2><B>  Employment Agreements    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The terms and conditions of the employment agreements of Mr.&nbsp;Marucci, Mr.&nbsp;Catlin, Dr.&nbsp;Davis and Dr.&nbsp;Keler are
governed by written employment contracts which became effective on January&nbsp;1, 2013. The terms and conditions of Ms.&nbsp;Crowley's employment agreement are governed by a written employment
contract which became effective on August&nbsp;10, 2016. The employment agreements provide, among other things, for:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> current annual base salary ($587,680 in the case of Mr.&nbsp;Marucci, $342,413 in the case of Mr.&nbsp;Catlin, $442,562 in the case of
Dr.&nbsp;Davis, $419,761 in the case of Dr.&nbsp;Keler and $331,720 in the case of Ms.&nbsp;Crowley) or such greater amount as may from time to time be determined by the Board of Directors or
the Compensation Committee thereof; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> eligibility for an annual bonus with a current bonus target (60% of base salary in the case of Mr.&nbsp;Marucci, 40% of base salary in the
case of Mr.&nbsp;Catlin, 40% of base salary in the case of Dr.&nbsp;Davis, 40% of base salary in the case of Dr.&nbsp;Keler and 35% of base salary in the case of Ms.&nbsp;Crowley); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> a lump sum severance payment equal to 100% (200% in the case of Mr.&nbsp;Marucci only) of the executive's then-existing annual base salary in
the event that the executive's employment is terminated without cause or the executive resigns "for good reason" (as defined in the employment agreement) and 25% accelerated vesting of any unvested
equity awards; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> accelerated vesting of any unvested equity awards (as defined in the employment agreement) and a lump sum cash payment equal to twenty-four
(24)&nbsp;times the executive's highest monthly base compensation (not including bonus) during the twenty-four month period preceding the date of termination plus 150% (200% in the case of
Mr.&nbsp;Marucci only) of the highest one-year annual bonus actually received by the executive during the two full fiscal years preceding the date of termination in the event of termination without
cause or resignation "for good reason" by the executive within one year immediately following a change in control (as defined in the employment agreement). </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
employment agreements had an initial term through December&nbsp;31, 2015 (other than Ms.&nbsp;Crowley's employment agreement, which had an initial term through
December&nbsp;31, 2016) and shall automatically renew for additional one year terms unless either party gives ninety (90)&nbsp;days prior </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=33,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=266291,FOLIO='31',FILE='DISK105:[17ZAE1.17ZAE16401]DI16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_di16401_1_32"> </A>

<P style="font-family:times;"><FONT SIZE=2>written
notice of its intent not to renew. The Company may terminate the employment agreements without cause, on 90-days' prior notice, or for cause, subject to a 30-day cure period in certain
circumstances. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_pension_benefits"> </A>
<A NAME="toc_di16401_6"> </A>
<BR></FONT><FONT SIZE=2><B>  Pension Benefits    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our Named Executive Officers participate in qualified or nonqualified defined benefit plans sponsored by us. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_nonqualified_deferred_compensation"> </A>
<A NAME="toc_di16401_7"> </A>
<BR></FONT><FONT SIZE=2><B>  Nonqualified Deferred Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;None of our Named Executive Officers are covered by a defined contribution or other plan that provides for the deferral of compensation on a
basis that is not tax-qualified. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di16401_potential_payments_upon_termin__pot02940"> </A>
<A NAME="toc_di16401_8"> </A>
<BR></FONT><FONT SIZE=2><B>  Potential Payments Upon Termination of Employment or Change in Control    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Named Executive Officers have provisions in their employment agreements regarding severance upon certain termination events or acceleration
of stock options in the event of our change of control or termination following a change of control. These severance and acceleration provisions are described in "Employment Agreements," and certain
estimates of these change of control benefits are provided in the tables below. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=34,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=495472,FOLIO='32',FILE='DISK105:[17ZAE1.17ZAE16401]DI16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dk16401_1_33"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table describes the potential payments and benefits upon employment termination for our Named Executive Officers as if their employment had terminated as of
December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="102pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Executive benefits and payments<BR>
upon termination

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for no good<BR>
reason </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary<BR>
resignation<BR>
for good<BR>
reason(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex not<BR>
for cause(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Termination<BR>
by Celldex<BR>
for cause </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Voluntary termination<BR>
by the executive<BR>
for good reason<BR>
or termination by<BR>
Celldex without<BR>
cause in connection<BR>
with or following<BR>
change of control(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Anthony S. Marucci</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,175,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,175,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,175,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>605,848</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,223,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,223,406</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,829,254 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Avery W. Catlin</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>342,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>342,413</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>684,827</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>195,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,526</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,526</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35,526 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>377,939</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>377,939</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>915,353 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Thomas Davis, M.D.</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>442,562</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>442,562</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>885,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>247,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>490,608</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>490,608</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,180,671 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Tibor Keler, Ph.D.</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>419,761</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>419,761</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>839,522</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>238,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>48,046 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>467,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>467,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,126,068 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B><U>Elizabeth Crowley</U></B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Base Salary</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>331,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>331,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>663,440</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bonus</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>180,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity Awards Acceleration(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Continuation of Health Benefits</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151; </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>331,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>331,720</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>843,440 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Upon
termination without cause or resignation for good reason, the employee is generally entitled to a lump sum payment equal to 100% (200% in the case of
Mr.&nbsp;Marucci only) of the employee's then annual base salary, continuation of certain employee benefits and 25% accelerated vesting of any unvested equity awards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
employee is generally entitled to accelerated vesting of any unvested equity awards (as defined in the employment agreement) and a lump sum cash payment equal to
twenty-four (24)&nbsp;times the executive's highest monthly base compensation (not including bonus) during the twenty-four month </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=35,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=718677,FOLIO='33',FILE='DISK105:[17ZAE1.17ZAE16401]DK16401A.;5',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dk16401_1_34"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
<UL>

<P style="font-family:times;"><FONT SIZE=2>period
preceding the date of termination plus 150% (200% in the case of Mr.&nbsp;Marucci only) of the highest one-year annual bonus actually received by the executive during the two full fiscal
years preceding the date of termination in the event of termination without cause or resignation "for good reason" by the executive within one year immediately following a change in control (as
defined in the employment agreement).  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
value of each share subject to an option to purchase common stock that would be accelerated in the circumstances described above equals $3.54 per share (the
closing price on the last trading day of 2016), minus the exercise price per share;  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk16401_director_compensation"> </A>
<A NAME="toc_dk16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Director Compensation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective June 2016, Directors who are not our employees are each entitled to receive a retainer fee of $45,000 each fiscal year ("Annual
Retainer"). The Chairman of the Board is entitled to receive an annual retainer fee of $40,000 in addition to his or her Annual Retainer and any
retainer for committee service. The Chairperson of the Audit Committee of the Board of Directors is entitled to receive an annual retainer fee of $30,000 in addition to his or her Annual Retainer. The
Chairperson of the Compensation and Nominating and Corporate Governance Committees of the Board of Directors is entitled to receive an annual retainer fee of $25,000 in addition to his or her Annual
Retainer. Each committee member (other than the Chairperson of a committee) will receive an annual retainer of $15,000 in addition to his or her Annual Retainer. Stipends and retainers are paid in
advance on a quarterly basis. The Directors shall be reimbursed for necessary travel and business expenses as incurred but will not receive any additional fees for attending meetings or calls of the
Board of Directors. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;New
board members receive an initial stock option grant to purchase 8,000 shares of the Company's common stock upon joining the Board. In 2016, all non-employee directors received
(i)&nbsp;an annual grant of 10,000 shares of restricted stock each year and (ii)&nbsp;an annual stock option grant to purchase 15,000 shares of the Company's common stock following the Annual
Meeting of Stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2016, our non-employee directors had the following stock options outstanding: Larry Ellberger&#151;41,300, Herbert J. Conrad&#151;59,179, George
O. Elston&#151;59,179, Gerald McMahon&#151;8,000, Harry H. Penner, Jr.&#151;41,300 and Karen L. Shoos&#151;41,300. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table summarizes the annual compensation for our non-employee directors during 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="39pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="68pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned or<BR>
Paid in Cash<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Non-Equity<BR>
Incentive Plan<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value and<BR>
Nonqualified<BR>
Deferred<BR>
Compensation<BR>
Earnings </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Larry Ellberger</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>113,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>208,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>170,706</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George O. Elston(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>81,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>175,706</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gerald McMahon</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>20,062</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>29,687</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>78,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>173,206</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>77,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>171,956</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard A. van den Broek(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>68,069</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,256</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>162,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts in the Stock Awards column reflect the grant date fair value in accordance with U.S.&nbsp;GAAP of restricted stock awards made in 2016 to each of our
non-employee directors for awards pursuant to the 2008 Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of
forfeiture (so long </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=36,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=662632,FOLIO='34',FILE='DISK105:[17ZAE1.17ZAE16401]DK16401A.;5',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_dk16401_1_35"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>as
the director remains a member of the Board as of such date). For a discussion regarding the valuation of our stock awards for financial statement reporting purposes, please refer to Note&nbsp;2
in the Notes to the Financial Statements contained in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016. These amounts do not represent the actual amounts paid to the
directors or the actual value that may be realized by the directors for these awards during the year ended December&nbsp;31, 2016.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
amounts in the Option Awards column reflect the grant date fair value in accordance with U.S.&nbsp;GAAP of stock option awards made in 2016 to each of our
non-employee directors for awards pursuant to the 2008 Plan subject to a vesting schedule whereby an equal number of the shares of common stock shall become vested and no longer be subject to risk of
forfeiture (so long as the director remains a member of the Board as of such date). For a discussion regarding the valuation of our stock option awards for financial statement reporting purposes,
please refer to Note&nbsp;2 in the Notes to the Financial Statements contained in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016. These amounts do not represent
the actual amounts paid to the directors or the actual value that may be realized by the directors upon exercise of such stock options.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Mr.&nbsp;Elston's
term as director will expire at the 2017 Annual Meeting.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>On
December&nbsp;14, 2016, Mr.&nbsp;van den Broek resigned from the Board, effective immediately, due to increasing responsibilities in other endeavors. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, on November&nbsp;28, 2016, in connection with Dr.&nbsp;McMahon's employment separation with Kolltan Pharmaceuticals,&nbsp;Inc., we entered into a severance agreement
with Dr.&nbsp;McMahon whereby we agreed to pay Dr.&nbsp;McMahon up to 267,356 shares of our common stock less required tax and other withholdings. To date, 64,667 shares of common stock were
issued to Dr.&nbsp;McMahon, 35,796 shares have been withheld to satisfy tax withholdings and the remaining 166,893 shares of common stock, less applicable withholdings, are issuable to
Dr.&nbsp;McMahon in equal monthly installments through December 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk16401_compensation_committee__dk102479"> </A>
<A NAME="toc_dk16401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  Compensation Committee Interlocks and Insider Participation    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee of the Board of Directors is currently composed of the following three non-employee directors: James J. Marino,
Chair, Herbert J. Conrad and Harry H. Penner, Jr. None of these Compensation Committee members was an officer or employee of us during the year. No Compensation Committee interlocks between us and
another entity existed. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dk16401_risk_considerations"> </A>
<A NAME="toc_dk16401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  Risk Considerations    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not believe that our compensation practices and policies for our employees, including our executive officers, create risks or are likely
to create risks that are reasonably likely to have a material adverse effect on our results of operations or financial condition. The Compensation Committee considered our strategic goals and
operational practices and evaluated our incentive program design to assess whether these programs foster a business environment that might drive inappropriate decision-making or behavior. We are a
biopharmaceutical company that is generating a pipeline of drug candidates to treat cancer and other difficult-to-treat diseases and do not yet generate earnings. While a significant portion of our
executives' compensation is performance-based, we believe several features of our program mitigate inappropriate or excessive risk-taking that could harm shareholder value: we set performance goals
that we believe are reasonable and set targets with payouts at multiple levels of performance, rather than an "all or nothing" approach. As discussed above in our Compensation Discussion and Analysis
section we use a mix of performance goals in our annual and long-term incentive programs to align incentive compensation with a broad set of measures important to the creation of shareholder value. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=37,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1002616,FOLIO='35',FILE='DISK105:[17ZAE1.17ZAE16401]DK16401A.;5',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_do16401_1_36"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do16401_compensation_committee_report"> </A>
<A NAME="toc_do16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE REPORT*    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis with management and based on such review and
discussion of the Compensation Discussion and Analysis, the Compensation Committee recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement. </FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Compensation
Committee:<BR>
James J. Marino, Chair<BR>
Herbert J. Conrad<BR>
Harry H. Penner, Jr. </FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>

<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
foregoing report of the Compensation Committee is not to be deemed "filed" with the SEC (irrespective of any general incorporation language in any document filed
with the SEC) or subject to Regulation&nbsp;14A of the Securities Exchange Act of 1934, as amended, or to the liabilities of Section&nbsp;18 of the Securities Exchange Act of 1934, except to the
extent we specifically incorporate it by reference into a document filed with the SEC. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=38,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=679963,FOLIO='36',FILE='DISK105:[17ZAE1.17ZAE16401]DO16401A.;6',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dq16401_1_37"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq16401_report_of_the_audit_committee"> </A>
<A NAME="toc_dq16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF THE AUDIT COMMITTEE*    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The undersigned members of the Audit Committee of the Board of Directors of Celldex submit this report in connection with the committee's review
of the financial reports for the fiscal year ended December&nbsp;31, 2016 as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has reviewed and discussed with management the audited financial statements for Celldex for the fiscal year ended December&nbsp;31, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has discussed with representatives of PricewaterhouseCoopers&nbsp;LLP the matters which are required to be discussed with them under the
provisions of Auditing Standard No.&nbsp;1301, </FONT><FONT SIZE=2><I>Communications with Audit Committees</I></FONT><FONT SIZE=2>. That Auditing Standard requires the auditors to ensure that the
Audit Committee received information regarding the scope and results of the audit.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
Audit Committee has discussed with PricewaterhouseCoopers&nbsp;LLP, the independent registered public accounting firm, the auditors' independence from
management and Celldex including the matters in the written disclosures and the letter from the independent auditors required by PCAOB Rule&nbsp;3526. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the Audit Committee considered whether the provision of tax or other non-audit services by PricewaterhouseCoopers&nbsp;LLP is compatible with maintaining its independence.
In reliance on the reviews and discussions referred to above, the Audit Committee recommended to the Board of Directors (and the Board of Directors has approved) that the audited financial statements
be included in Celldex's Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016 for filing with the Securities and Exchange Commission. </FONT></P>

<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Audit
Committee:<BR>
George O. Elston, Chair<BR>
Larry Ellberger<BR>
Harry H. Penner, Jr. </FONT></P>

</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
</UL>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>The
foregoing report of the Audit Committee is not to be deemed "soliciting material" or deemed to be "filed" with the Securities and Exchange Commission (irrespective
of any general incorporation language in any document filed with the Securities and Exchange Commission) or subject to Regulation&nbsp;14A of the Securities Exchange Act of 1934, as amended, or to
the liabilities of Section&nbsp;18 of the Securities Exchange Act of 1934, except to the extent we specifically incorporate it by reference into a document filed with the Securities and Exchange
Commission. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=39,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=639946,FOLIO='37',FILE='DISK105:[17ZAE1.17ZAE16401]DQ16401A.;6',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ds16401_1_38"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Security Ownership of Certain Beneficial Owners and Management  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information as of April&nbsp;10, 2017 with respect to the beneficial ownership of common stock of the
Company by the following: (i)&nbsp;each of the Company's current directors; (ii)&nbsp;each of the director nominees; (iii)&nbsp;each of the Named Executive Officers; (iv)&nbsp;the current
executive officers; (v)&nbsp;all of the executive officers and directors as a group; and (vi)&nbsp;each person known by the Company to own beneficially more than five percent (5%) of the
outstanding shares of the Company's common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the following table, beneficial ownership is determined in accordance with the applicable SEC rules and the information is not necessarily indicative of beneficial
ownership for any other purpose. Except as otherwise noted in the footnotes to the table, we believe that each person or entity named in the table has sole voting and investment power with respect to
all shares of the Company's common stock shown as beneficially owned by that person or entity (or shares such power with his or her spouse). Under the SEC's rules, shares of the Company's common stock
issuable under options that are exercisable on or within 60&nbsp;days after April&nbsp;10, 2017 ("Presently Exercisable Options") are deemed outstanding and therefore included in the number of
shares reported as beneficially owned by a person or entity named in the table and are used to compute the percentage of the common stock beneficially owned by that person or entity. These shares are
not, however, deemed outstanding for computing the percentage of the common stock beneficially owned by any other person or entity. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=475159,FOLIO='38',FILE='DISK105:[17ZAE1.17ZAE16401]DS16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_ds16401_1_39"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
percentage of the common stock beneficially owned by each person or entity named in the following table is based on 125,104,714 shares of common stock outstanding as of
April&nbsp;10, 2017 plus any shares issuable upon exercise of Presently Exercisable Options held by such person or entity. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="93pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="84pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Business Address of Beneficial Owners*

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Amount and Nature<BR>
of Beneficial<BR>
Ownership(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage of<BR>
Common Stock(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>5% Holders</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FMR&nbsp;LLC<BR>
245 Summer Street<BR>
Boston, MA 02210</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>19,330,211</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>15.5</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>BlackRock,&nbsp;Inc.<BR>
55 East 52<SUP>nd</SUP>&nbsp;Street<BR>
New York, NY 10055</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>7,889,061</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>6.3</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The Vanguard Group<BR>
100 Vanguard Blvd.<BR>
Malvern, PA 19355</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>7,788,557</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>6.2</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>KLP Enterprises,&nbsp;LLC<BR>
35 Windsor Road,<BR>
North Haven, CT 06473</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>6,865,006</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(6)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>5.5</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Franklin Resources,&nbsp;Inc.<BR>
One Franklin Parkway<BR>
San Mateo, CA 94403-1906</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>6,233,265</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(7)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>5.0</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Columbia Wanger Asset Management,&nbsp;LLC<BR>
227 West Monroe Street, Suite&nbsp;3000<BR>
Chicago, IL 60606</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>6,195,855</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(8)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>5.0</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>Directors and Executive Officers</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Keith L. Brownlie</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Avery W. Catlin</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>519,559</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(9)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Herbert J. Conrad</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>70,962</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(10)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Elizabeth Crowley</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>176,758</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(11)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Thomas Davis, M.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>833,495</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(12)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Larry Ellberger</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>88,083</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(13)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>George Elston</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>70,962</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(14)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tibor Keler, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>936,013</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(15)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Theresa LaVallee, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Anthony S. Marucci</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1,773,823</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(16)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>1.4</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>James J. Marino</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>15,997</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Gerald McMahon, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>231,560</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(17)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Harry H. Penner, Jr.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>56,499</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(18)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ronald Pepin, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>400,374</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(19)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Karen L. Shoos</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>56,416</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(20)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Richard Wright, Ph.D</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>101,560</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>(21)</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>**</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><I>All Directors and Executive Officers as a group (16&nbsp;persons)</I></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5,332,061</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(22)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.1</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, the address is c/o Celldex Therapeutics,&nbsp;Inc., Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, NJ 08827.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>**</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Less
than 1%. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=577347,FOLIO='39',FILE='DISK105:[17ZAE1.17ZAE16401]DS16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_ds16401_1_40"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Unless
otherwise indicated, the persons shown have sole voting and investment power over the shares listed.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Common
stock includes all outstanding common stock plus, as required for the purpose of determining beneficial ownership (in accordance with Rule&nbsp;13d-3(d)(1)
of the Securities Exchange Act of 1934, as amended), all common stock subject to any right of acquisition, through exercise or conversion of any security, within 60&nbsp;days of the record date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
solely on information set forth in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;14, 2017 by FMR&nbsp;LLC ("FMR") reporting that FMR:
(i)&nbsp;beneficially owned 19,330,211 shares, including 7,827,066 shares held in the name of Fidelity Select Biotechnology Portfolio.; (ii)&nbsp;had the sole power to dispose or direct the
disposition of 19,330,211 shares; and (iii)&nbsp;had the sole power to vote or to direct the vote of 1,911,665 shares. In addition, the Schedule&nbsp;13G/A shows that the following entities
beneficially own certain of the shares reported: FMR&nbsp;Co.,&nbsp;Inc. (beneficially owns 5% or more) and Fidelity Institutional Asset Management Trust Company. The Schedule&nbsp;13G/A also
shows that Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of&nbsp;FMR. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners,
directly or through trusts, of Series&nbsp;B voting common shares of FMR, representing 49% of the voting power of FMR. The Johnson family group and all other Series&nbsp;B shareholders have
entered into a shareholders' voting agreement under which all Series&nbsp;B voting common shares will be voted in accordance with the majority vote of Series&nbsp;B voting common shares.
Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of
1940, to form&nbsp;a controlling group with respect to FMR. Neither FMR nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment
companies registered under the Investment Company Act (the "Fidelity Funds"), advised by Fidelity Management&nbsp;&amp; Research Company, a wholly-owned subsidiary of FMR, which power resides with the
Fidelity Funds' Board of Trustees. Fidelity Management&nbsp;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity Funds' Board of Trustees.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
solely on information set forth in a Schedule&nbsp;13G/A filed with the SEC by BlackRock,&nbsp;Inc. on January&nbsp;23, 2017 reporting sole power to vote
or direct the vote over 7,680,798 shares and the sole power to dispose or to direct the disposition of 7,889,061 shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
solely on information set forth in a Schedule&nbsp;13G/A filed with the SEC by The Vanguard Group on February&nbsp;10, 2017, reporting sole power to vote
or direct the vote over 116,747 shares, shared power to vote or direct the vote over 4,641 shares, sole power to dispose or to direct the disposition of 7,672,269 shares and shared dispositive power
over 116,288 shares. The shares reported include 111,647 shares held by Vanguard Fiduciary Trust Company, a wholly-owned subsidiary of The Vanguard Group,&nbsp;Inc. and 9,741 shares held by Vanguard
Investments Australia,&nbsp;Ltd., a wholly-owned subsidiary of The Vanguard Group,&nbsp;Inc.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
solely on information set forth in a Schedule&nbsp;13G filed with the SEC by KLP Enterprises,&nbsp;LLC on December&nbsp;9, 2016 reporting shared voting
and dispositive power with regard to 6,865,006 shares. As the manager of KLP Enterprises,&nbsp;LLC, Andrew D. Wingate may be deemed to share beneficial ownership with respect to shares held by KLP
Enterprises,&nbsp;LLC. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=671505,FOLIO='40',FILE='DISK105:[17ZAE1.17ZAE16401]DS16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_ds16401_1_41"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
solely on information set forth in a Schedule&nbsp;13G/A filed with the SEC by Franklin Resources,&nbsp;Inc. on February&nbsp;9, 2017, reporting that
Franklin Advisers,&nbsp;Inc. has the sole power to vote or direct the vote over 6,200,365 shares and has sole power to dispose or direct the disposition of 6,200,365 shares and Fiduciary Trust
Company International has the sole power to vote or direct the vote over 32,900 shares and the sole power to dispose or direct the disposition of 32,900 shares. The securities are beneficially owned
by one or more open- or closed-end investment companies or other managed accounts that are investment management clients of investment managers that are direct and indirect subsidiaries (each, an
"Investment Management Subsidiary" and, collectively, the "Investment Management Subsidiaries") of Franklin Resources&nbsp;Inc. ("FRI"). The voting and investment powers held by Franklin Mutual
Advisers,&nbsp;LLC ("FMA"), an indirect wholly-owned Investment Management Subsidiary, are exercised independently from FRI and from all other Investment Management Subsidiaries. Charles B. Johnson
and Rupert&nbsp;H. Johnson, Jr. (the "Principal Shareholders") each own in excess of 10% of the outstanding common stock of FRI and are the principal stockholders of FRI. FRI, the Principal
Shareholders and each of the Investment Management Subsidiaries believe that they are not acting as a "group" and that the shares held by each other need not be aggregated for purposes of
Section&nbsp;13(d).
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Based
solely on information set forth in a Schedule&nbsp;13G filed with the SEC by Columbia Wagner Asset Management,&nbsp;LLC (CWAM) on February&nbsp;10, 2017
reporting that CWAM beneficially owns 6,195,855 shares, of which 6,019,590 shares are held by Columbia Acorn Fund and the remaining shares are held by various other funds or accounts managed
by&nbsp;CWAM. CWAM does not directly own any shares of common stock of the issuer. As the investment adviser of Columbia Acorn Fund and various other investment companies and managed accounts, CWAM
may be deemed to beneficially own the shares reported herein by Columbia Acorn Fund and by various other funds or accounts managed by&nbsp;CWAM. CWAM disclaims beneficial ownership of any shares
reported herein.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
430,527 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
49,129 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
169,436 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
825,127 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
31,250 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
49,129 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
917,145 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
1,721,391 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(17)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>On
November&nbsp;28, 2016, in connection with Dr.&nbsp;McMahon's employment separation with Kolltan Pharmaceuticals,&nbsp;Inc., we entered into a severance
agreement with Dr.&nbsp;McMahon whereby we agreed to pay Dr.&nbsp;McMahon up to 267,356 shares of our common stock less </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=927349,FOLIO='41',FILE='DISK105:[17ZAE1.17ZAE16401]DS16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_ds16401_1_42"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <UL>

<P style="font-family:times;"><FONT SIZE=2>required
tax and other withholdings. To date, 64,667 shares of common stock were issued to Dr.&nbsp;McMahon, 35,796 shares have been withheld to satisfy tax withholdings and the remaining 166,893
shares of common stock, less applicable withholdings, are issuable to Dr.&nbsp;McMahon in equal monthly installments through December 2018.  </FONT></P>

</UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(18)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
31,250 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(19)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
400,374 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(20)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
31,250 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(21)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
101,560 shares of common stock underlying options which are or may be exercisable as of April&nbsp;10, 2017 or 60&nbsp;days after such date.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(22)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Please
refer to footnotes 9&nbsp;-&nbsp;21.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Section&nbsp;16(a) Beneficial Ownership Reporting Compliance  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Securities Exchange Act of 1934, as amended, requires Celldex's directors and executive officers, and persons who
are beneficial owners of more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the Securities and Exchange Commission (the "SEC").
These persons are required by SEC regulations to furnish us with copies of all Section&nbsp;16(a) forms they file. To our knowledge, based solely on a review of the copies of such reports furnished
to us and written representations that no other reports were required during the fiscal year ended December&nbsp;31, 2016, all reports required to be filed under Section&nbsp;16(a) were filed on a
timely basis. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transactions with Related Persons  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;It is our policy that all employees and directors, as well as their family members, must avoid any activity that is or has the appearance of
conflicting with Celldex's business interest. This policy is included in our Code of Business Conduct and Ethics. All directors and officers of Celldex complete a directors and officers questionnaire
at the beginning of each year, in which they are asked to disclose family relationships and other related party transactions. Our Audit Committee must review and approve all related party
transactions, as defined in Item&nbsp;404 of Regulation&nbsp;S-K. Our Audit Committee's procedures for reviewing related party transactions are not in writing. Other than
compensation arrangements for our Named Executive Officers and directors, which are described in the section entitled "Executive Compensation," since January&nbsp;1, 2016, there have been no
transactions or series of similar transactions to which we were a party or will be a party, in which:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amounts involved exceeded or will exceed $120,000; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any of our directors, executive officers or holders of more than 5% of our capital stock, or any member of the immediate family of the
foregoing persons, had or will have a direct or indirect material interest. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE<BR>
FOR THE ELECTION OF THE DIRECTOR NOMINEES</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=44,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=863081,FOLIO='42',FILE='DISK105:[17ZAE1.17ZAE16401]DS16401A.;12',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_du16401_1_43"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="du16401_proposal_2__ratify_the_appoint__pro06313"> </A>
<A NAME="toc_du16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 2: RATIFY THE APPOINTMENT OF<BR>  PRICEWATERHOUSECOOPERS&nbsp;LLP AS OUR INDEPENDENT REGISTERED<BR>  PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017    <BR>    <BR>    (Proposal No.&nbsp;2)    <BR>
 </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit Committee has reappointed PricewaterhouseCoopers&nbsp;LLP as our independent registered public accounting firm to audit the
financial statements of the Company for the fiscal year ending December&nbsp;31, 2017, and has further directed that management submit their selection of independent registered public accounting
firm for ratification by our stockholders at the Annual Meeting of Stockholders. A representative of PricewaterhouseCoopers&nbsp;LLP is expected to attend the Annual Meeting and will have an
opportunity to make a statement, if he or she desires, and will be available to respond to appropriate questions. Neither the accounting firm nor any of its members have any direct or indirect
financial interest in or any connection with us in any capacity other than as public registered accounting firm. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Principal Accountant Fees and Services  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table summarizes the fees for professional services rendered by PricewaterhouseCoopers&nbsp;LLP, our independent registered
public accounting firm, for each of the last two fiscal years: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="13pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Fee Category

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=1><B>(In thousands)</B></FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>856</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>603</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit-Related Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>254</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>938</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>873 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Represents fees, including out of pocket expenses, for professional services provided in connection with the audit of our annual audited
financial statements and of our internal control over financial reporting, the review of our quarterly financial statements included in our Forms&nbsp;10-Q, accounting consultations or advice on
accounting matters necessary for the rendering of an opinion on our financial statements, services provided in connection with the offerings of our common stock and audit services provided in
connection with other statutory or regulatory filings. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Audit-Related Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit-related fees are for assurance and other activities not explicitly related to the audit of our financial statements including due
diligence in connection with the Kolltan acquisition. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax fees are associated with tax compliance and tax planning related activities. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


All Other Fees  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All other fees consist of fees relating to an accounting research tool. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is responsible for appointing, setting compensation and overseeing the work of the independent auditors. The Audit Committee has established a policy regarding
pre-approval of </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=45,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=719477,FOLIO='43',FILE='DISK105:[17ZAE1.17ZAE16401]DU16401A.;5',USER='CHE106465',CD='24-APR-2017;09:47' -->
<A NAME="page_du16401_1_44"> </A>

<P style="font-family:times;"><FONT SIZE=2>all
auditing services and the terms thereof and non-audit services (other than non-audit services prohibited under Section&nbsp;10A(g) of the Exchange Act or the applicable rules of the SEC or the
Public Company Accounting Oversight Board) to be provided to Celldex by the independent auditor. However, the pre-approval requirement may be waived with respect to the provision of non-audit services
for Celldex if the "de minimus" provisions of Section&nbsp;10A(i)(1)(B) of the Exchange Act are satisfied. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee has considered whether the provision of Audit-Related Fees, Tax Fees, and All Other Fees as described above is compatible with maintaining
PricewaterhouseCoopers&nbsp;LLP's independence and has determined that such services for fiscal years 2016 and 2015 were compatible. All such services were approved by the Audit Committee pursuant
to Rule&nbsp;2-01 of Regulation&nbsp;S-X under the Exchange Act to the extent that rule was applicable. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee is responsible for reviewing and discussing the audited financial statements with management, discussing with the independent registered public accountants the
matters required in Auditing Standards No.&nbsp;1301, receiving written disclosures from the independent registered public accountants required by the applicable requirements of the Public Company
Accounting Oversight
Board regarding the independent registered public accountants' communications with the Audit Committee concerning independence and discussing with the independent registered public accountants their
independence, and recommending to the Board of Directors that the audit financial statements be included in our annual report on Form&nbsp;10-K. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE<BR>
FOR THE RATIFICATION OF THE INDEPENDENT REGISTERED PUBLIC<BR>
ACCOUNTING FIRM  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=46,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=322665,FOLIO='44',FILE='DISK105:[17ZAE1.17ZAE16401]DU16401A.;5',USER='CHE106465',CD='24-APR-2017;09:47' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dw16401_1_45"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dw16401_proposal_3__approval,_in_accor__pro01135"> </A>
<A NAME="toc_dw16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 3: APPROVAL, IN ACCORDANCE WITH THE APPLICABLE RULES OF THE NASDAQ STOCK MARKET, OF THE ISSUANCE OF SHARES OF OUR COMMON STOCK IN CONNECTION WITH MILESTONE PAYMENTS THAT MAY  BECOME PAYABLE IN THE FUTURE TO
FORMER SECURITYHOLDERS OF KOLLTAN PHARMACEUTICALS,&nbsp;INC.    <BR>    <BR>    (Proposal No.&nbsp;3)    <BR>
</B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Background of the Proposal  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our acquisition of Kolltan Pharmaceuticals,&nbsp;Inc. (the "Kolltan Acquisition") was consummated on November&nbsp;29, 2016 (the "Closing").
The terms of the Kolltan Acquisition require us to pay certain Milestone Payments (as defined and described below) to the former stockholders of Kolltan upon achievement of certain preclinical and
clinical development milestones related to Kolltan's development programs and/or Celldex's development programs and certain commercial milestones related to Kolltan's product candidates after the
Closing. The Milestone Payments may be paid, at our sole election, in cash, in shares of our common stock or a combination of both (except
with respect to non-accredited former shareholders of Kolltan to whom we will pay cash). We are submitting this Proposal 3 to you in order to obtain the requisite stockholder authorization in
accordance with NASDAQ Marketplace Rules so that we may make the Milestone Payments in shares of our common stock, if we so choose, as more fully described below. Although the proposal to approve the
issuance of shares of our common stock to make Milestone Payments that become payable to the former stockholders of Kolltan is related to the Kolltan Acquisition, you will not be voting to approve the
Kolltan Acquisition, because it has already been completed. Your vote only relates to whether any Milestone Payments, which may become due, are made only in cash, or whether the Company has the
flexibility to make such payments in cash or stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms of Kolltan Acquisition  </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As previously reported, on November&nbsp;1, 2016, we entered into the Merger Agreement with Kolltan, two of our wholly-owned subsidiaries, and
Shareholder Representative Services&nbsp;LLC, solely in its capacity as the Stockholders Representative (together with its permitted successors, the "Stockholders Representative") pursuant to which
we acquired Kolltan Pharmaceuticals,&nbsp;Inc. ("Kolltan"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Kolltan Acquisition closed on November&nbsp;29, 2016. In addition, capitalized terms used in this "</FONT><FONT SIZE=2><I>Terms of Kolltan Acquisition</I></FONT><FONT SIZE=2>"
section without definition shall have the meanings ascribed to such terms in the Merger Agreement. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Aggregate Merger Consideration  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the terms of the Merger Agreement, at the Closing we agreed to pay the following consideration to the former Kolltan
securityholders: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>An
aggregate of 18,257,996 shares of our common stock to former Kolltan securityholders and an aggregate of 437,901 shares of our common stock to certain officers of
Kolltan in lieu of cash severance obligations (the "Closing Merger Consideration").
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>If
earned after the Closing, certain Milestone Payments in an amount of up to $172.5&nbsp;million in the aggregate, payable in shares of our common stock or cash,
in our sole discretion (except with respect to non-accredited former shareholders of Kolltan to whom we will pay cash), in the event of the achievement of certain preclinical and clinical development
milestones related to Kolltan's development programs and/or Celldex's development programs and certain commercial milestones related to Kolltan's product candidates (each a </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=47,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=758273,FOLIO='45',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dw16401_1_46"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>"Milestone")
(such payments, the "Milestone Payments", and together with the Closing Merger Consideration, the "Merger Consideration"). The Milestone Payments that may become payable after Closing
(including the relevant payment procedures) are described in greater particularity under the caption "Mechanics of Milestone Payments" below. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Merger Consideration as provided in the Merger Agreement was negotiated at arms' length between the parties. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Payment of Closing Merger Consideration  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the Merger Agreement, at the Closing, we issued 18,257,996 shares of our common stock to former Kolltan securityholders. In
addition, we agreed to issue an aggregate of 437,901 shares of our common stock to certain officers of Kolltan, less required tax withholding, in lieu of cash severance obligations, of which 175,778
shares have been issued to date. The remaining shares, less required tax withholding, are issuable in equal monthly installments through December 2018. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=48,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1004989,FOLIO='46',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dw16401_1_47"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Mechanics of Milestone Payments  </I></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions of the Merger Agreement, upon the achievement of each of the milestones specified below, we will be required
to pay to the former Kolltan stockholders the Milestone Payment specified: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="64%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="32%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Milestone

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Dollar Amount of<BR>
Milestone Payment<BR> </B></FONT><FONT SIZE=1><B><I>(payable in stock or cash, in<BR>
Celldex's discretion)</I></B></FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Successful Completion of a Phase&nbsp;I Clinical Trial for KTN0158</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>$25.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Successful Completion of a Phase&nbsp;II Clinical Trial for KTN3379 or KTN0158, whichever occurs first</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$20.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>The TAM Program progresses into IND Enabling Studies but in no event prior to Successful Completion of a toxicology study in
non-human primates</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$10.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initiation of a Phase&nbsp;II(b) Clinical Trial for Varlilumab under a Partnership Agreement</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$15.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Successful Completion of the METRIC Study, but in no event prior to the entering into of a Partnership Agreement for
world-wide rights or rights in either or both of the United States or the European Union with respect to the study compound</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$10.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Initiation of a Phase&nbsp;II Clinical Trial for any Celldex Early Stage Compound</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$10.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>First FDA or EMA Marketing Approval of a Surviving Company Product in the U.S. or a European Market, as
applicable</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$50.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Achievement of $200&nbsp;million in Annual Net Sales for a Kolltan Product (the "First Kolltan Commercial Milestone") net of
any Third-Party Payments made by Celldex, its Affiliates or its Product Transferees in connection with such Kolltan Products</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>$25.0&nbsp;million</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>In the event that Celldex or Surviving Company enters into or closes one or more Partnership Agreements with respect to the TAM Program
(each, a "TAM Partnership") within eighteen&nbsp;(18)&nbsp;months after the Closing, or in the event that Celldex or Surviving Company enters into or closes one or more TAM Partnerships within the six (6)&nbsp;months immediately thereafter with a
third party with whom Celldex or the Surviving Company was in negotiations or discussions during the initial eighteen (18)&nbsp;month period, then the Stockholders shall receive:</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>payment equal to fifty percent&nbsp;(50%) of any Upfront Payments received by Celldex or its Affiliates under the terms of
each TAM Partnership; provided, however, that any such payments shall not exceed $10.0&nbsp;million in the aggregate</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Milestone Payment shall be payable only once, upon the first occurrence of the applicable Milestone. In addition, the first Milestone Payment to be paid (i)&nbsp;will be
accompanied by payment of any Closing Shortfall and (ii)&nbsp;will be reduced by $2.5&nbsp;million. We are required to notify the Stockholders Representative within 10 business days of the
achievement of a Milestone (the "Milestone Date"), provided that, with respect to the First Kolltan Commercial Milestone, such notice is due within 30&nbsp;days of the end of the calendar month in
which the First Kolltan Commercial Milestone is achieved. We may pay each Milestone Payment in cash, shares of our common stock or a combination thereof, in our sole discretion. Shares of our common
stock included in a Milestone Payment shall be valued at the Parent Stock Value as of the relevant Milestone Date. For purposes of the Merger </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=49,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=629168,FOLIO='47',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dw16401_1_48"> </A>

<P style="font-family:times;"><FONT SIZE=2>Agreement,
"Parent Stock Value" means the average of the closing sale prices per share of our common stock as reported on the NASDAQ (or other national exchange upon which the our common stock is then
listed) for the five (5)&nbsp;trading day period ending three (3)&nbsp;calendar days prior to the date such Milestone is achieved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Merger Agreement provides that notwithstanding our discretion to pay each Milestone Payment in cash, shares or a combination thereof, we agree to use commercially reasonable efforts
to cause a sufficient portion of each Milestone Payment and any other payment due to former Kolltan stockholders under the Merger Agreement to be paid in shares of our common stock such that the
transactions consummated by the Merger Agreement will satisfy the "continuity of interest" requirements set forth in Treasury Regulation Section&nbsp;1.368-1(e) and other applicable law. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Need for Stockholder Approval  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the NASDAQ Global Market, and we are subject to the NASDAQ listing standards set forth in its Marketplace Rules.
Although we were not required to obtain stockholder approval in connection with the issuance of the Closing Merger Consideration because the shares of our common stock issued at Closing constituted
less than 20% of our outstanding shares, we are required under Marketplace Rule&nbsp;5635(a) to seek stockholder approval for the issuance of shares of common stock in connection with the Milestone
Payments as further described below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ
Marketplace Rule&nbsp;5635(a) requires stockholder approval prior to the issuance of securities in connection with the acquisition of the stock or assets of another company,
including pursuant to an "earn-out" or similar provision, where due to the present or potential issuance of common stock (or securities convertible into or exercisable for common stock), other than a
public offering for cash, the common stock to be issued (a)&nbsp;constitutes voting power in excess of 20% of the outstanding voting power prior to the issuance or (b)&nbsp;is or will be in excess
of 20% of the outstanding common stock prior to the issuance. The shares issued as the Closing Merger Consideration did not constitute more than 20% of our total shares of common stock outstanding, so
we were not required to obtain stockholder approval for the issuance of these shares. The Closing Merger Consideration constituted an amount of our common stock equivalent to approximately 18.5% of
our outstanding common stock as of the November&nbsp;1, 2016, the execution date of the Merger Agreement. The issuance of additional shares of common stock to former Kolltan stockholders in
connection with the Milestone Payments would be aggregated with the shares we issued as Closing Merger Consideration for purposes of NASDAQ Marketplace Rule&nbsp;5635(a). Accordingly, issuing
additional shares of common stock as Milestone
Payments to the former Kolltan stockholders may result in the aggregate number of shares issued by us in connection with the Kolltan Acquisition exceeding 20% of our total shares outstanding prior to
the Kolltan Acquisition. Therefore, we are requesting stockholder approval for Proposal 3 under this NASDAQ listing standard to ensure that we have stockholder approval to issue shares of common stock
as Milestone Payments to the extent that any such shares issued, when aggregated with shares previously issued in connection with the Kolltan Acquisition, exceed 20% of our common stock outstanding
prior to the Kolltan Acquisition. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Merger Agreement, we agreed to seek stockholder approval at our stockholders meeting next following the execution of the Merger Agreement for the potential issuance of
shares of our common stock pursuant to the Merger Agreement in excess of 19.99% of our outstanding shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the Marketplace Rules of the NASDAQ Stock Market, the 18,257,996 shares issued to the former Kolltan securityholders and any part of the 437,901 shares issued to certain
former Kolltan officers in lieu of cash severance obligations are not entitled to vote on this Proposal 3 and are not counted in determining votes cast for purposes of this Proposal 3. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=50,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=364005,FOLIO='48',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dw16401_1_49"> </A>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Consequences if Proposal 3 is Approved  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Proposal 3 is approved and we obtain stockholder authorization to issue in connection with the Kolltan Acquisition shares of common
stock in excess of 20% of our outstanding shares, and (i)&nbsp;assuming all $172.5&nbsp;million of Milestone Payments were to become payable, (ii)&nbsp;further assuming we elected to pay all
such Milestone Payments in shares of our common stock, and (iii)&nbsp;further assuming a market price of $3.30, based on the closing price of our common stock on April&nbsp;10, 2017, then, we
would issue to the former stockholders of Kolltan in connection with such Milestone Payments an aggregate of 52,272,727 shares of our common stock, or approximately 42% of our outstanding shares as of
April&nbsp;10, 2017. The actual number of shares that may become issuable as Milestone Payments will depend on multiple factors including the Milestones that are actually achieved, the amount of the
corresponding Milestone Payments that we elect to pay in shares of our common stock, and the market price of our common stock at the time that we pay the corresponding Milestone Payment in shares of
our common stock. For purposes of the Milestone Payments, our common stock will be valued at the average of the closing sale prices per share of our common stock as reported on the NASDAQ (or other
national exchange upon which our common stock is then listed) for the five (5)&nbsp;trading day period ending three (3)&nbsp;calendar days prior to the date such Milestone is achieved. While we
believe that having the ability to pay Milestone Payments in shares of common stock offers benefits to the Company and its stockholders, including conservation of cash, the payment of Milestone
Payments in shares of common stock may cause substantial dilution to the equity interest of our current stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Certain Consequences if Proposal 3 is Not Approved  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If this Proposal 3 is not approved by the stockholders, we would not be able to make Milestone Payments in shares of common stock to the extent
Milestones are achieved because that would result in stock payments when aggregated with the shares issued as Closing Merger Consideration in excess of 20% of our outstanding shares prior to the
Kolltan Acquisition. In such event, we would need to make the Milestone Payments in cash, in order to maintain compliance with applicable NASDAQ listing requirements. We expect we would need to raise
additional financing if we decide to make the Milestone Payments in cash to the extent any Milestones are achieved. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Furthermore,
in the event this proposal is not approved, we intend to solicit such approval at next year's annual meeting. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of the Common Stock That May Be Issued In Connection With Milestone Payments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following summary description of the material features of our common stock is qualified in its entirety by reference to the applicable
provisions of Delaware law, and also by reference to our amended and restated certificate of incorporation, as amended, our bylaws, and the instruments governing our securities that are exercisable
for or convertible into shares of our common stock, which are on file with the Securities and Exchange Commission. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General; Shares Outstanding  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the NASDAQ Global Market under the trading symbol "CLDX". We are authorized to issue 297,000,000 shares of common
stock pursuant to our amended and restated certificate of incorporation, as amended. As of April&nbsp;10, 2017, there were 125,104,714 shares of our common stock outstanding. Additionally, on such
date we had outstanding options to purchase an aggregate of 10,159,130 shares of our common stock at a weighted average
exercise price of $11.11 per share. On April&nbsp;10, 2017, the closing sale price of a share of our common stock as reported on NASDAQ was $3.30. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=51,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=952032,FOLIO='49',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dw16401_1_50"> </A>
<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Par Value  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The par value of our common stock is $0.001 per share. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board of Directors may, out of funds legally available, at any regular or special meeting, declare dividends to the holders of shares of our
common stock as and when they deem expedient, subject to the rights of holders of the preferred stock, if any. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock entitles the holders to one vote per share on all matters requiring a vote of the stockholders, including the
election of directors. No holders of shares of common stock shall have the right to vote such shares cumulatively in any election for the board of directors. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rights Upon Liquidation  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders of our common stock will be entitled to share
equally in our assets available for distribution after payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in full. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Miscellaneous  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No holders of shares of our common stock shall have any preemptive rights to subscribe for, purchase or receive any shares of any class, whether
now or hereafter authorized, or any options or warrants to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be issued, sold or
offered for sale by us. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Fully Paid and Nonassessable  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares of common stock that may be issued as in connection with the Milestone Payments will be fully paid and nonassessable. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Holders  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of April&nbsp;10, 2017, there were approximately 350 holders of record of our common stock. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Provisions  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions in our third restated certificate of incorporation, as amended, and applicable Delaware corporate law may have the effect of
discouraging a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders receiving a substantial premium over the current market
price of our shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of our corporation. These provisions may also
tend to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to elect even a single director. Certain of these provisions are
summarized below. </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Undesignated Preferred Stock.&nbsp;&nbsp;&nbsp;&nbsp; </I></FONT><FONT SIZE=2>The ability to authorize undesignated preferred stock makes it possible for our Board of Directors to
issue preferred stock with voting or other rights or
preferences that could impede the success of any attempt to acquire us. The ability to issue preferred stock may have the effect of deferring hostile takeovers or delaying changes in control or
management of our company. </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=52,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=145516,FOLIO='50',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dw16401_1_51"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Special Meetings.&nbsp;&nbsp;&nbsp;&nbsp; </I></FONT><FONT SIZE=2>Our bylaws provide that special meetings of the stockholders may, unless otherwise prescribed by law, only be called
by the Chairman of the Board (if any),
the President, the Secretary or by resolution of the directors. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare
Trust Company, N.A. is presently the transfer agent and registrar for our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Resale Limitations  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The offer and sale of the shares of our common stock issued or to be issued pursuant to the Merger Agreement (including the Closing Merger
Consideration and any Milestone Payments that become payable in the future which we elect to pay in shares) has been made in a private placement in reliance upon the exemption from registration
provided by Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), for transactions by an issuer not involving a public offering, and Regulation&nbsp;D under the
Securities Act. All certificates evidencing shares of our common stock issued or issuable in connection with the Kolltan Acquisition bore or will bear, as applicable, a standard restrictive legend
under the Securities Act. Any shares of our common stock issued in connection with the Kolltan Acquisition may not be sold or transferred unless registered under the Securities Act or unless an
exemption from registration is available. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Registration Rights  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the terms of the Merger Agreement, we agreed to file with the Securities and Exchange Commission, as promptly as practical following the
Closing Date, but in any event not later than sixty&nbsp;(60)&nbsp;following the Closing Date, a registration statement covering the resale of the shares of our common stock issued at Closing and
to use reasonable efforts to cause such registration statement to be declared effective as soon as reasonably practicable after filing. In January 2017, we filed a registration statement on
Form&nbsp;S-3 covering the registration of 18,369,107 shares issued in connection with the Kolltan Acquisition and such registration statement was declared effective February&nbsp;13, 2017. We
further agreed to use reasonable best efforts to maintain the continuous effectiveness of such registration statement until the earlier of (i)&nbsp;the date all such registration shares have been
sold pursuant to such registration statement, or (ii)&nbsp;such time as all such registration shares may be sold under Rule&nbsp;144 of the Securities Act. We also agreed, if any shares are issued
as part of a Milestone Payment to file registration statements covering the resale of such shares of our common stock, if any, as promptly as practical, but in any event not later than forty-five
(45)&nbsp;days following issuance of any such shares. We agreed to pay all expenses associated with the preparation and filing of such registration statements and any amendments or supplements
thereto, and any actions or filings necessary to maintain the effectiveness of such registration statements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Interests of Certain Persons in the Proposal and Past Contacts  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Kolltan Acquisition, Theresa LaVallee, Ph.D. (Kolltan's Senior Vice President, Translational Medicine prior to the
Kolltan Acquisition) entered into an employment agreement with us on November&nbsp;29, 2016, and was appointed as our Senior Vice President, Regulatory and Precision Medicine. Dr.&nbsp;LaVallee's
employment agreement provided for, among other things, an annual base salary of $322,400, eligibility for an annual bonus having a target of 35% of her then base salary and certain severance payments
if her employment was terminated "without cause" or she resigned "for good reason" (as defined in her employment agreement). Dr.&nbsp;LaVallee has informed Celldex of her decision to relocate to the
West Coast to be closer to family and, as such, has provided notice of her resignation which will be effective during the second quarter of 2017. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;14, 2016, we appointed Gerald McMahon, Ph.D., who served as President, Chief Executive Officer and member of the board of directors of Kolltan prior to the Kolltan
Acquisition. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=53,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=975773,FOLIO='51',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dw16401_1_52"> </A>

<P style="font-family:times;"><FONT SIZE=2>Previously,
on November&nbsp;28, 2016, in connection with Dr.&nbsp;McMahon's employment separation with Kolltan Pharmaceuticals,&nbsp;Inc., we entered into a severance agreement with
Dr.&nbsp;McMahon whereby we agreed to pay Dr.&nbsp;McMahon up to 267,356 shares of our common stock less required tax and other withholdings. To date, 64,667 shares of common stock were issued to
Dr.&nbsp;McMahon, 35,796 shares have been withheld to satisfy tax withholdings and the remaining 166,893 shares of common stock, less applicable withholdings, are issuable to Dr.&nbsp;McMahon in
equal monthly installments through December 2018. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
other former stockholders of Kolltan also have an interest in this Proposal 3 insofar as approval of the proposal would enable them to be paid any Milestone Payments as become due in
shares of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required for Approval; Effectiveness  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of the holders of a majority of the total votes cast in person or by proxy at the Annual Meeting will be required to
approve the issuance of shares of our common stock in connection with the Milestone Payments. Abstentions and broker non-votes will not be counted as votes cast and therefore will not affect the
determination as to whether this Proposal 3 is approved. Pursuant to the Marketplace Rules of the NASDAQ Stock Market, however, the 18,257,996 shares issued to the former Kolltan securityholders and
any part of the 437,901 shares issuable to certain former officers of Kolltan that have already been issued are not entitled to vote on this Proposal 3 and are not counted in determining votes cast
for purposes of this Proposal 3. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR" THE APPROVAL, IN ACCORDANCE WITH THE APPLICABLE RULES OF THE NASDAQ STOCK MARKET, OF THE ISSUANCE OF SHARES
OF OUR COMMON STOCK IN CONNECTION WITH MILESTONE PAYMENTS THAT MAY BECOME PAYABLE IN THE FUTURE TO FORMER SECURITYHOLDERS OF KOLLTAN PHARMACEUTICALS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=54,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=475730,FOLIO='52',FILE='DISK105:[17ZAE1.17ZAE16401]DW16401A.;13',USER='CHE106465',CD='24-APR-2017;09:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_dy16401_1_53"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dy16401_proposal_4__approve_the_amendm__pro03323"> </A>
<A NAME="toc_dy16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 4: APPROVE THE AMENDMENT TO THE<BR>  2008 STOCK OPTION AND INCENTIVE PLAN    <BR>    <BR>    (Proposal No.&nbsp;4)    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders are requested in this Proposal 4 to approve an amendment to our 2008 Stock Option and Incentive Plan as amended and restated
effective as of June&nbsp;10, 2015 (the "2008 Plan") to increase the number of shares reserved for issuance thereunder by 5,650,000 to 20,000,000 shares. The general purpose of our 2008 Plan is to
provide a means whereby eligible employees, officers, non-employee directors and other individual service providers develop a sense of proprietorship and personal involvement in the development and
financial success of the Company and to encourage them to devote their best efforts to the business of the Company, thereby advancing the interests of the Company and its stockholders. Our Board
believes that the 2008 Plan advances our interests by enhancing our ability to (i)&nbsp;attract and retain employees, officers, non-employee directors and other individual service providers,
(ii)&nbsp;provide incentives for such persons to exert maximum efforts for the success of the Company and its subsidiaries, and (iii)&nbsp;reward such persons for these efforts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
March&nbsp;1, 2017, the Board of Directors approved an amendment to the 2008 Plan, subject to approval at this Annual Meeting by our stockholders, to increase the number of shares
reserved for issuance thereunder by 5,650,000 to 20,000,000 shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board of Directors believes that the approval of the amendment to the 2008 Plan is important to our continued success. In particular, the Board of Directors believes that our
employees are our most valuable assets and that the awards permitted under the 2008 Plan are vital to our ability to attract and retain outstanding and highly skilled individuals in the extremely
competitive labor markets in which we operate. Such awards also are crucial to our ability to motivate our employees to achieve our goals. The amendment to our 2008 Plan is intended to ensure that we
have sufficient shares reserved for issuance under the 2008 Plan to provide incentives to our participant base. We expect that we will use approximately 2,000,000 to 2,500,000 shares each year to
issue equity awards to attract new hires and retain existing employees. We are asking to increase the option pool so that we have sufficient shares available new and existing employees and independent
contractors for the next three years. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
below is a summary of the 2008 Plan and a discussion of the federal income tax consequences of the issuance and exercise of incentives under the 2008 Plan to recipients and
to us. This summary of the 2008 Plan is qualified entirely by reference to the complete text of the 2008 Plan, a copy of which is attached to this proxy statement as </FONT><FONT SIZE=2><B><I>Annexure
A</I></B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of the 2008 Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan may be administered by the Board of Directors, or the compensation committee or similar committee of the Board of Directors (the
"administrator"). The administrator, at its discretion, may grant a variety of stock incentive awards based on our Common Stock. Awards under the 2008 Plan include stock options (both incentive
options and non-qualified options), stock appreciation rights, restricted stock, deferred stock, cash-based awards, performance shares, unrestricted stock and dividend equivalent rights. These awards
are described in greater detail below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
maximum number of shares of Common Stock that can be issued under the 2008 Plan is 14,350,000 shares of which no more than 500,000 shares will be available for grants in the form of
restricted stock, deferred stock, performance shares or unrestricted stock. Based solely upon the closing price of the Common Stock as reported by NASDAQ on April&nbsp;10, 2017, the maximum
aggregate market value of the securities to be issued under the 2008 Plan would be $47.4&nbsp;million. If this amendment is approved, the maximum number of shares of Common Stock issuable under the
2008 Plan will increase from 14,350,000 shares to 20,000,000 shares. For years, we have successfully used </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=55,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=47754,FOLIO='53',FILE='DISK105:[17ZAE1.17ZAE16401]DY16401A.;5',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dy16401_1_54"> </A>

<P style="font-family:times;"><FONT SIZE=2>stock
options to attract, retain and motivate employees in a highly competitive marketplace. Option grants have been given to a broad base of employees and Named Executive Officers. We believe that
our stock option program has been very successful over the years in motivating our employees while enhancing shareholder value and therefore it is very valuable to us that we be able to continue
offering option grants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares issued by Celldex under the 2008 Plan may be authorized but unissued shares, or shares reacquired by Celldex (subject to the limitation set forth below). For purposes of
determining the aggregate number of shares of common stock that may be issued under the 2008 Plan, the following shares will be counted as issued and, therefore, may not be made subject to new awards
under the 2008 Plan:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of common stock repurchased by us with option proceeds; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of common stock that are tendered (by either actual delivery or attestation) or withheld to either pay the exercise price of a stock
option granted under the 2008 Plan or to satisfy tax withholding obligations associated with an award granted under the 2008 Plan; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> shares of common stock that are covered by stock appreciation rights to the extent that such stock appreciation rights are exercised and
settled in shares of common stock, whether or not shares of common stock are actually issued to the grantee upon such exercise. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
ensure that certain awards under the 2008 Plan, including restricted stock, deferred stock, cash-based awards and performance shares, qualify as "performance-based compensation" under
Section&nbsp;162(m) of the Internal Revenue Code of 1986, as amended (the "Code"), the 2008 Plan provides that the administrator may require that vesting or grants of such awards be conditioned on
the satisfaction of performance criteria that may include any of the following: (i)&nbsp;our return on equity, assets, capital or investment, (ii)&nbsp;our pre-tax or after-tax profit levels or
that of any subsidiary, division, operating unit or business segment, or any combination of the foregoing; (iii)&nbsp;cash flow, funds from operations, year-end cash and equivalents balance or
similar measure; (iv)&nbsp;total shareholder return;
(v)&nbsp;changes in the market price of our stock; (vi)&nbsp;sales or market share; (vii)&nbsp;earnings per share; (viii)&nbsp;partnerships, collaborations, joint ventures, alliances and
similar arrangements involving us; (ix)&nbsp;mergers, acquisitions and business combinations of or by us; or (x)&nbsp;our rights to intellectual property and scientific discoveries. The
administrator will select the particular performance criteria within 90&nbsp;days following the commencement of a performance cycle (or, if shorter, within the maximum period allowed under
Section&nbsp;162(m) of the Code). Subject to adjustments for stock splits and similar events, for awards intended to qualify for the exception for "qualified performance-based compensation" under
Section&nbsp;162(m) of the Code, it will limit the number of shares payable to any one participant in respect of any one calendar year with respect to restricted stock awards, deferred stock awards
or performance share awards to 250,000 shares in the aggregate, and will further limit the dollar value payable to any one participant in respect of any one calendar year on awards denominated in cash
to $1,000,000. For stock options or stock appreciation rights, no more than 2,000,000 shares may be granted to any one individual during any calendar year period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plan Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan is administered by our Board of Directors or by the compensation committee or a similar committee of
the Board of
Directors. The administrator of the 2008 Plan has full power and authority to select the participants to whom awards will be granted, to make any combination of awards to participants, to accelerate
the exercisability or vesting of an award only upon a grantee's death, a grantee's "disability" (as defined in the 2008 Plan) or a "change of control" (as defined in the 2008 Plan) or "sale event" (as
defined in the 2008 Plan) and to determine the specific terms and conditions of each award, subject to the provisions of the 2008 Plan. The administrator may delegate to the Chief Executive Officer
the authority to grant awards to individuals who are not subject to the reporting and other provisions of Section&nbsp;16 of the Securities Exchange Act of 1934, as amended, and are not Covered
Employees, provided that the administrator fixes the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=56,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=167615,FOLIO='54',FILE='DISK105:[17ZAE1.17ZAE16401]DY16401A.;5',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dy16401_1_55"> </A>

<P style="font-family:times;"><FONT SIZE=2>maximum
number of shares that may be awarded and provides specific guidelines regarding such awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Eligibility and Limitations on Grants.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All full-time and part-time officers, employees, non-employee directors and other key persons
are eligible to
participate in the 2008 Plan, subject to the discretion of the administrator. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The exercise price of stock options awarded under the 2008 Plan may not be less than the fair market value of the Common
Stock on the
date of the option grant, except that for a grant of
an incentive stock option to any employee who is an owner of more than 10&nbsp;percent of the voting power of Celldex, the exercise price of stock options awarded under the 2008 Plan may not be less
than 110% of the fair market value of the Common Stock on the date of the option grant. The term of each stock option may not exceed 10&nbsp;years from the date of grant, except that for a grant of
an incentive stock option to any employee who is an owner of more than 10&nbsp;percent of the voting power of Celldex the term of each stock option may not exceed 5&nbsp;years from the date of
grant. The administrator will determine at what time or times each option may be exercised. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award a stock appreciation right either as a freestanding award or in tandem with a
stock option.
The administrator may award stock appreciation rights subject to such conditions and restrictions as the administrator may determine. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award shares to participants subject to such conditions and restrictions as the administrator
may determine.
These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with Celldex through a specified restricted period. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award deferred stock units to participants subject to such conditions and restrictions as the
administrator may
determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with Celldex through a specified restricted period. At the end of the
deferral period, the participants shall be paid, to the extent vested, in shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrestricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may grant (or sell at par value or for a higher purchase price determined by the Administrator)
shares that are
free from any restrictions under the 2008 Plan. Unrestricted stock may be issued to participants in recognition of past services or other valid consideration, and may be issued in lieu of cash
compensation to be paid to such individuals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash-Based Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may in its discretion grant awards entitling the grantee to receive cash-denominated payments and
determine the
terms and conditions of the cash-based award. Each cash-based award will specify a cash-denominated payment amount, formula or payment ranges as determined by the administrator. Payment with respect
to a cash-based award may be made in cash or stock, as the administrator determines. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Performance Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may grant performance share awards that entitle the recipient to acquire shares of Common Stock
upon the
attainment of specified performance goals. The administrator determines the performance goals, performance periods and other terms of any such awards. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividend Equivalent Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The administrator may award a dividend equivalent right either as a freestanding award or in tandem with
another award
under the 2008 Plan. The administrator may award dividend equivalent rights subject to such conditions and restrictions as the administrator may determine. Dividend equivalents credited to the holder
may be paid currently or may be deemed to be reinvested in additional shares of stock, which may thereafter accrue additional equivalents. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=57,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=446964,FOLIO='55',FILE='DISK105:[17ZAE1.17ZAE16401]DY16401A.;5',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dy16401_1_56"> </A>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tax Withholding.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Participants in the 2008 Plan are responsible for the payment of any federal, state or local taxes that the Company is
required by
law to withhold upon any option exercise or vesting of other awards. Subject to approval by the administrator, participants may elect to have the minimum tax withholding obligations satisfied either
by authorizing the Company to withhold shares to be issued pursuant to an option exercise or other award, or by transferring to the Company shares having a value equal to the amount of such taxes. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change of Control Provisions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the occurrence of a "change in control" (as defined in the 2008 Plan), all outstanding stock options,
 stock
appreciation rights and dividend equivalent rights will not automatically become fully exercisable and all other outstanding awards with conditions and restrictions relating solely to the passage of
time and continued employment or service will not be fully vested, if provision is made in connection with the change of control for the assumption or continuation by the successor entity of such
outstanding equity awards, or the substitution of such outstanding awards with new awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares
and, if appropriate, the per share exercise prices, as such parties shall agree. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Amendments and Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The 2008 Plan is available for the grant of new awards until June&nbsp;9, 2025
(or April&nbsp;16, 2025 with respect to incentive stock options). In addition, the board of directors may amend or discontinue the 2008 Plan at any time, and the administrator may amend or cancel
any outstanding award for the purpose of satisfying changes in law or for any other lawful purpose. No such amendment may adversely affect the rights under any outstanding award without the holder's
consent. Except in connection with a merger, consolidation, reorganization, recapitalization, reclassification, stock dividend, stock split or other similar transaction or change in our capital stock,
the administrator may not, without obtaining stockholder approval, reprice or otherwise reduce the exercise price of outstanding stock options or stock appreciation rights or cancel outstanding
options with an exercise price above the current stock price in exchange for cash or securities. Additionally, stockholder approval will be required to amend the 2008 Plan if the administrator
determines that this approval is required to ensure that incentive stock options qualify as such under the Code, or that compensation earned under awards qualifies as performance-based compensation
under the Code or as required under the applicable securities exchange or market system rules. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Tax Aspects Under the Code  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of the principal federal income tax consequences of certain transactions under the 2008 Plan. It does not describe
all federal tax consequences under the 2008 Plan, nor does it describe state or local tax consequences. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No taxable income is generally realized by the optionee upon the grant or exercise of an incentive option. If shares
issued to an
optionee pursuant to the exercise of an incentive option are sold or transferred after two years from the date of grant and after one year from the date of exercise, then (i)&nbsp;upon sale of such
shares, any amount realized in excess of the option price (the amount paid for the shares) will be taxed to the optionee as a long-term capital gain, and any loss sustained will be a long-term capital
loss, and (ii)&nbsp;there will be no deduction for the Company for federal income tax purposes. The exercise of an incentive option will give rise to an item of tax preference that may result in
alternative minimum tax liability for the optionee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
shares acquired upon the exercise of an incentive option are disposed of prior to the expiration of the two-year and one-year holding periods described above (a "disqualifying
disposition"), generally (i)&nbsp;the optionee will realize ordinary income in the year of disposition in an amount equal to the excess (if any) of the fair market value of the shares at exercise
(or, if less, the amount realized on a sale of such shares) over the option price thereof, and (ii)&nbsp;the Company will be entitled to deduct such </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>56</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=58,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=53312,FOLIO='56',FILE='DISK105:[17ZAE1.17ZAE16401]DY16401A.;5',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dy16401_1_57"> </A>

<P style="font-family:times;"><FONT SIZE=2>amount.
Special rules will apply where all or a portion of the exercise price of the incentive option is paid by tendering shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
an incentive option is exercised at a time when it no longer qualifies for the tax treatment described above (e.g.,&nbsp;if the holding periods described above are not satisfied),
the option is treated as a non-qualified option. In addition, an incentive option will not be eligible for the tax treatment described above if it is exercised more than three months following
termination of employment (or one year in the case of termination of employment by reason of disability). In the case of termination of employment by reason of death, the three-month rule does not
apply. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Non-Qualified Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;No income is realized by the optionee at the time the option is granted. Generally (i)&nbsp;at exercise,
ordinary income is
realized by the optionee in an amount equal to the difference between the option price and the fair market value of the shares on the date of exercise, and the Company receives a tax deduction for the
same amount, and (ii)&nbsp;at disposition, appreciation or depreciation after the date of exercise is treated as either short-term or long-term capital gain or loss depending on how long the shares
have been held. Special rules will apply where all or a portion of the exercise price of the non-qualified option is paid by tendering shares. Upon exercise, the optionee will also be subject to
Social Security taxes on the excess of the fair market value over the exercise price of the option. </FONT></P>


<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Parachute Payments  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The vesting of any portion of an option or other award that is accelerated due to the occurrence of a change in control may cause a portion of
the payments with respect to such accelerated awards to be treated as "parachute payments" as defined in Section&nbsp;280G of the Code. Any such parachute payments may be non-deductible to the
Company, in whole or in part, and may subject the recipient to a non-deductible 20% federal excise tax on all or a portion of such payment (in addition to other taxes ordinarily payable). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Limitation on the Company's Deductions  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of Section&nbsp;162(m) of the Code, the Company's deduction for certain awards under the 2008 Plan may be limited to the extent
that the Chief Executive Officer or other executive officer whose compensation is required to be reported in the summary compensation table receives compensation in excess of $1&nbsp;million a year
(other than performance-based compensation that otherwise meets the requirements of Section&nbsp;162(m) of the Code). The 2008 Plan is structured to allow grants to qualify as performance-based
compensation. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation Plan Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of December&nbsp;31, 2016 regarding shares of our common stock that may be issued under our
existing equity compensation plans, including our 2008 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>57</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=59,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=796176,FOLIO='57',FILE='DISK105:[17ZAE1.17ZAE16401]DY16401A.;5',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_dy16401_1_58"> </A>

<P style="font-family:times;"><FONT SIZE=2>Stock
Option and Incentive Plan (the "2008 Plan") and our 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:62%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"130%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="130%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="121pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="131pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity Compensation Plan Information </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon exercise<BR>
of outstanding options<BR>
and rights(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted average<BR>
exercise price of<BR>
outstanding options<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available for<BR>
future issuance under equity<BR>
compensation plan<BR>
(excluding securities<BR>
referenced in column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,218,710</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,655,871</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include any Restricted Stock as such shares are already reflected in our outstanding shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the 2008 Plan, 2004 ESPP Plan and Celldex Research's 2005 Equity Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include purchase rights accruing under the 2004 ESPP Plan because the purchase price (and therefore the number of shares to be purchased) will not be
determined until the end of the purchase period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
shares available for future issuance under the 2008 Plan and the 2004 ESPP Plan of which 302,660 shares are available for grants in the form of restricted
stock, deferred stock, performance shares or unrestricted stock under the 2008 Plan.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Plan Benefits  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Incentive awards under the 2008 Plan are subject to the discretion of the Compensation Committee. Therefore, it is generally not possible to
determine the incentives awards that will be granted or awarded under the 2008 Plan in the future to any person or the incentive awards that would have been granted or awarded if this amendment to our
2008 Plan had been in effect in the year ended December&nbsp;31, 2016. However, irrespective of whether the amendment to our 2008 Plan is approved, we expect to issue restricted stock and options to
each of our non-employee directors following the Annual Meeting in accordance with our non-employee director compensation policy, which is described in more detail in the section titled "Director
Compensation." Furthermore, information about awards granted in 2016 to our Named Executive Officers can be found in the table under the heading "Grants of Plan-Based Awards" in the section titled
"Executive Compensation." </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of the holders of a majority of the votes cast in person or by proxy at the Annual Meeting will be required to approve the
amendment to the 2008 Plan to increase the shares of common stock reserved for issuance thereunder by 5,650,000 to 20,000,000 shares. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" APPROVAL OF THE AMENDMENT TO OUR 2008 STOCK OPTION AND INCENTIVE PLAN.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>58</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=60,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=829596,FOLIO='58',FILE='DISK105:[17ZAE1.17ZAE16401]DY16401A.;5',USER='CHE106465',CD='24-APR-2017;09:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ea16401_1_59"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ea16401_proposal_5__approval_of_an_ame__pro03310"> </A>
<A NAME="toc_ea16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 5: APPROVAL OF AN AMENDMENT TO THE<BR>  2004 EMPLOYEE STOCK PURCHASE PLAN    <BR>    <BR>    (Proposal No.&nbsp;5)    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders are requested in this Proposal 5 to approve an amendment to our 2004 Employee Stock Purchase Plan (the "2004 Plan") to increase the
number of shares of our common stock reserved for issuance thereunder from 200,000 shares to 400,000 shares, which was adopted by the Board of Directors on March&nbsp;1, 2017, subject to the
approval by our stockholders. Over the past several years, we have expanded our employee base. Approval of the amendment to the 2004 Plan is intended to ensure that we have sufficient shares reserved
for issuance under the 2004 Plan to provide incentives to our expanded participant base. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Immediately
below is a summary of the existing 2004 Plan and a discussion of the federal income tax consequences of the issuance and exercise of options to purchase shares of our common
stock under the 2004 Plan to recipients and to us. This summary of the existing 2004 Plan is qualified entirely by reference to the complete text of the 2004 Plan, a copy of which is attached to this
proxy statement as </FONT><FONT SIZE=2><B><I>Annexure B</I></B></FONT><FONT SIZE=2>. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Description of the Existing 2004 Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The 2004 Plan was approved by our stockholders on May&nbsp;13, 2004 and has subsequently been amended such that 200,000 shares of our common
stock are reserved for issuance thereunder. The closing price of our common stock as reported by the NASDAQ Global Market on April&nbsp;10, 2017 was $3.30. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under
the 2004 Plan, eligible employees may authorize Celldex to deduct amounts from their pay, which amounts are used to enable the employees to purchase shares of Celldex common stock.
The 2004 Plan is intended to be an "employee stock purchase plan" under Section&nbsp;423(b) of the Internal Revenue Code of 1986, as amended, (the "Code"). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan is administered by Celldex's Board of Directors or a person or persons appointed by the Board of Directors for such purpose. The 2004 Plan provides that all employees of
Celldex and certain of its subsidiaries whose customary employment is for more than 20&nbsp;hours per week and more than five months in any calendar year are eligible to participate in the 2004 Plan
following sixty days of active employment, provided, however, that persons who are deemed under Section&nbsp;423(b) of the Code to own five percent (5%) or more of Celldex's voting stock are
excluded from participation. As of December&nbsp;31, 2016, approximately 207 employees were eligible to participate in the 2004 Plan, of whom 17% enrolled in the 2004 Plan for the purchase period
beginning January&nbsp;1, 2017. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan provides for two purchase periods each year, the first commencing on January&nbsp;1 of each year and continuing through June&nbsp;30 of such year, and the second
commencing on July&nbsp;1 of each year and continuing through December&nbsp;31 of such year. Eligible employees may elect to become participants in the 2004 Plan by enrolling prior to each
semi-annual purchase period. Shares are purchased through the accumulation of payroll deductions of not less than one percent (1%) nor more than fifteen percent (15%) of each participant's
compensation. No employee may be granted an option under the 2004 Plan which permits the right to purchase shares of common stock at a rate that exceeds $25,000 (determined on the date of grant) for
each calendar year the option is outstanding. The number of shares to be purchased is determined by dividing the participant's balance in the plan account on the last day of the purchase period by the
purchase price per share for the stock. The purchase price per share will be the lower of 85% of the fair market value of the common stock as of either the beginning or ending date of the semi-annual
purchase period of shares for the participant's account. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>59</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=61,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=263097,FOLIO='59',FILE='DISK105:[17ZAE1.17ZAE16401]EA16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_ea16401_1_60"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
option granted under the 2004 Plan is not transferable by the participant except by will or by the laws of descent and distribution. Employees may cease their participation in the
offering at any time during a purchase period, and participation automatically ceases on termination of employment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares that are reserved for issuance under the 2004 Plan is subject to adjustment for stock splits and similar events. The proceeds received by Celldex from exercise under
the 2004 Plan will be used for the general purposes of Celldex. Shares issued under the 2004 Plan may be from authorized but unissued shares or shares reacquired by Celldex and held in its treasury,
or any other proper source. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan shall remain in full force and effect until suspended or discontinued by the Board of Directors. The Board of Directors may amend the 2004 Plan at any time and for any
purposes permitted by law, and may terminate the 2004 Plan at any time. Any amendment to the 2004 Plan that increases the number of shares available under the 2004 Plan and certain other amendments
that are required to be approved by stockholders to comply with Section&nbsp;423(b) of the Code must be approved by stockholders. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Income Tax Considerations Under the 2004 Plan  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of the federal income tax consequences resulting from the issuance and exercise of options to purchase shares of
common stock under the 2004 Plan: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2004 Plan is intended to qualify as an "employee stock purchase plan" as defined in Section&nbsp;423(b) of the Code. As a result, an employee will not recognize income for federal
income tax purposes at the time of the transfer of shares of common stock to the employee pursuant to the exercise of an option granted under the 2004 Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
shares acquired under the 2004 Plan are sold more than two years after the first day of the purchase period pursuant to which the shares were purchased, no taxable income results if
the proceeds of the sale are equal to or less than the price paid for the shares. If the proceeds of the sale are higher than the purchase price, the employee will recognize ordinary income for the
year in which the sale occurs equal to the lesser of (i)&nbsp;fifteen percent (15%) of the fair market value of the common stock on the first day of the purchase period pursuant to which the shares
were purchased or (ii)&nbsp;the excess of the amount actually received for the shares over the amount paid. In addition, the employee may recognize long-term capital gain or loss in an amount equal
to the difference between the proceeds of the sale and the employee's basis in the shares (i.e.,&nbsp;the employee's purchase price plus the amount taxed to the employee as ordinary income). No
deduction is allowed to the company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
shares acquired under the 2004 Plan are sold within two (2)&nbsp;years of the first day of the purchase period pursuant to which the shares were purchased, the employee will
recognize ordinary income equal to the difference between the fair market value of the shares on the exercise date and the employee's purchase price. This amount is reportable as ordinary income even
if no profit was realized on the sale of shares or the shares were sold at a loss. Long-term or short-term (depending on the holding period for the shares) capital gain or loss will be recognized in
an amount equal to the difference between the proceeds of sale and the employee's basis in the shares (i.e.,&nbsp;the employee's purchase price plus the amount taxed to the employee as ordinary
income). The amount reportable as ordinary income from a sale made within two years of the first day of the purchase period pursuant to which the shares were purchased will generally be allowed as a
tax deduction to the company. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Equity Compensation Plan Information  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information as of December&nbsp;31, 2016 regarding shares of our common stock that may be issued under our
existing equity compensation plans, including our 2008 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>60</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=62,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=132833,FOLIO='60',FILE='DISK105:[17ZAE1.17ZAE16401]EA16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_ea16401_1_61"> </A>

<P style="font-family:times;"><FONT SIZE=2>Stock
Option and Incentive Plan (the "2008 Plan") and our 2004 Employee Stock Purchase Plan (the "2004 ESPP Plan"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="97pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="92pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="97pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=8 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Equity Compensation Plan Information </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
to be issued upon<BR>
exercise of<BR>
outstanding options<BR>
and rights(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighted average<BR>
exercise price of<BR>
outstanding options<BR>
and rights </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of securities<BR>
remaining available<BR>
for future issuance<BR>
under equity<BR>
compensation plan<BR>
(excluding securities<BR>
referenced in<BR>
column (a)) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Equity compensation plans approved by security holders(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>10,218,710</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>11.14</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>3,655,871</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include any Restricted Stock as such shares are already reflected in our outstanding shares.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Consists
of the 2008 Plan, 2004 ESPP Plan and Celldex Research's 2005 Equity Incentive Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Does
not include purchase rights accruing under the 2004 ESPP Plan because the purchase price (and therefore the number of shares to be purchased) will not be
determined until the end of the purchase period.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>Includes
shares available for future issuance under the 2008 Plan and the 2004 ESPP Plan of which 302,660 shares are available for grants in the form of restricted
stock, deferred stock, performance shares or unrestricted stock under the 2008 Plan.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


New Plan Benefits  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Future benefits available under the 2004 Plan are subject to the participation level of our employees and to our stock price at the time of any
purchases and are, therefore, not determinable at this time. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Vote Required  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The affirmative vote of the holders of a majority of the votes cast in person or by proxy at the Annual Meeting will be required to approve the
amendment to the 2004 Plan to increase the shares of common stock reserved for issuance thereunder to 400,000. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD OF DIRECTORS RECOMMENDS THAT STOCKHOLDERS VOTE "FOR" APPROVAL OF THE AMENDMENT TO OUR 2004 EMPLOYEE STOCK PURCHASE PLAN.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>61</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=63,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=596832,FOLIO='61',FILE='DISK105:[17ZAE1.17ZAE16401]EA16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_ec16401_1_62"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ec16401_proposal_6__advisory_vote_on_e__pro02568"> </A>
<A NAME="toc_ec16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 6: ADVISORY VOTE ON EXECUTIVE COMPENSATION    <BR>    <BR>    (Proposal No.&nbsp;6)    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, and Section&nbsp;14A of the Securities Exchange
Act of 1934, as amended, or the Exchange Act, our stockholders are entitled to vote to approve, on an advisory (nonbinding) basis, the compensation of our Named Executive Officers as disclosed in this
proxy statement in accordance with the Securities and Exchange Commission's rules. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described in detail under the heading "Compensation of Executive Officers&#151;Compensation Discussion and Analysis," our executive compensation programs are designed to retain
and incentivize the high quality executives whose efforts are key to our long-term success. Under these programs, our Named Executive Officers are rewarded on the basis of individual and corporate
performance measured against established corporate and strategic goals. Please read the section of this proxy statement under the heading "Compensation of Executive Officers&#151;Compensation
Discussion and Analysis" for additional details about our executive compensation programs, including information about the fiscal year 2016 compensation of our Named Executive Officers. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee of our Board of Directors continually reviews the compensation programs for our Named Executive Officers to ensure they achieve the desired goals of aligning
our executive compensation structure with our stockholders' interests and current market practices. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are asking our stockholders to indicate their support for our Named Executive Officer compensation as described in this proxy statement. This proposal, commonly known as a
"say-on-pay" proposal, gives our stockholders the opportunity to express their views on our Named Executive Officers' compensation. This vote is not intended to address any specific item of
compensation, but rather the overall compensation of our Named Executive Officers and the philosophy, policies and practices described in this proxy statement. Accordingly, we are asking our
stockholders to cast a non-binding advisory vote "FOR" the following resolution at the Annual Meeting: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"RESOLVED,
that the compensation of the Named Executive Officers, as disclosed in the Company's Proxy Statement for the 2017 Annual Meeting of Stockholders pursuant to Item&nbsp;402 of
Regulation&nbsp;S-K, including the Compensation Discussion and Analysis, compensation tables and narrative disclosure is hereby APPROVED." </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
say-on-pay vote is advisory, and therefore not binding on Celldex Therapeutics, the Compensation Committee or our Board of Directors. Nevertheless, our Board of Directors and our
Compensation Committee value the opinions of our stockholders, whether expressed through this vote or otherwise, and accordingly, the Board and Compensation Committee intend to consider the results of
this vote among the many factors they consider in making determinations in the future regarding executive compensation arrangements. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder
approval of this Proposal No.&nbsp;6 will require the affirmative vote of the holders of a majority of the votes cast in person or by proxy at the Annual Meeting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD RECOMMENDS A VOTE FOR THIS PROPOSAL NO. 6</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>62</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=64,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=688407,FOLIO='62',FILE='DISK105:[17ZAE1.17ZAE16401]EC16401A.;8',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_ec16401_1_63"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ec16401_proposal_7__advisory_vote_on_t__pro04541"> </A>
<A NAME="toc_ec16401_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL 7: ADVISORY VOTE ON THE FREQUENCY OF STOCKHOLDER ADVISORY VOTES ON EXECUTIVE COMPENSATION    <BR>    <BR>    (Proposal No.&nbsp;7)    <BR>    </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Dodd-Frank Act and Section&nbsp;14A of the Exchange Act also enables our stockholders to indicate their preference regarding how
frequently we should seek non-binding advisory votes on the compensation of our Named Executive Officers, as disclosed in our proxy statements pursuant to the SEC's compensation disclosure rules. By
voting on this Proposal No.&nbsp;7, stockholders may indicate whether they would prefer an advisory vote on the compensation of our Named Executive Officers once every one, two, or three years.
Alternatively, stockholders may abstain from casting a vote. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Since
2011, we have sought an advisory vote on executive compensation at each annual meeting of our stockholders. After careful consideration of this proposal, our Board of Directors has
determined that an advisory vote on executive compensation that occurs every year continues to be the most appropriate alternative for Celldex, and therefore our Board of Directors recommends that you
vote for a one-year interval for the stockholder advisory votes on executive compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
formulating its recommendation, our Board considered that an annual advisory vote on executive compensation will allow our stockholders to provide us with their direct input on our
compensation philosophy, policies and practices as disclosed in our proxy statements every year. The Board's determination was influenced by the fact that the compensation of our Named Executive
Officers is evaluated, adjusted and approved on an annual basis. As part of the annual review process, the Board believes that stockholder sentiment should be a factor that is taken into consideration
by the Board and the Compensation Committee in making decisions with respect to executive compensation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
the Board believes that its recommendation is appropriate at this time, stockholders are not voting to approve or disapprove that recommendation, but are instead asked to indicate
their preference, on an advisory basis, as to whether the non-binding stockholder advisory votes on the approval of our Named Executive Officer compensation practices should be held every year, every
two years or every three years. The option among those choices receiving the highest number of votes cast in person or by proxy at the Annual Meeting will be deemed to be the frequency preferred by
our stockholders. The Board and the Compensation Committee value the opinions of our stockholders in this matter and, to the extent there is any significant vote in favor of one frequency over the
other options, even if less than a majority of the votes cast support such frequency, the Board will consider our stockholders' concerns and evaluate any appropriate next steps. However, because this
vote is advisory and not binding on the Board of Directors or Celldex in any way, the Board may decide that it is in the best interests of our stockholders and Celldex to hold stockholder advisory
votes on executive compensation more or less frequently than the option approved by our stockholders. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE BOARD RECOMMENDS A VOTE OF EVERY 1 YEAR ON THIS PROPOSAL NO.&nbsp;7</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>63</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=65,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=76672,FOLIO='63',FILE='DISK105:[17ZAE1.17ZAE16401]EC16401A.;8',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_ec16401_1_64"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ec16401_stockholder_proposals"> </A>
<A NAME="toc_ec16401_3"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS    <BR>    </B></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Proposals for 2018 Annual Meeting  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any stockholder proposals submitted pursuant to Exchange Act Rule&nbsp;14a-8 for inclusion in Celldex's proxy statement and form of proxy for
our 2018 Annual Meeting must be received by Celldex on or before December&nbsp;26, 2017 in order to be considered for inclusion in our proxy statement and form of proxy. Such proposal must also
comply with the requirements as to form and substance established by the SEC if such proposals are to be included in the proxy statement and form of proxy. Any such proposal shall be mailed to:
Celldex Therapeutics,&nbsp;Inc., Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton, NJ 08827, Attn.: Secretary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
by-laws state that the stockholder must provide timely written notice of such nomination or proposal and supporting documentation as well as be present at such meeting, either in
person or by a representative. A stockholder's notice shall be timely received by Celldex at our principal executive office not less than seventy-five (75)&nbsp;days nor more than one hundred twenty
(120)&nbsp;days prior to the anniversary date of the immediately preceding annual meeting (the "Anniversary Date"); provided, however, that in the event the annual meeting is scheduled to be held on
a date more than thirty&nbsp;(30)&nbsp;days before the Anniversary Date or more than sixty (60)&nbsp;days after the Anniversary Date, a stockholder's notice shall be timely if received by
Celldex at our principal executive office not later than the close of business on the later of (i)&nbsp;the seventy-fifth (75<SUP>th</SUP>) day prior to the scheduled date of such annual meeting
or (ii)&nbsp;the fifteenth (15<SUP>th</SUP>) day following the day on which such public announcement of the date of such annual meeting is first made by Celldex. Proxies solicited by our Board of
Directors will confer discretionary voting authority with respect to these proposals, subject to SEC rules and
regulations governing the exercise of this authority. Any such proposal shall be mailed to: Celldex Therapeutics,&nbsp;Inc., Perryville III Building, 53 Frontage Road, Suite&nbsp;220, Hampton,
NJ&nbsp;08827, Attn.: Secretary. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ec16401_where_you_can_find_additional_informaiton"> </A>
<A NAME="toc_ec16401_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND ADDITIONAL INFORMAITON    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company files annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to
the public over the Internet at the SEC's website at </FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>. The SEC's website contains reports, proxy statements and other information
regarding issuers, such as Celldex Therapeutics,&nbsp;Inc., that file electronically with the SEC. You may also read and copy any document we file with the SEC at the SEC's Public Reference Room,
located at 100&nbsp;F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of its Public Reference Room. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
SEC allows the Company to "incorporate by reference" certain information the Company files with it, which means that the Company can disclose important information to you by
referring you to those documents. The information incorporated by reference is considered to be part of this Proxy Statement, and information that the Company files later with the SEC will
automatically update and supersede previously filed information, including information contained in this document. We are incorporating by reference the following, which include the information
required by Item&nbsp;13(a) of Schedule&nbsp;14A and further information concerning the transactions described in Proposal 3:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Sections of our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, filed with the SEC on March&nbsp;14, 2017:
"Part&nbsp;II. Item&nbsp;7&#151;Management's Discussion and Analysis of Financial Condition and Results of Operations," "Part&nbsp;II. Item&nbsp;8&#151;Financial Statements and
Supplementary Data," "Part&nbsp;II. Item&nbsp;7A&#151;Quantitative and Qualitative Disclosure About Market Risk" and "Part&nbsp;II. Item&nbsp;9&#151;Changes in and Disagreements
With Accountants on Accounting and Financial Disclosure;" and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>64</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=66,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1034642,FOLIO='64',FILE='DISK105:[17ZAE1.17ZAE16401]EC16401A.;8',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_ec16401_1_65"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Current Reports on Form&nbsp;8-K filed with the SEC on November&nbsp;1, 2016 and November&nbsp;29, 2016 (as amended by Amendment
No.&nbsp;1 on Form&nbsp;8-K/A filed with the SEC on February&nbsp;7, 2017) excluding any information deemed "furnished" and not "filed" pursuant to Item&nbsp;2.02 or 7.01 of Form&nbsp;8-K
and exhibits filed on such form that are related to such item. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, all documents we file under Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Proxy Statement and before the date of the Annual Meeting are
incorporated by reference into and deemed a part of this Proxy Statement from the date of filing of those documents. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
person, including any beneficial owner, to whom this Proxy Statement is delivered may request copies of reports, proxy statements or other information concerning the Company
(including the documents incorporated by reference herein) without charge, by written or telephonic request directed to our Corporate Secretary at Celldex Therapeutics,&nbsp;Inc., Perryville III
Building, 53 Frontage Road, Suite&nbsp;220, Hampton, NJ 08827. A request for copies of reports, proxy statements or other information concerning the Company (including the documents incorporated by
reference herein) must set forth a good-faith representation that the requesting party was either a holder of record or a beneficial owner of our common stock on April&nbsp;20, 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>65</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=67,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=284676,FOLIO='65',FILE='DISK105:[17ZAE1.17ZAE16401]EC16401A.;8',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_ec16401_1_66"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="ec16401_other_matters"> </A>
<A NAME="toc_ec16401_5"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of the date of this proxy statement, the Board of Directors does not intend to present at the Annual Meeting any matters other than those
described herein and does not presently know of any matters that will be presented by other parties. If any other matter requiring a vote of the stockholders should come before the meeting, it is the
intention of the persons named in the proxy to vote with respect to any such matter in accordance with the recommendation of the Board of Directors or, in the absence of such a recommendation, in
accordance with the best judgment of the proxy holder. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>By Order of the Board of Directors</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>/s/&nbsp;AVERY W. CATLIN<BR>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2><I>Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>Hampton,
NJ<BR>
May&nbsp;3, 2017 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>66</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=68,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=20157,FOLIO='66',FILE='DISK105:[17ZAE1.17ZAE16401]EC16401A.;8',USER='CHE106465',CD='24-APR-2017;09:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lc16401_appendix_a"> </A>
<A NAME="toc_lc16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Appendix A    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="lc16401_celldex_therapeutics,_inc._200__cel03899"> </A>
<A NAME="toc_lc16401_2"> </A></FONT> <FONT SIZE=2><B>  CELLDEX THERAPEUTICS,&nbsp;INC.<BR>  2008 STOCK OPTION AND INCENTIVE PLAN<BR>  as amended and restated effective as of June&nbsp;10, 2015    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;GENERAL PURPOSE OF THE PLAN; DEFINITIONS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
name of the plan is the Celldex Therapeutics,&nbsp;Inc. 2008 Stock Option and Incentive Plan (the "Plan"). The purpose of the Plan is to encourage and enable the officers,
employees, Non-Employee Directors and other key persons (including consultants and prospective employees) of Celldex Therapeutics,&nbsp;Inc. (the "Company") and its Subsidiaries upon whose judgment,
initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a
direct stake in the Company's welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company's behalf
and strengthening their desire to remain with the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following terms shall be defined as set forth below: </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Act"</I></FONT><FONT SIZE=2> means the Securities Act of 1933, as amended, and the rules and regulations thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Administrator"</I></FONT><FONT SIZE=2> means either the Board or the compensation committee of the Board or a similar committee performing the functions of the
compensation committee and which is comprised of not less than two Non-Employee Directors who are independent. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Award"</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>"Awards,"</I></FONT><FONT SIZE=2> except where referring to a particular category of grant under the
Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Deferred Stock Awards, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards,
Performance Share Awards and Dividend Equivalent Rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Award Agreement"</I></FONT><FONT SIZE=2> means a written or electronic agreement setting forth the terms and provisions applicable to an Award granted under the
Plan. Each Award Agreement is subject to the terms and conditions of the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Board"</I></FONT><FONT SIZE=2> means the Board of Directors of the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Cash-Based Award"</I></FONT><FONT SIZE=2> means an Award entitling the recipient to receive a cash-denominated payment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Change of Control"</I></FONT><FONT SIZE=2> is defined in Section&nbsp;20. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Code"</I></FONT><FONT SIZE=2> means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Covered Employee"</I></FONT><FONT SIZE=2> means an employee who is a "Covered Employee" within the meaning of Section&nbsp;162(m) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Date of Grant</I></FONT><FONT SIZE=2>" means the date on which an Award under the Plan is granted by the Administrator, or such later date as the Administrator
may specify to be the effective date of an Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Deferred Stock Award"</I></FONT><FONT SIZE=2> means an Award of phantom stock units to a grantee. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Disability</I></FONT><FONT SIZE=2>" means a grantee being considered "disabled" within the meaning of Section&nbsp;409A and Treasury
Regulation&nbsp;1.409A-3(i)(4), as well as any successor regulation or interpretation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Dividend Equivalent Right"</I></FONT><FONT SIZE=2> means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on
the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=69,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=74011,FOLIO='blank',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Effective Date"</I></FONT><FONT SIZE=2> means the date on which the amended and restated Plan is approved by stockholders as set forth in Section&nbsp;22. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Exchange Act"</I></FONT><FONT SIZE=2> means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Fair Market Value"</I></FONT><FONT SIZE=2> of a share of Stock shall be, as applied to a specific date (i)&nbsp;the closing price of a share of Stock as of the
date of determination on the principal established stock exchange or national market system on which the Stock is then traded (or, if there is no trading in the Stock as of such date, the closing
price of a share of Stock on the most recent date preceding the date of determination on which trades of the Stock were recorded), or (ii)&nbsp;if the shares of Stock are not then traded on an
established stock exchange or national market system but are then traded in an over-the-counter market, the average of the closing bid and asked prices for the shares of Stock in such over-the-counter
market as of the date of determination (or, if there are no closing bid and asked prices for the shares of Stock as of such date, the average of the closing bid and the asked prices for the shares of
Stock on the most recent date preceding such date on which such closing bid and asked prices are available on such over-the-counter market), or (iii)&nbsp;if the shares of Stock are not then listed
on a national securities exchange or national market system or traded in an over-the-counter market, the price of a share of Stock as determined by the Administrator in its discretion in a manner
consistent with Section&nbsp;409A of the Code and Treasury Regulation&nbsp;1.409A-1(b)(5)(iv), as well as any successor regulation or interpretation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Incentive Stock Option"</I></FONT><FONT SIZE=2> means any Stock Option designated and qualified as an "incentive stock option" as defined in Section&nbsp;422
of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Non-Employee Director"</I></FONT><FONT SIZE=2> means a member of the Board who is not also an employee of the Company or any Subsidiary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Non-Qualified Stock Option"</I></FONT><FONT SIZE=2> means any Stock Option that is not an Incentive Stock Option. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Option"</I></FONT><FONT SIZE=2> or </FONT><FONT SIZE=2><I>"Stock Option"</I></FONT><FONT SIZE=2> means any option to purchase shares of Stock granted pursuant
to Section&nbsp;5. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance-Based Award"</I></FONT><FONT SIZE=2> means any Restricted Stock Award, Deferred Stock Award, Performance Share Award or Cash-Based Award granted to a
Covered Employee that is intended to qualify as "performance-based compensation" under Section&nbsp;162(m) of the Code and the regulations promulgated thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Criteria"</I></FONT><FONT SIZE=2> means the performance criteria used in performance goals governing Performance-based Awards granted to Covered
Employees which may include any or all of the following: (i)&nbsp;the Company's return on equity, assets, capital or investment, (ii)&nbsp;pre-tax or after-tax profit levels of the Company or any
Subsidiary, a division, an operating unit or a business segment of the Company, or any combination of the foregoing; (iii)&nbsp;cash flow, funds from operations, year-end cash and equivalents
balance or similar measure; (iv)&nbsp;total shareholder return; (v)&nbsp;changes in the market price of the Stock; (vi)&nbsp;sales or market share; (vii)&nbsp;earnings per share;
(viii)&nbsp;partnerships, collaborations, joint ventures, alliances and similar arrangements involving the Company; (ix)&nbsp;mergers, acquisitions and business combinations of or by the Company;
or (x)&nbsp;the Company's rights to intellectual property and scientific discoveries. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Cycle"</I></FONT><FONT SIZE=2> means one or more periods of time, which may be of varying and overlapping durations, as the Administrator may select,
over which the attainment of one or more Performance Criteria will be measured for the purpose of determining a grantee's right to and the payment of a Restricted Stock Award, Deferred Stock Award,
Performance Share Award or Cash-Based Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Goals"</I></FONT><FONT SIZE=2> means, for a Performance Cycle, the specific goals established in writing by the Administrator for a Performance Cycle
based upon the Performance Criteria. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=70,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=567009,FOLIO='A-2',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Performance Share Award"</I></FONT><FONT SIZE=2> means an Award entitling the recipient to acquire shares of Stock upon the attainment of specified Performance
Goals. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Restricted Stock Award"</I></FONT><FONT SIZE=2> means an Award entitling the recipient to acquire, at such purchase price (which may be zero) as determined by
the Administrator, shares of Stock subject to such restrictions and conditions as the Administrator may determine at the time of grant. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Sale Event"</I></FONT><FONT SIZE=2> shall mean (i)&nbsp;the sale of all or substantially all of the assets of the Company on a consolidated basis to an
unrelated person or entity, (ii)&nbsp;a merger, reorganization or consolidation in which the outstanding shares of Stock are converted into or exchanged for securities of the successor entity and
the holders of the Company's outstanding voting power immediately prior to such transaction do not own a majority of the outstanding voting power of the successor entity immediately upon completion of
such transaction, or (iii)&nbsp;the sale of all of the Stock of the Company to an unrelated person or entity. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Sale Price</I></FONT><FONT SIZE=2>" means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders,
per share of Stock pursuant to a Sale Event. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Section&nbsp;409A"</I></FONT><FONT SIZE=2> means Section&nbsp;409A of the Code and the regulations and other guidance promulgated thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Stock"</I></FONT><FONT SIZE=2> means the Common Stock, par value $.01 per share, of the Company, subject to adjustments pursuant to Section&nbsp;3. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Stock Appreciation Right"</I></FONT><FONT SIZE=2> means an Award entitling the recipient to receive shares of Stock having a value equal to the excess of the
Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation
Right shall have been exercised. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Subsidiary"</I></FONT><FONT SIZE=2> means any corporation or other entity (other than the Company) in which the Company has at least a 50&nbsp;percent
interest, either directly or indirectly. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Ten Percent Owner"</I></FONT><FONT SIZE=2> means an employee who owns or is deemed to own (by reason of the attribution rules of Section&nbsp;424(d) of the
Code) more than 10&nbsp;percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"</FONT><FONT
SIZE=2><I>Unrestricted Stock Award"</I></FONT><FONT SIZE=2> means an Award of shares of Stock free of any restrictions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Administration of Plan.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan shall be administered by the Administrator. To the extent advisable or
otherwise required by applicable law, regulation or rule, it is intended that each member of the Administrator shall qualify as (i)&nbsp;a "non-employee director" under Rule&nbsp;16b-3,
(ii)&nbsp;an "outside director" under Section&nbsp;162(m) of the Code and the regulations thereunder and (iii)&nbsp;an "independent director" under the rules of any national securities exchange
on which the shares of Stock are then listed. If it is later determined that one or more members of the Administrator do not so qualify, actions taken by the Administrator shall be valid despite such
failure to qualify. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Powers of Administrator.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall have the power and authority to grant Awards consistent
with the terms of the Plan, including the power and authority: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;to
select the individuals to whom Awards may from time to time be granted; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;to
determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock
Awards, Deferred Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, Performance Share </FONT></P>

</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=71,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=53582,FOLIO='A-3',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_4"> </A>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Awards
and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;to
determine the number of shares of Stock to be covered by any Award; </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;to
determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and
conditions may differ among individual Awards and grantees, and to approve the form of written instruments evidencing the Awards; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v)&nbsp;&nbsp;to
accelerate the exercisability or vesting of all or any portion of any Award upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a
Change of Control or Sale Event; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi)&nbsp;&nbsp;subject
to the provisions of Section&nbsp;5(b), to extend at any time the period in which Stock Options may be exercised; and </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii)&nbsp;&nbsp;at
any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem
advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to
decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Delegation of Authority to Grant Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to applicable law, the Administrator, in its discretion,
may delegate to the Chief Executive Officer of the Company all or part of the Administrator's authority and duties with respect to the granting of Options, to individuals who are (i)&nbsp;not
subject to the reporting and other provisions of Section&nbsp;16 of the Exchange Act and (ii)&nbsp;not Covered Employees. Any such delegation by the Administrator shall include a limitation as to
the amount of Options that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may
revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator's delegate or delegates that were consistent with the terms of the
Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Award Agreement.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Awards under the Plan shall be evidenced by Award Agreements that set forth the terms,
conditions and limitations for each Award which may include, without limitation, the term of an Award, the provisions applicable in the event employment or service terminates, and the Company's
authority to unilaterally or bilaterally amend, modify, suspend, cancel or rescind an Award. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Indemnification.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither the Board nor the Administrator, nor any member of either or any delegate thereof,
shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any
delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable
attorneys' fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company's articles or bylaws or any directors' and officers' liability insurance coverage which
may be in effect from time to time and/or any indemnification agreement between such individual and the Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Stock Issuable.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The maximum number of shares of Stock reserved and available for issuance under the Plan
shall be 14,350,000 shares, subject to adjustment as provided in Section&nbsp;3(b) (the "</FONT><FONT SIZE=2><I>Share Reserve</I></FONT><FONT SIZE=2>"); provided that not more than 500,000 shares
shall be issued in the form of Unrestricted Stock </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=72,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=355842,FOLIO='A-4',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2>Awards,
Restricted Stock Awards, Deferred Stock Awards or Performance Share Awards. For purposes of this limitation, the shares of Stock underlying the Awards granted under the Plan that are
forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan. Shares (i)&nbsp;tendered or withheld in payment
of an Option, (ii)&nbsp;tendered or withheld to satisfy any tax withholding obligation or (iii)&nbsp;repurchased by the Company with Option proceeds, shall not revert to or be added back to the
Share Reserve. Further, shares of Stock covered by a Stock Appreciation Right, to the extent that it is exercised and settled in shares of Stock, and whether or not shares of Stock are actually issued
to the grantee upon the exercise of the Stock Appreciation Right, shall be considered issued or transferred pursuant to the Plan. Subject to such overall limitations, shares of Stock may be issued up
to such maximum number pursuant to any type or types of Award; provided, however, that Stock Options or Stock Appreciation Rights with respect to no more than 2,000,000 shares of Stock may be granted
to any one individual grantee during any one calendar year period. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the
Company. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Changes in Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to Section&nbsp;3(c) hereof, if, as a result of any reorganization,
recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company's capital stock, the outstanding shares of Stock are increased or decreased
or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash
assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the
outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or
proportionate adjustment in (i)&nbsp;the maximum number of shares reserved for issuance under the Plan, including the maximum number of
shares that may be issued in the form of Unrestricted Stock Awards, Restricted Stock Awards, Deferred Stock Awards or Performance Share Awards, (ii)&nbsp;the number of Stock Options or Stock
Appreciation Rights that can be granted to any one individual grantee in one calendar year and the maximum number of shares that may be granted under a Performance-Based Award, (iii)&nbsp;the number
and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iv)&nbsp;the repurchase price, if any, per share subject to each outstanding Restricted Stock Award,
and (v)&nbsp;the price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e.,&nbsp;the
exercise price multiplied by the number of Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also
make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends
paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be
issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Mergers and Other Transactions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon the effective time of the Sale Event, the Plan and all outstanding
Awards granted hereunder shall terminate, unless provision is made in connection with the Sale Event in the sole discretion of the parties thereto for the assumption or continuation by the successor
entity of Awards theretofore granted, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and,
if appropriate, the per share exercise prices, as such parties shall agree (after taking into account any acceleration hereunder). In the event of such termination, (i)&nbsp;the Company shall have
the option (in its sole discretion) to make or provide for a cash payment to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to
the difference between (A)&nbsp;the Sale Price multiplied by the number of shares of Stock subject to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=73,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=877387,FOLIO='A-5',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2>outstanding
Options and Stock Appreciation Rights (to the extent then exercisable (after taking into account any acceleration hereunder) at prices not in excess of the Sale Price) and (B)&nbsp;the
aggregate exercise price of all such outstanding Options and Stock Appreciation Rights; or (ii)&nbsp;each grantee shall be permitted, within a specified period of time prior to the consummation of
the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights held by such grantee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Substitute Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may grant Awards under the Plan in substitution for stock and stock
based awards held by employees, directors or other key persons of another corporation in connection with the merger or consolidation of the employing corporation with the Company or a Subsidiary or
the acquisition by the Company or a Subsidiary of property or stock of the employing corporation. The Administrator may direct that the substitute awards be granted on such terms and conditions as the
Administrator considers appropriate in the circumstances. Any substitute Awards granted under the Plan shall not count against the share limitation set forth in Section&nbsp;3(a). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;ELIGIBILITY</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grantees
under the Plan will be such full or part-time officers and other employees, Non-Employee Directors and key persons (including consultants and prospective employees) of the
Company and its Subsidiaries as are selected from time to time by the Administrator in its sole discretion. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STOCK OPTIONS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any
Subsidiary that is a "subsidiary corporation" within the meaning of Section&nbsp;424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a
Non-Qualified Stock Option. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stock
Options granted pursuant to this Section&nbsp;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent
with the terms of the Plan, as the Administrator shall deem desirable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The exercise price per share for the Stock covered by a Stock Option granted pursuant to
this Section&nbsp;5 shall be determined by the Administrator at the time of grant but shall not be less than 100&nbsp;percent of the Fair Market Value on the Date of Grant. In the case of an
Incentive Stock Option that is granted to a Ten Percent Owner, the option price of such Incentive Stock Option shall be not less than 110&nbsp;percent of the Fair Market Value on the Date of Grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Option Term.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be
exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no
more than five years from the Date of Grant. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercisability; Rights of a Stockholder.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Options shall become exercisable at such time or times,
whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may accelerate the exercisability of all or any portion of any Stock Option
upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a Change of Control or Sale Event. An optionee shall
have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=74,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=849721,FOLIO='A-6',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Method of Exercise.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Options may be exercised in whole or in part, by giving written notice of exercise
to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods to the extent provided in the Option Award Agreement: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;In
cash, by certified or bank check or other instrument acceptable to the Administrator; </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;Through
the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the optionee on the open market or that are beneficially owned by
the optionee and are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date. To the extent required to avoid
variable accounting treatment under applicable accounting rules, such surrendered shares shall have been owned by the optionee for at least six months; or </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;By
the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company
cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker
shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>Payment
instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the
exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full
purchase price for such shares and the fulfillment of any other requirements contained in the Option Award Agreement or applicable provisions of laws (including the satisfaction of any withholding
taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation
method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for
itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless
exercise of Stock Options may be permitted through the use of such an automated system. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Annual Limit on Incentive Stock Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;To the extent required for "incentive stock option" treatment
under Section&nbsp;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan
and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that
any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STOCK APPRECIATION RIGHTS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise Price of Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The exercise price of a Stock Appreciation Right shall not be
less than 100&nbsp;percent of the Fair Market Value of the Stock on the Date of Grant. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Grant and Exercise of Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights may be granted by the
Administrator independently of any Stock Option granted pursuant to Section&nbsp;5 of the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Terms and Conditions of Stock Appreciation Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Stock Appreciation Rights shall be subject to such terms
and conditions as shall be determined from time to time by the Administrator. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=75,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=741062,FOLIO='A-7',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;RESTRICTED STOCK AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nature of Restricted Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall determine the restrictions and conditions
applicable to each Restricted Stock Award at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established performance goals
and objectives. The grant of a Restricted Stock Award is contingent on the grantee executing the Restricted Stock Award Agreement. The terms and conditions of each such Award Agreement shall be
determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights as a Stockholder.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Upon execution of the Restricted Stock Award Agreement and payment of any
applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Stock, subject to such conditions contained in the Restricted Stock Award
Agreement.
Unless the Administrator shall otherwise determine, (i)&nbsp;uncertificated Restricted Stock shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that
they are subject to forfeiture until such Restricted Stock are vested as provided in Section&nbsp;7(d) below, and (ii)&nbsp;certificated Restricted Stock shall remain in the possession of the
Company until such Restricted Stock is vested as provided in Section&nbsp;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of
transfer as the Administrator may prescribe. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Restrictions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Restricted Stock may not be sold, assigned, transferred, pledged or otherwise encumbered or
disposed of except as specifically provided herein or in the Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to
Section&nbsp;18 below, in writing after the Award Agreement is issued if a grantee's employment (or other service relationship) with the Company and its Subsidiaries terminates for any reason, any
Restricted Stock that has not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed
to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee's legal representative simultaneously with such termination of employment (or other
service relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of unvested
Restricted Stock that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Vesting of Restricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator at the time of grant shall specify the date or dates and/or
the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Stock and the Company's right of repurchase or forfeiture shall
lapse. Notwithstanding the foregoing, in the event that any such Restricted Stock granted to employees shall have a performance-based goal, the restriction period with respect to such shares shall not
be less than one year, and in the event any such Restricted Stock granted to employees shall have a time-based restriction, the total restriction period with respect to such shares shall not be less
than three years; provided, however, that Restricted Stock with a time-based restriction may become vested incrementally over such three-year period. Subsequent to such date or dates and/or the
attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Stock and shall be deemed
"vested." Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section&nbsp;18 below, in writing after the Award Agreement is issued (but in such
case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a grantee's Disability, or (3)&nbsp;a Change of Control or Sale Event), a grantee's rights in any
shares of Restricted Stock that have not vested shall automatically terminate upon the grantee's termination of employment (or other service relationship) with the Company and its Subsidiaries and
such shares shall be subject to the provisions of Section&nbsp;7(c) above. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=76,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=7864,FOLIO='A-8',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;8.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;DEFERRED STOCK AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nature of Deferred Stock Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator shall determine the restrictions and conditions
applicable to each Deferred Stock Award at the time of grant. Conditions may be based on continuing employment (or other service relationship) and/or achievement of pre-established performance goals
and objectives. The grant of a Deferred Stock Award is contingent on the grantee executing the Deferred Stock Award Agreement. The terms and conditions of each such Award Agreement shall be determined
by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Notwithstanding the foregoing, in the event that any such Deferred Stock Award granted to employees
shall have a performance-based goal, the restriction period with respect to such Award shall not be less than one year, and in the event any such Deferred Stock Award granted to employees shall have a
time-based restriction, the total restriction period with respect to such Award shall not be less than three years; provided, however, that any Deferred Stock Award with a time-based restriction may
become vested incrementally over such three-year period. At the end of the deferral period, the Deferred Stock Award, to the extent vested, shall be settled in the form of shares of Stock. To the
extent that a Deferred Stock Award is subject to Section&nbsp;409A, it may contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order for such
Award to comply with the requirements of Section&nbsp;409A. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Election to Receive Deferred Stock Awards in Lieu of Compensation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may, in its sole
discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of a Deferred Stock Award. Any such election shall be made in writing
and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section&nbsp;409A and such other rules and procedures established by the
Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of phantom stock units based on the Fair Market Value of Stock on the date the
compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what
circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights as a Stockholder.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A grantee shall have the rights as a stockholder only as to shares of Stock
acquired by the grantee upon settlement of a Deferred Stock Award; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the phantom stock units
underlying his Deferred Stock Award, subject to such terms and conditions as the Administrator may determine. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award Agreement or,
subject to Section&nbsp;18 below, in writing after the Award Agreement is issued (but in such case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a
grantee's Disability, or (3)&nbsp;a Change of Control or Sale Event), a grantee's right in all Deferred Stock Awards that have not vested shall automatically terminate upon the grantee's termination
of employment (or cessation of service relationship) with the Company and its Subsidiaries for any reason. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;9.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;UNRESTRICTED STOCK AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant or Sale of Unrestricted Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may, in its sole discretion, grant (or sell at par value or such higher purchase
price
determined by the Administrator) an Unrestricted Stock Award under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash
compensation due to such grantee. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;10.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;CASH-BASED AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Grant of Cash-Based Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may, in its sole discretion, grant Cash-Based Awards to any grantee in such number or
amount and upon
such terms, and subject to such conditions, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=77,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=632413,FOLIO='A-9',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2>as
the Administrator shall determine at the time of grant. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains,
the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated
payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be
made in cash or in shares of Stock, as the Administrator determines. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;11.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;PERFORMANCE SHARE AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Nature of Performance Share Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may, in its sole discretion, grant Performance Share
Awards independent of, or in connection with, the granting of any other Award under the Plan. The Administrator shall determine whether and to whom Performance Share Awards shall be granted, the
Performance Goals, the periods during which performance is to be measured, and such other limitations and conditions as the Administrator shall determine. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights as a Stockholder.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A grantee receiving a Performance Share Award shall have the rights of a
stockholder only as to shares actually received by the grantee under the Plan and not with respect to shares subject to the Award but not actually received by the grantee. A grantee shall be entitled
to receive shares of Stock under a Performance Share Award only upon satisfaction of all conditions
specified in the Performance Share Award agreement (or in a performance plan adopted by the Administrator). </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award agreement or,
subject to Section&nbsp;18 below, in writing after the Award agreement is issued (but in such case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a
grantee's Disability, or (3)&nbsp;a Change of Control or Sale Event), a grantee's rights in all Performance Share Awards shall automatically terminate upon the grantee's termination of employment
(or cessation of service relationship) with the Company and its Subsidiaries for any reason. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;12.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;PERFORMANCE-BASED AWARDS TO COVERED EMPLOYEES</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Performance-Based Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any employee or other key person providing services to the Company and who is
selected by the Administrator may be granted one or more Performance-Based Awards in the form of a Restricted Stock Award, Deferred Stock Award, Performance Share Awards or Cash-Based Award payable
upon the attainment of Performance Goals that are established by the Administrator and relate to one or more of the Performance Criteria, in each case on a specified date or dates or over any period
or periods determined by the Administrator. The Administrator shall define in an objective fashion the manner of calculating the Performance Criteria it selects to use for any Performance Period.
Depending on the Performance Criteria used to establish such Performance Goals, the Performance Goals may be expressed in terms of overall Company performance or the performance of a division,
business unit, or an individual. The Administrator, in its discretion, may adjust or modify the calculation of Performance Goals for such Performance Period in order to prevent the dilution or
enlargement of the rights of an individual (i)&nbsp;in the event of, or in anticipation of, any unusual or extraordinary corporate item, transaction, event or development, (ii)&nbsp;in recognition
of, or in anticipation of, any other unusual or nonrecurring events affecting the Company, or the financial statements of the Company, or (iii)&nbsp;in response to, or in anticipation of, changes in
applicable laws, regulations, accounting principles, or business conditions provided however, that the Administrator may not exercise such discretion in a manner that would increase the
Performance-Based Award granted to a Covered Employee. Each Performance-Based Award shall comply with the provisions set forth below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Grant of Performance-Based Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;With respect to each Performance-Based Award granted to a Covered
Employee, the Administrator shall select, within the first 90&nbsp;days of a Performance Cycle (or, if shorter, within the maximum period allowed under Section&nbsp;162(m) of the </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=78,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=394402,FOLIO='A-10',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2>Code)
the Performance Criteria for such grant, and the Performance Goals with respect to each Performance Criterion (including a threshold level of performance below which no amount will become
payable with respect to such Award). Each Performance-Based Award will specify the amount payable,
or the formula for determining the amount payable, upon achievement of the various applicable performance targets. The Performance Criteria established by the Administrator may be (but need not be)
different for each Performance Cycle and different Performance Goals may be applicable to Performance-Based Awards to different Covered Employees. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Payment of Performance-Based Awards.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Following the completion of a Performance Cycle, the Administrator
shall meet to review and certify in writing whether, and to what extent, the Performance Goals for the Performance Cycle have been achieved and, if so, to also calculate and certify in writing the
amount of the Performance-Based Awards earned for the Performance Cycle. The Administrator shall then determine the actual size of each Covered Employee's Performance-Based Award, and, in doing so,
may reduce or eliminate the amount of the Performance-Based Award for a Covered Employee if, in its sole judgment, such reduction or elimination is appropriate. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Maximum Award Payable.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The maximum Performance-Based Award payable to any one Covered Employee under the
Plan in respect of any calendar year is (i)&nbsp;250,000 shares of Stock (subject to adjustment as provided in Section&nbsp;3(b) hereof) for a Performance-Based Award that is a Restricted Stock
Award, Deferred Stock Award or Performance Share Award and (ii)&nbsp;$1,000,000 in value for a Performance-Based Award that is a Cash-Based Award. In the case of Performance Goals based on
Performance Cycles beginning and ending in different calendar years, the number of shares of Stock or cash amount which is paid in respect of each calendar year during the Performance Cycle shall be
determined by multiplying the total number of shares of Stock or cash amount, as applicable, paid for the Performance Cycle by a fraction, of which (i)&nbsp;the numerator is the number of days
during the Performance Cycle in that particular calendar year, and (ii)&nbsp;the denominator is the total number of days during the Performance Cycle. The limitations in this Section&nbsp;12(d)
shall be interpreted and applied in a manner consistent with Section&nbsp;162(m) of the Code and the regulations thereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;13.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;DIVIDEND EQUIVALENT RIGHTS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Dividend Equivalent Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;A Dividend Equivalent Right may be granted hereunder to any grantee as a
component of a Deferred Stock Award, Restricted Stock Award or Performance Share Award or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the
Award Agreement. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter
accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the
Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a
component of a Deferred Stock Award, Restricted Stock Award or Performance Share Award may provide that such Dividend Equivalent Right shall be settled upon settlement or payment of, or lapse of
restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award. A Dividend Equivalent Right granted
as a component of a Deferred Stock Award, Restricted Stock Award or Performance Share Award may also contain terms and conditions different from such other Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Interest Equivalents.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Any Award under this Plan that is settled in whole or in part in cash on a deferred
basis may provide in the grant for interest equivalents to be credited with respect to such cash payment. Interest equivalents may be compounded and shall be paid upon such terms and conditions as may
be specified by the grant. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=79,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=327759,FOLIO='A-11',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may otherwise be provided by the Administrator either in the Award Agreement or,
subject to Section&nbsp;18 below, in writing after the Award Agreement is issued (but in such case only with respect to acceleration of vesting upon (1)&nbsp;a grantee's death, (2)&nbsp;a
grantee's Disability, or (3)&nbsp;a Change of Control or Sale Event), a grantee's rights in all Dividend Equivalent Rights or interest equivalents granted as a component of a Deferred Stock Award,
Restricted Stock Award or Performance Share Award that has not vested shall automatically terminate upon the grantee's termination of employment (or cessation of service relationship) with the Company
and its Subsidiaries for any reason. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;14.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;TRANSFERABILITY OF AWARDS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Transferability.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as provided in Section&nbsp;14(b) below, during a grantee's lifetime, his or her
Awards shall be exercisable only by the grantee, or by the grantee's legal representative or guardian in the event of the grantee's incapacity. No Awards shall be sold, assigned, transferred or
otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of
any kind, and any purported transfer in violation hereof shall be null and void. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Administrator Action.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding Section&nbsp;14(a), the Administrator, in its discretion, may
provide either in the Award Agreement regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Awards (other than any
Incentive Stock Options) to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that
the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Family Member.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;For purposes of Section&nbsp;14(b), "family member" shall mean a grantee's child,
stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law,
including adoptive relationships, any person sharing the grantee's household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50&nbsp;percent of
the beneficial interest, a
foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50&nbsp;percent of the voting
interests. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Designation of Beneficiary.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each grantee to whom an Award has been made under the Plan may designate a
beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee's death. Any such designation shall be on a form provided for that purpose by
the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the
grantee, the beneficiary shall be the grantee's estate. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;15.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;TAX WITHHOLDING</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Payment by Grantee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each grantee shall, no later than the date as of which the value of an Award or of any
Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the
Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to
the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company's obligation to deliver evidence of book entry (or stock
certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=80,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=44230,FOLIO='A-12',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Payment in Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Subject to approval by the Administrator, a grantee may elect to have the Company's
minimum required tax withholding obligation satisfied, in whole or in part, by authorizing the Company to withhold from shares of Stock to be issued pursuant to any Award a number of shares with an
aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;16.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;SECTION&nbsp;409A AWARDS.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent applicable, it is intended that the Plan and all Awards hereunder comply with the requirements of Section&nbsp;409A or an exemption thereto, and the Plan and all Award
Agreements shall be interpreted and applied by the Administrator in a manner consistent with this intent in order to avoid the imposition of any additional tax under Section&nbsp;409A.
Notwithstanding anything in the Plan or an Award Agreement to the contrary, in the event that any provision of the Plan or an Award
Agreement is determined by the Administrator, in its sole discretion, to not comply with the requirements of Section&nbsp;409A or an exemption thereto, the Administrator shall, in its sole
discretion, have the authority to take such actions and to make such interpretations or changes to the Plan or an Award Agreement as the Administrator deems necessary, regardless of whether such
actions, interpretations, or changes shall adversely affect a grantee, subject to the limitations, if any, of applicable law. To the extent that any Award is determined to constitute "nonqualified
deferred compensation" within the meaning of Section&nbsp;409A (a "</FONT><FONT SIZE=2><I>409A Award</I></FONT><FONT SIZE=2>"), the Award shall be subject to such additional rules and requirements
as specified by the Administrator from time to time in order to comply with Section&nbsp;409A. In this regard, if any amount under a 409A Award is payable upon a "separation from service" (within
the meaning of Section&nbsp;409A) to a grantee who is then considered a "specified employee" (within the meaning of Section&nbsp;409A), then no such payment shall be made prior to the date that is
the earlier of (i)&nbsp;six months and one day after the grantee's separation from service, or (ii)&nbsp;the grantee's death, but only to the extent such delay is necessary to prevent such payment
from being subject to interest, penalties and/or additional tax imposed pursuant to Section&nbsp;409A. Further, the settlement of any such Award may not be accelerated except to the extent permitted
by Section&nbsp;409A. In no event whatsoever shall the Company be liable for any additional tax, interest or penalties that may be imposed on any grantee by Section&nbsp;409A or any damages for
failing to comply with Section&nbsp;409A. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;17.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;TRANSFER, LEAVE OF ABSENCE, ETC.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of the Plan, the following events shall not be deemed a termination of employment: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;a
transfer to the employment of the Company from a Subsidiary or from the Company to a Subsidiary, or from one Subsidiary to another; or </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;an
approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee's right to re-employment is guaranteed
either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;18.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;AMENDMENTS AND TERMINATION</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or
for any other lawful purpose, but no such action shall (a)&nbsp;adversely affect rights under any outstanding Award without the holder's consent or (b)&nbsp;except as provided in
Section&nbsp;3(b) or 3(c), without the prior approval of the Company's stockholders, (1)&nbsp;reduce the exercise price of or otherwise reprice, including through replacement grants, any
outstanding Stock Option or Stock Appreciation Right or (2)&nbsp;cancel in exchange for, or otherwise exchange for, cash or other securities any outstanding Stock Option or Stock Appreciation Right
with an exercise price at or above the then-current Fair Market Value of the Stock. To the extent required under the rules of any securities exchange or market system on which the Stock </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=81,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=238898,FOLIO='A-13',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2>is
listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section&nbsp;422 of the Code or
to ensure that compensation earned under Awards qualifies as performance-based compensation under Section&nbsp;162(m) of the Code, Plan amendments shall be subject to approval by the Company
stockholders entitled to vote at a meeting of stockholders. Nothing in this Section&nbsp;18 shall limit the Administrator's authority to take any action permitted pursuant to Section&nbsp;3(c). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;19.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;STATUS OF PLAN</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights
greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator
may authorize the creation of trusts or other arrangements to meet the Company's obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such
trusts or other arrangements is consistent with the foregoing sentence. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;20.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;CHANGE OF CONTROL PROVISIONS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the occurrence of a Change of Control as defined in this Section&nbsp;20: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;Unless
provision is made in connection with the Change of Control for the assumption or continuation by the successor entity of Awards theretofore granted, or the
substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise
prices, as such parties shall agree, each outstanding Stock Option, Stock Appreciation Right and Dividend Equivalent Right shall automatically become fully exercisable. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;Unless
provision is made in connection with the Change of Control for the assumption or continuation by the successor entity of Awards theretofore granted, or the
substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares as such parties shall agree,
(i)&nbsp;conditions and restrictions on each outstanding Restricted Stock Award, Deferred Stock Award and Performance Share Award which relate solely to the passage of time and continued employment
will be removed. Performance or other
conditions (other than conditions and restrictions relating solely to the passage of time and continued employment) will continue to apply unless otherwise provided in the applicable Award Agreement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;"Change
of Control" shall mean the occurrence of any one of the following events: </FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&nbsp;any
"</FONT><FONT SIZE=2><I>Person</I></FONT><FONT SIZE=2>," as such term is used in Sections&nbsp;13(d) and 14(d) of the Act (other than the Company, any of its
Subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its Subsidiaries), together with all "affiliates"
and "associates" (as such terms are defined in Rule&nbsp;12b-2 under the Act) of such person, shall become the "beneficial owner" (as such term is defined in Rule&nbsp;13d-3 under the Act),
directly or indirectly, of securities of the Company representing 25&nbsp;percent or more of the combined voting power of the Company's then outstanding securities having the right to vote in an
election of the Company's Board of Directors ("Voting Securities") (in such case other than as a result of an acquisition of securities directly from the Company); or </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii)&nbsp;&nbsp;persons
who, as of the Effective Date, constitute the Company's Board of Directors (the "Incumbent Directors") cease for any reason, including, without limitation, as a
result of a tender offer, proxy contest, merger or similar transaction, to constitute at least a majority of the Board, provided that any person becoming a director of the Company subsequent to the </FONT></P>

</UL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=14,SEQ=82,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=252545,FOLIO='A-14',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_15"> </A>
<UL>
<UL>

<P style="font-family:times;"><FONT SIZE=2>Effective
Date shall be considered an Incumbent Director if such person's election was approved by or such person was nominated for election by either (A)&nbsp;a vote of at least a majority of the
Incumbent Directors or (B)&nbsp;a vote of at least a majority of the Incumbent Directors who are members of a nominating committee comprised, in the majority, of Incumbent Directors; but provided
further, that any such person whose initial assumption of office is in connection with an actual or threatened election contest relating to the election of members of the Board of Directors or other
actual or threatened solicitation of proxies or consents by or on behalf of a </FONT><FONT SIZE=2><I>Person</I></FONT><FONT SIZE=2> other than the Board, including by reason of agreement intended to
avoid or settle any such actual or threatened contest or solicitation, shall not be considered an Incumbent Director; or </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii)&nbsp;&nbsp;the
consummation of (A)&nbsp;any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger,
would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule&nbsp;13d-3 under the Act), directly or indirectly, shares representing in the aggregate
more than 50&nbsp;percent of the voting shares of the
corporation issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), (B)&nbsp;any sale, lease, exchange or other transfer (in one transaction or a
series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company; or </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv)&nbsp;&nbsp;the
stockholders of the Company shall approve any plan or proposal for the liquidation or dissolution of the Company. </FONT></P>

</UL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, a "Change of Control" shall not be deemed to have occurred for purposes of the foregoing clause&nbsp;(i) solely as the result of an acquisition of
securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of shares of Voting Securities beneficially owned by any person
to 25&nbsp;percent or more of the combined voting power of all then outstanding Voting Securities; </FONT><FONT SIZE=2><I>provided</I></FONT><FONT SIZE=2>, </FONT> <FONT SIZE=2><I>however</I></FONT><FONT SIZE=2>, that if any person referred to in
this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities
(other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company), then a </FONT><FONT SIZE=2><I>"Change of
Control"</I></FONT><FONT SIZE=2> shall be deemed to have occurred for purposes of the foregoing clause&nbsp;(i). </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;21.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;GENERAL PROVISIONS</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;No Distribution.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Administrator may require each person acquiring Stock pursuant to an Award to represent
to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Delivery of Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding any provision of the Plan to the contrary, unless otherwise determined by
the Administrator or required by any applicable law, rule or regulation, any obligation set forth in the Plan pertaining to the delivery or issuance of stock certificates evidencing shares of Stock
may be satisfied by having issuance and/or ownership of such shares recorded on the books and records of the Company (or, as applicable, its transfer agent or stock plan administrator). Stock
certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States
mail, addressed to the grantee, at the grantee's last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent
of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee's last known address on file with the
Company, notice of issuance and recorded the issuance in its records (which may include electronic "book entry" records). Notwithstanding anything herein to the contrary, the Company shall not be
required to issue or deliver any shares of Stock pursuant to the exercise of any Award, unless and until </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=15,SEQ=83,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=185220,FOLIO='A-15',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lc16401_1_16"> </A>

<P style="font-family:times;"><FONT SIZE=2>the
Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery of such shares is in compliance with
all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. All shares of Stock
delivered pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign
jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate to reference
restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and
representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to
require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the
discretion of the Administrator. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Stockholder Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Until Stock is deemed delivered in accordance with Section&nbsp;21(b), no right to
vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or
any other action by the grantee with respect to an Award. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Other Compensation Arrangements; No Employment Rights.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained in this Plan shall prevent the
Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this
Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Trading Policy Restrictions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Option exercises and other Awards under the Plan shall be subject to such
Company's insider trading policy and procedures, as in effect from time to time. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Forfeiture of Awards under Sarbanes-Oxley Act.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the Company is required to prepare an accounting
restatement due to the material noncompliance of the Company, as a result of misconduct, with any financial reporting requirement under the securities laws, then any grantee who is one of the
individuals subject to automatic forfeiture under Section&nbsp;304 of the Sarbanes-Oxley Act of 2002 shall reimburse the Company for the amount of any Award received by such individual under the
Plan during the 12-month period following the first public issuance or filing with the United States Securities and Exchange Commission, as the case may be, of the financial document embodying such
financial reporting requirement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;22.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;EFFECTIVE DATE OF PLAN</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
amended and restated Plan shall become effective upon approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present. No grants of
Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the
date the amended and restated Plan is approved by the Board. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>SECTION&nbsp;23.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;GOVERNING LAW</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law
principles. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="lc16401_adoption_and_approval___lc102105"> </A>
<A NAME="toc_lc16401_3"> </A>
<BR></FONT><FONT SIZE=2>ADOPTION AND APPROVAL OF PLAN (AS AMENDED AND RESTATED):    <BR></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Date
Amended and Restated Plan Adopted by Board: April&nbsp;17, 2015<BR>
Date Amended and Restated Plan Adopted by Stockholders/Effective Date: June&nbsp;10, 2015 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>A-16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=16,SEQ=84,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=665585,FOLIO='A-16',FILE='DISK105:[17ZAE1.17ZAE16401]LC16401A.;7',USER='CHE106465',CD='24-APR-2017;09:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A
NAME="page_lk16401_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->
<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><A
NAME="lk16401_appendix_b"> </A>
<A NAME="toc_lk16401_1"> </A>
<BR></FONT><FONT SIZE=2><B>  Appendix B    <BR>    </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="lk16401_celldex_therapeutics,_inc._200__cel03304"> </A>
<A NAME="toc_lk16401_2"> </A></FONT> <FONT SIZE=2><B>CELLDEX THERAPEUTICS,&nbsp;INC.</B></FONT><BR><FONT SIZE=2><B>2004 EMPLOYEE STOCK PURCHASE PLAN</B></FONT><FONT SIZE=2><B><BR>  As amended effective as of July&nbsp;1, 2015    <BR>
</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Purpose.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Celldex Therapeutics,&nbsp;Inc. 2004 Employee Stock Purchase Plan (the "Plan")
is to provide eligible employees of Celldex Therapeutics,&nbsp;Inc. (the "Company") and certain of its subsidiaries with opportunities to purchase shares of the Company's common stock, par value
$.01 per share (the "Common Stock"). Two Hundred Thousand (200,000) shares of Common Stock in the aggregate have been approved and reserved for this purpose. The Plan is intended to constitute an
"employee stock purchase plan" within the meaning of Section&nbsp;423(b) of the Internal Revenue Code of 1986, as amended (the "Code"), and shall be interpreted in accordance with that intent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Administration.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan will be administered by the person or persons (the "Administrator") appointed by the
Company's Board of Directors (the "Board") for such purpose. The Administrator has authority to make rules and regulations for the administration of the Plan, and its interpretations and decisions
with regard thereto shall be final and conclusive. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination
made in good faith with respect to the Plan or any option granted hereunder. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Offerings.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company will make one or more offerings to eligible employees to purchase Common Stock under
the Plan ("Offerings"). Unless otherwise determined by the Administrator, each Offering will begin on the first business day occurring on or after each January&nbsp;1 and July&nbsp;1 and will end
on the last business day occurring on or before the following June&nbsp;30 and December&nbsp;31, respectively. The Administrator may, in its discretion, designate a different period for any
Offering, provided that no Offering shall exceed 27&nbsp;months in duration or overlap any other Offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Eligibility.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each individual classified as an employee (within the meaning of Section&nbsp;3401(c) of the
Code and the regulations thereunder) by the Company or a Designated Subsidiary (as defined in Section&nbsp;12) on the Company's or the Designated Subsidiary's payroll records during the relevant
participation period are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the "Offering Date") they are
customarily employed by the Company or a Designated Subsidiary for more than 20&nbsp;hours a week and more than five months in the calendar year during which the Offering Date occurs or in the
calendar year immediately preceding such year, and have completed at least 30&nbsp;days of employment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Participation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An employee eligible on any Offering Date may participate in such Offering by submitting an
enrollment form to his appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established for the Offering). The form will
(a)&nbsp;state a whole percentage to be deducted from his Compensation (as defined in Section&nbsp;12) per pay period, (b)&nbsp;authorize the purchase of Common Stock for him in each Offering in
accordance with the terms of the Plan and (c)&nbsp;specify the exact name or names in which shares of Common Stock purchased for him are to be issued pursuant to Section&nbsp;11. An employee who
does not enroll in accordance with these procedures will be deemed to have waived his right to participate. Unless an employee files&nbsp;a new enrollment form or withdraws from the Plan, his
deductions and purchases will continue at the same percentage of Compensation for future Offerings, provided he remains eligible. Notwithstanding the foregoing, participation in the Plan will neither
be permitted nor be denied contrary to the requirements of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Employee Contributions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each eligible employee may authorize payroll deductions at a minimum of one percent
(1%) up to a maximum of fifteen percent (15%) of his Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=85,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=592660,FOLIO='B-1',FILE='DISK105:[17ZAE1.17ZAE16401]LK16401A.;4',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lk16401_1_2"> </A>

<P style="font-family:times;"><FONT SIZE=2>made
by each participating employee for each Offering. No interest will accrue or be paid on payroll deductions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Deduction Changes.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Except as may be determined by the Administrator in advance of an Offering, an employee
may not increase or decrease his payroll deduction during any Offering, but may increase or decrease his payroll deduction with respect to the next Offering (subject to the limitations of
Section&nbsp;6) by filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established for the Offering). The Administrator may,
in advance of any Offering, establish rules permitting an employee to increase, decrease or terminate his payroll deduction during an Offering. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Withdrawal.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;An employee may withdraw from participation in the Plan by delivering a written notice of
withdrawal to his appropriate payroll location. The employee's withdrawal will be effective as of the next business day. Following an employee's withdrawal, the Company will promptly refund to him his
entire account balance under the Plan (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. The employee may not begin
participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section&nbsp;5. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Grant of Options.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;On each Offering Date, the Company will grant to each eligible employee who is then a
participant in the Plan an option ("Option") to purchase on the last day of such Offering (the "Exercise Date"), at the Option Price hereinafter provided for, (a)&nbsp;a number of shares of Common
Stock determined by dividing such employee's accumulated payroll deductions on such Exercise Date by the lower of (i)&nbsp;85% of the Fair Market Value of the Common Stock on the Offering Date, or
(ii)&nbsp;85% of the Fair Market Value of the Common Stock on the Exercise Date, or (b)&nbsp;such other lesser maximum number of shares as shall have been established by the Administrator in
advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each employee's Option shall be exercisable only to the extent of such employee's
accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased under each Option (the "Option Price") will be 85% of the Fair Market Value of the Common Stock on the
Offering Date or the Exercise Date, whichever is less. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
the foregoing, no employee may be granted an option hereunder if such employee, immediately after the option was granted, would be treated as owning stock possessing five
percent (5%) or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section&nbsp;12). For purposes of the preceding
sentence, the attribution rules of Section&nbsp;424(d) of the Code shall apply in determining the stock ownership of an employee, and all stock which the employee has a contractual right to purchase
shall be treated as stock owned by the employee. In addition, no employee may be granted an Option which permits his rights to purchase stock under the Plan, and any other employee stock purchase plan
of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of
such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply
with Section&nbsp;423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Exercise of Option and Purchase of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each employee who continues to be a participant in the Plan on
the Exercise Date shall be deemed to have exercised his Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his
accumulated payroll deductions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in an employee's account at the end of an
Offering will be refunded to the employee promptly. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=86,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=505115,FOLIO='B-2',FILE='DISK105:[17ZAE1.17ZAE16401]LK16401A.;4',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lk16401_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Certificates.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Certificates representing shares of Common Stock purchased under the Plan may be
issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee
to be his, or their, nominee for such purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Definitions.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;The
term "Compensation" means the amount of base pay, prior to salary reduction pursuant to either Sections&nbsp;125, 132(f) or 401(k) of the Code, but excluding
overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise of Company stock options,
and similar items. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;The
term "Designated Subsidiary" means any present or future Subsidiary (as defined below) that has been designated by the Board to participate in the Plan. The Board
may so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by stockholders. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&nbsp;&nbsp;The
term "Fair Market Value of the Common Stock" as of any date of determination shall be (i)&nbsp;the closing price of a share of Common Stock as of such date on the
principal established stock exchange or national market system on which the Common Stock is then traded (or, if there is no trading in the Common Stock as of such date, the closing price of a share of
Common Stock on the most recent date preceding such date on which trades of the Common Stock were recorded), or (ii)&nbsp;if the shares of Common Stock are not then traded on an established stock
exchange or national market system but are
then traded in an over-the-counter market, the average of the closing bid and asked prices for the shares of Common Stock in such over-the-counter market as such date (or, if there are no closing bid
and asked prices for the shares of Stock as of such date, the average of the closing bid and the asked prices for the shares of Common Stock on the most recent date preceding such date on which such
closing bid and asked prices are available on such over-the-counter market), or (iii)&nbsp;if the shares of Common Stock are not then listed on a national securities exchange or national market
system or traded in an over-the-counter market, the price of a share of Common Stock as determined by the Administrator in its discretion in a manner consistent with Section&nbsp;409A of the Code
and Treasury Regulation&nbsp;1.409A-1(b)(5)(iv), as well as any successor regulation or interpretation. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&nbsp;&nbsp;The
term "Parent" means a "parent corporation" with respect to the Company, as defined in Section&nbsp;424(e) of the Code. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&nbsp;&nbsp;The
term "Subsidiary" means a "subsidiary corporation" with respect to the Company, as defined in Section&nbsp;424(f) of the Code. </FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights on Termination of Employment.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If a participating employee's employment terminates for any reason
before the Exercise Date for any Offering, no payroll deduction will be taken from any pay due and owing to the employee and the balance in his account will be paid to him or, in the case of his
death, to his designated beneficiary as if he had withdrawn from the Plan under Section&nbsp;8. An employee will be deemed to have terminated employment, for this purpose, if the corporation that
employs him, having been a Designated Subsidiary, ceases to be a Subsidiary, or if the employee is transferred to any corporation other than the Company or a Designated Subsidiary. An employee will
not be deemed to have terminated employment, for this purpose, if the employee is on an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if
the employee's right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides
in writing. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=87,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=138550,FOLIO='B-3',FILE='DISK105:[17ZAE1.17ZAE16401]LK16401A.;4',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lk16401_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Special Rules.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding anything herein to the contrary, the Administrator may adopt special rules
applicable to the employees of a particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a
jurisdiction where such Designated Subsidiary has employees; provided that such rules are consistent with the requirements of Section&nbsp;423(b) of the Code. Such special rules may include (by way
of example, but not by way of limitation) the establishment of a method for employees of a given Designated Subsidiary to fund the purchase of shares other than by payroll deduction, if the payroll
deduction method is prohibited by local law or is otherwise impracticable. Any special rules established pursuant to this Section&nbsp;14 shall, to the extent possible, result in the employees
subject to such rules having substantially the same rights as other participants in the Plan. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Optionees Not Stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Neither the granting of an Option to an employee nor the deductions from his pay
shall constitute such employee a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Rights Not Transferable.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Rights under the Plan are not transferable by a participating employee other than
by will or the laws of descent and distribution, and are exercisable during the employee's lifetime only by the employee. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Application of Funds.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;All funds received or held by the Company under the Plan may be combined with other
corporate funds and may be used for any corporate purpose. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Adjustment in Case of Changes Affecting Common Stock.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;In the event of a subdivision of outstanding shares of
Common Stock, or the payment of a dividend in Common Stock, the number of shares approved for the Plan, and the share limitation set forth in Section&nbsp;9, shall be increased proportionately, and
such other adjustment shall be made as may be deemed equitable by the Administrator. In the event of any other change affecting the Common Stock, such adjustment shall be made as may be deemed
equitable by the Administrator to give proper effect to such event. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Amendment of the Plan.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Board may at any time, and from time to time, amend the Plan in any respect,
except that without the approval, within 12&nbsp;months of such Board action, by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any
other change that would require stockholder approval in order for the Plan, as amended, to qualify as an "employee stock purchase plan" under Section&nbsp;423(b) of the Code. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Insufficient Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If the total number of shares of Common Stock that would otherwise be purchased on any
Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned
among participants in proportion to the amount of payroll deductions accumulated on behalf of each participant that would otherwise be used to purchase Common Stock on such Exercise Date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Termination of the Plan.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan may be terminated at any time by the Board. Upon termination of the Plan,
all amounts in the accounts of participating employees shall be promptly refunded. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Governmental Regulations.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Company's obligation to sell and deliver Common Stock under the Plan is
subject to obtaining all governmental approvals required in connection with the authorization, issuance, or sale of such stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Plan shall be governed by Massachusetts law except to the extent that such law is preempted by federal law. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Issuance of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Shares may be issued upon exercise of an Option from authorized but unissued Common
Stock, from shares held in the treasury of the Company, or from any other proper source. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=88,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=140618,FOLIO='B-4',FILE='DISK105:[17ZAE1.17ZAE16401]LK16401A.;4',USER='CHE106465',CD='24-APR-2017;09:48' -->
<A NAME="page_lk16401_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Tax Withholding.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Participation in the Plan is subject to any minimum required tax withholding on income of
the participant in connection with the Plan. Each employee agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to deduct any such taxes from any payment of any
kind otherwise due to the employee, including shares issuable under the Plan. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;25.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Notification Upon Sale of Shares.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Each employee agrees, by entering the Plan, to give the Company prompt
notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26.</FONT><FONT
SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;Effective Date and Approval of Shareholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Plan was adopted by the Board of Directors on
March&nbsp;31, 2004 and was effective upon approval by the stockholders of the Company on May&nbsp;13, 2004. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>B-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=89,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=871107,FOLIO='B-5',FILE='DISK105:[17ZAE1.17ZAE16401]LK16401A.;4',USER='CHE106465',CD='24-APR-2017;09:48' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">VOTE BY   INTERNET - www.proxyvote.com Use the Internet to transmit your voting   instructions and for electronic delivery of information up until 11:59 P.M.   Eastern Time the day before the cut-off date or meeting date. Have your proxy   card in hand when you access the web site and follow the instructions to   obtain your records and to create an electronic voting instruction form.   CELLDEX THERAPEUTICS, INC. PERRYVILLE III BUILDING 53 FRONTAGE ROAD, SUITE   220 HAMPTON, NJ 08827 ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS If you   would like to reduce the costs incurred by our company in mailing proxy   materials, you can consent to receiving all future proxy statements, proxy   cards and annual reports electronically via e-mail or the Internet. To sign   up for electronic delivery, please follow the instructions above to vote   using the Internet and, when prompted, indicate that you agree to receive or   access proxy materials electronically in future years. VOTE BY PHONE -   1-800-690-6903 Use any touch-tone telephone to transmit your voting   instructions up until 11:59 P.M. Eastern Time the day before the cut-off date   or meeting date. Have your proxy card in hand when you call and then follow   the instructions. VOTE BY MAIL Mark, sign and date your proxy card and return   it in the postage-paid envelope we have provided or return it to Vote   Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. TO VOTE,   MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR   RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY   WHEN SIGNED AND DATED. For All Withhold All For All Except To withhold   authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and   write the number(s) of the The Board of Directors recommends you vote FOR the   following: nominee(s) on the line below. 0 0 0 1. Election of Directors   Nominees 01 Larry Ellberger 06 Gerald McMahon 02 Anthony S. Marucci 07 Harry   H. Penner, Jr. 03 Keith L. Brownlie 08 Karen L. Shoos 04 Herbert J. Conrad 05   James J. Marino The Board of Directors recommends you vote FOR proposals 2   through 6. For 0 Against 0 Abstain 0 For 0 Against 0 Abstain 0 2 To ratify   the appointment of PricewaterhouseCoopers LLP as our independent registered   public accounting firm for the year ending December 31, 2017. 6To approve, on   an advisory basis, the compensation of the Company's Named Executive Officers   as disclosed in this proxy statement. 0 0 0 3 To approve, in accordance with   the applicable rules of the NASDAQ Stock Market, the issuance The Board of Directors   recommends you vote 1 YEAR on the following proposal: 7 To indicate, on an   advisory basis, the preferred frequency of stockholder 1 year 2 years 3 years   0 Abstain 0 of shares of our common stock in connection with Milestone   Payments that may become payable in the future to former securityholders of   Kolltan Pharmaceuticals, Inc. under the terms of the Merger Agreement we   entered into in November 2016. To approve an amendment to our 2008 Stock   Option and Incentive Plan to increase the shares reserved for issuance   thereunder by 5,650,000 shares to 20,000,000 shares. 0 0 advisory votes on   the compensation of the Company's Named Executive Officers. 0 0 0 4 NOTE: In   their discretion, upon such other business as may properly come before the   annual meeting or any adjournment or postponement. 0 0 0 5 To approve an   amendment to our 2004 Employee Stock Purchase Plan to increase the shares   reserved for issuance thereunder by 200,000 shares to 400,000 shares. Please   sign exactly as your name(s) appear(s) hereon. When signing as attorney,   executor, administrator, or other fiduciary, please give full title as such.   Joint owners should each sign personally. All holders must sign. If a   corporation or partnership, please sign in full corporate or partnership   name, by authorized officer. Signature [PLEASE SIGN WITHIN BOX] Date   Signature (Joint Owners) Date 0000333978_1 R1.0.1.15 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="960" height="1242" src="g22642bgi001.jpg"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=90,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=567743,FOLIO='',FILE="DISK114:[17ZAE2.17ZAE16402]2264-2-BG_ZAE16402.CHC",USER="SCAVALI",CD='Apr 27 11:05 2017' -->

<br clear="all" style="page-break-before:always;">
<div>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">Important   Notice Regarding the Availability of Proxy Materials for the Annual Meeting:   The Notice &amp; Proxy Statement and Annual Report on Form 10-K are available   at www.proxyvote.com CELLDEX THERAPEUTICS, INC. Annual Meeting of   Stockholders June 15, 2017 9:00 a.m. This proxy is solicited by the Board of   Directors The undersigned hereby appoints Avery W. Catlin and Anthony S. Marucci,   and each of them, as the true and lawful attorneys, agents and proxies of the   undersigned, with full power of substitution, and hereby authorizes them to   represent and to vote, as designated on the reverse side, all shares of   common stock of Celldex Therapeutics, Inc. held of record by the undersigned   on April 20, 2017 at the Annual Meeting of Stockholders to be held at the   Olde Mill Inn, 225 Route 202, Basking Ridge, New Jersey 07920, on June 15,   2017 at 9:00 a.m. local time, or at any adjournment or postponement thereof.   This proxy, when properly executed, will be voted in the manner directed   herein. If no such direction is made, this proxy will be voted in accordance   with the Board of Directors' recommendations. Continued and to be signed on   reverse side 0000333978_2 R1.0.1.15 </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="960" height="1242" src="g22642bgi002.jpg"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=91,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=354004,FOLIO='',FILE="DISK114:[17ZAE2.17ZAE16402]2264-2-BG_ZAE16402.CHC",USER="SCAVALI",CD='Apr 27 11:05 2017' -->

<BR>
<P><br><A NAME="17ZAE16401_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc16401_1">ABOUT THE MEETING</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de16401_1">PROPOSAL 1: TO ELECT EIGHT DIRECTORS TO SERVE UNTIL THE NEXT ANNUAL MEETING AND UNTIL THEIR SUCCESSORS HAVE BEEN DULY ELECTED AND QUALIFIED</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de16401_2">(Proposal No. 1)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dg16401_1">Compensation Discussion and Analysis</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_1">Summary Compensation Table</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_2">Grants of Plan-Based Awards</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_3">Outstanding Equity Awards at Fiscal Year-End</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_4">Option Exercises and Stock Vested</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_5">Employment Agreements</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_6">Pension Benefits</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_7">Nonqualified Deferred Compensation</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di16401_8">Potential Payments Upon Termination of Employment or Change in Control</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk16401_1">Director Compensation</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk16401_2">Compensation Committee Interlocks and Insider Participation</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dk16401_3">Risk Considerations</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do16401_1">COMPENSATION COMMITTEE REPORT</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq16401_1">REPORT OF THE AUDIT COMMITTEE</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_du16401_1">PROPOSAL 2: RATIFY THE APPOINTMENT OF PRICEWATERHOUSECOOPERS LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2017 (Proposal No. 2)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dw16401_1">PROPOSAL 3: APPROVAL, IN ACCORDANCE WITH THE APPLICABLE RULES OF THE NASDAQ STOCK MARKET, OF THE ISSUANCE OF SHARES OF OUR COMMON STOCK IN CONNECTION WITH MILESTONE PAYMENTS THAT MAY BECOME PAYABLE IN THE FUTURE
TO FORMER SECURITYHOLDERS OF KOLLTAN PHARMACEUTICALS, INC. (Proposal No. 3)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dy16401_1">PROPOSAL 4: APPROVE THE AMENDMENT TO THE 2008 STOCK OPTION AND INCENTIVE PLAN (Proposal No. 4)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ea16401_1">PROPOSAL 5: APPROVAL OF AN AMENDMENT TO THE 2004 EMPLOYEE STOCK PURCHASE PLAN (Proposal No. 5)</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ec16401_1">PROPOSAL 6: ADVISORY VOTE ON EXECUTIVE COMPENSATION (Proposal No. 6)</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ec16401_2">PROPOSAL 7: ADVISORY VOTE ON THE FREQUENCY OF STOCKHOLDER ADVISORY VOTES ON EXECUTIVE COMPENSATION (Proposal No. 7)</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ec16401_3">STOCKHOLDER PROPOSALS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ec16401_4">WHERE YOU CAN FIND ADDITIONAL INFORMAITON</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_ec16401_5">OTHER MATTERS</A></FONT><BR>

<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lc16401_1">Appendix A</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lc16401_2">CELLDEX THERAPEUTICS, INC. 2008 STOCK OPTION AND INCENTIVE PLAN as amended and restated effective as of June 10, 2015</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lc16401_3">ADOPTION AND APPROVAL OF PLAN (AS AMENDED AND RESTATED)</A></FONT><BR>
<!-- TOC_BEGIN -->
<UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lk16401_1">Appendix B</A></FONT><BR>
</UL>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_lk16401_2">CELLDEX THERAPEUTICS, INC. 2004 EMPLOYEE STOCK PURCHASE PLAN As amended effective as of July 1, 2015</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=SCAVALI,SEQ=,EFW="2231947",CP="CELLDEX THERAPEUTICS, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g22642bgi001.jpg
<DESCRIPTION>G22642BGI001.JPG
<TEXT>
begin 644 g22642bgi001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" 3: \ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6I:M;:
M2MLUV75;FX2W1@N0';A<^@)XS[BKM9GB32/[=\/WE@KA))4S$Y_@D!W(WX,
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M.C _=8'L:Y]? US?QZ;!?PQVEO:W$TDBVVHSRN0T6U2LC88'=VSC [YQ38/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX$F,B N)6+%E0MT3H%/(XX.:W1::/X9T^XECMH;2V=AYOEQ9W$G:!@ D\G
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MGGMY"R?OXT(WL!G(P#N /4>_%&P#M#T^^TZ\N9[BV!:\\II2D@^5\,7/N 2
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M4R64DK0#S&;RV;E\G)Y^?//K6%?6&JW\\MS<Z9>O:R7!<627BQR?ZJ-48L'
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M'RG9"$W!6P>5?CD?G0!O-HUD]Q+.T/[R4.'.X\[U56[]PB_E3UTVU7['B/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 <SJ&LWT/BF"V+?9=,9UB$I@5UGE*L[+NW H J]=IYS4WA[4K^ZU35+.
M_,!-H8]OEQ&,Y8$\9)W)@##<$_-P,5DWNK:)!XSN+/\ LNVEU*66& LQYD$B
M_O&QC'RQ@9/4CCI4.G>*=.TC2[N32]%:.%;Z."-(R2UQ&RAA*!C.-@8@>BCI
MFA :&L:OJC^*ETK2V>.%(8VFE2S\\*[LP&X[UV@!<]^M9$'C?5I;F^DMXX9[
M=7:*-)(&C",TPB@._/SJWS$X'&TC.:<?'L-I++>1:3#'+<*\TRR7.R:5$D,*
M!5P=SG:WR\8QC/-.N;BVM)]2M;CP[8M8V$4=H?+G9GD5VW11A2@&=Q4\GY=V
M030@$NO&VH:7>O#=FVN8+*>5+JX2(IE B;2!DX(ED"GD]*O6NI:PNKM]OU&T
MAL[6PBO+T?9.4+9W)NW?[#'./2LV35='M9!I6I:!;1*&DM;H)+OC1$59E.<#
M.6=1S@[CWKKK6PL]6TW[5>6$:OJ,44ES&QSG !53ZXH Y;3/&UYJUF1";-)K
MB]=(753*L$ A$V6"GYG XP/XC[5+8>)-7U;4[2WM+E'M_(B>2ZMK!GC<N6.3
MN<%!L"GH?O&K_BJ+1=-^R&[TJ&?[?>QI(0=OE_*5,O']U>#TX-5XUTF*RT_Q
M!#HZ17EW/## B2LHP6$:' XX09QCH,4 ;/BS5)=%\/37-JH-P7CBB'EF3YF<
M+PHY; ).!UQ7+CQ=K+Z5-,K62-;6<FH">2 _Z1#N(A&P-\A?:V>3CCC)XZ[Q
M#/:VFGI=75M]J>&:,V\6<%IBVU,>G+=>W6N.N]4TBTM;&63P_:?:X)[B*.,R
M_*&CDY5&V_,6<_*" ,^F*$!;E\>N=7U6*(VIM['3Y9/+#;I/M$>W<#SPN7"C
MCDJU;7AG4=1N;G4+'5'@FELC$#-#&4!9D#,A&3RN1WZ$5CE]'O=;ET%-!AFC
MM8I8L+)B3&U';C@;68JN=V=PY'>FP:BL.AW/V71[6V72[M&*)=MY<DA&<!U0
MEY S!2,'+=S0!V[LD:-(Y554$LS< #W-<1:^)]7\QK>[%O%?275O$+;[.1Y0
MD<Y8/N(D0HCD,,'(.1VKL;;S;O38_P"T;:..66/]] &\Q5R.5S@9].E4%\):
M&EB]FNFP"!W#E0#G<.ASU&.@]* ,:'7-4U+^QVM9[>+^T+VX S!O_P!&0MM/
MWAR0J\_[=0W^MZY8OXAN$O+>>WTXB*WA6T^:25U!5<[N<%T'3GGI72_\(_IG
MVZTO!9QK/9Q^5;LN0(EZ8 '&/PI;G0=-N[2YM9[1'AN9?/F7)&]^/F)'?Y1^
M0H B\.RW\^GM+J4DC2,Y"K+:BW90/]G<WYYJG=:KJ0\5Q65H]M-;*0;B-4;,
M,>PG>\F<*Q; "X.1D_39L-/MM,M%MK./RX5)(7<6Z\GDDFJ'_"*:-Y]W-]B7
MS+P.+@[V_>;OO9&<<T 85MXDUB4B(26<BW<Z0VUXL++$"%=YBH+9D1508;C<
M3Z"NB\.:A/JOAVPOKI%2:XA61@@P#GH0.V1S^-1)X3T1-/%B-/C-JKB18V+,
M%;&WC)XXXQTQ6LJJB!44*JC  & !0 ZBBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0:1#K>FK:SW4MKB:.
M1)864.KJP*XW CJ!VK3K)\1023VEHL<;N1?6[':,D 2*2?P'- &:_A07\4&?
M$>IRW-E<.Z72O"9(R4VLG"8Q@]",\TZ3P8[7@O(O$&KPW)@2"66-HLRA2Q!;
M*$9^8],57TFRN-&\!L\<DT5Q"[W3F; 9\2%F#<#[RC&3ZU4N+O6G,,ZR:FLL
M\:SV<4,(:,N[L3',<<!4*#DCC)&30!K3>"K*;4'N#=WRPRS+<3VB2@0SRKC#
ML,9S\H) (!P,BK=SX;M;J?5Y7DF#:K:K:S $850& *\=?G/7/:J&DWVHS:O;
M6UQ'>A83=BX>2$K&Q\P>5AL8;Y3QC^=)<2:W'=M;1"=H3,T'G;<_+(=PDS_T
MS *_4T 3S>"],G:42><8I[-;.XB# +.J_<=N/OKV88_E59_ EC-'<17VI:C>
M7%Q"(%FN)E:2.(,&*KA0.H7)()/'-9OVO7E%PT;:J\ZJSW4;P?)&5D7:(3CY
MLINZ$Y'7FI+FXU2[GGO8(;]$#3+&WD$2I 3;Y**1UP)" 1G(/'&* -*;P9I#
MZAJ%^LTL374\$\X1UV+)"^\'IQD]?Z4ZR\(Z;;ZHD\%[=O#!,]Q%8^>#!#(Q
M;<P4#/4MP3@$GBJ-E:SOX1UU/+O96FFD,1N8BLLJ[5 )7 /;TS46S58_$/VC
MRIUM/,9+AHXR)"GVB79MXQMY4MWVG- &MK'@^'6-3FNSJ6HVHN(%MIXK9U59
M4!8X.5)'WST(ZU'_ ,(;'#J<MWINK:A8)((E>WMS'Y9$:A%'S(3T&.M5O"D^
MM2ZI.-4:YQY;&:.6-@B2;A@1DH!C&?NE@>#G/7+<:G8+<PPS:VH$]T\)BA\P
MO.9,HK$K_JRI!'\));)&* -H^!X\WZ+K&IK9WS3M+:!H_+S+NW8^3/5LCFKH
M\)Z?_;6G:H?--SI]O]GBR1AAC +#') +8_WC4>JKJLUWIJV\DT1$,LLRQ8V/
M*H0HK$C[I.?3/-<[976NO9'[7/JJVYDC^U.ENQGC8AMVP&,?+N" A0P S@T
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M2!'CEC6(M"/W#$,I"8_U@&#N)['%3O<ZOH4$UQ+<WMW';BWEVS@9E:0,CH,
M=&V'';\: -1/"-G#K%O>3:A?2I#.TUM:33AHXY"#DKD;NA;C) ]*Z*N<UI-3
MM=&L4MY)I[N..3S)43<2XMY,'IQ\^,?@*72H]2M%U.">XO+D+#')#).HW;V0
M[@" .A X[9H Z*FNZH 78*"0!DXY/05QEM#KD7DRO?:E*R"RD*.B[7:1MLRD
M;>@49Q_#UJMI]YK4^ID.NIM!(\+NMS <1N)U# '8 ,(3G;D<9![T =W'-'+G
MRY$?&"=ISUZ4^N&T^RU23[#9"2^L;<K$LCPH%8 6YXW%3CY\?CQ58:MJ@NM.
M%[>:A%=M+9Q^3'$OE.K;?,\SCY6)W<9!QC P30!Z%17(:S>:A_PD\L%G/?[X
MTMF@AAB#0L6=P_F'!P-H[D=..:HS/K4-E%)/=:UF99I%^SPAV$P?$:,-O";?
M7@\Y- '>T5QRMKMQ?7,4DUS;Q- WD2;,(+D*I8$_\\P<[2>OS\\+6WX<NY]2
MTL:C/O47CF:*)Q_JX\ */R&?^!4 :U%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A7GA&QO?.,DUVIFG
MDN&*2 '<\?E'MT"<#TS26'@S2=+ODN;&*2 )()%A5_W88(T8.#_LL>];U% &
M/I/A?3]'E\V!'DD$21*\Q#%0I8\''!)=B?4FEN/#5E<V]_%(TX-[<+<O(KX=
M)%V[2IQQC8N.M:]% '-3^!-*N;2XMYVNG^TIMED:7YW)<.6SC[Q(7VP  !6[
M!;R17,\C3LT<FT1Q8 6, 8X^M6** ,S5]!M-;&+SS"OD2P85L8$@ 8_7 X/;
M)JO;^%+*VO+>=9;ITMMAB@>7,2NJ>6'"^NW\.^,\UMT4 4M5TN'5[,6\[RQ[
M9$E22)L,CJP92#R.H[UF/X+TM_(&;A4CC$3H)>)UW^9\^>3ER2<8SDYXKH**
M .??P=9-]IVW-]&9UE5&24 P"5M\GEG'!8]SDCMBI[3PS:VME86IGN)H;&83
M0K(5 R 0H(50"!G(]P#6S10 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !534=3
MMM*@2:[=E1W$:A49RS'H  "235NJE]8)?&V+NR_9YUG&.Y&>#^= &6WB/0M6
MM98Y=UQ"$64QR6KL' 8#Y5*_,0V 0,D'K0/&6FF>)?WXA>&61Y6A=1$8V"E&
M!&0V3TZ]/44V?PC%+;)$E[/&R1O&K@*?O2B0Y!&",K@@\$$U / UO]D^SO>S
MM&QF+_)&-WF%&Z!<##(I&!CL<T 7F\5Z;Y<>UYA+*758FMY ZLH!.Y=N5 #
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MZ0,HA5TC9%100%*;<,<'[Q&<@'M4EGX1M[.P^R+<S,@^SC<P7.(7W+T'?H:
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M(L>G-F,$Y+?NV3D_1LUDV_@2TMEE$5U*F,&V98HPT!#AP=VW+8*C[V>.* -
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M1LX_^MP>?:J$'C'1)[>*9KZ*%9I7B02G:25;:3],XY]Q3 T-MIJUA)!)Y=U
MW[N0,,AB.N17'6L$/A_0X);$)I27-Y-'=7J6^]HT5Y-@(((QP "1@9]Q7:SW
M]K:NZSSI&R1-,P8XP@ZM]!6=>^+='L4O"][&\EG&9)8D.7 '7 [GD9],\XI
M9M_K&J)X(M[\2I;7;,OF2/$5RF2-V"&"%@ ?F&!G!K.77KUPDS3R6$4XA\Z[
M:T!=?W;$9&"/F8#GI@\8R*ZV#7--N;X64-Y$]R4#^4#SC&?SP0<=<5!JHT?4
M4\C4)$/DSB/_ %C(R2%<@;E(()4^O0T <WIFMZW=PVMZ][F(?8P\(M0!+YI
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M Y/?-3W?B'3;#2OM]U<1)$%9\!@QRIPP&#@D$X.*A.@/_8$FG"9 SW+3A]G
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M(X)!\RJA,HC;[P!!&3P1UK.NO&%VLEP+6"Q9+<7$CM+.5W)"X4A< \G/T!H
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MD5#.899IR9(2TI=3N96)XQR"#GJ<5H:AX6OKO^THXY(E@(+6:%N\CJ\RMP<
ME=HX/#'CM0!TEM86%JD;6MM;1*GW#&B@#C'&/;BIF6'SEE81^:H**YQD9P2,
M^^!Q["N=L=&6P\(W]MJ:"WAEWN8XB)/)! ^Z$11D$;L*O6LR3PYJ6HZ=;W=U
M8VEU=74,AGAN7*""63;MD'!Y55"]B,<'K0!V7V:USGRH<B7S<[1]_'WOKCO4
M":+I7V6>!-/L_(N&W3((5VR'U88P37,77AG6)(Y[11;R0F269;AI2'=GMVCP
M5QQ\QR3GH:ZW3[.+3["&UMXHX8XU "1C"@]_UH FBBC@B2*%%CC0!511@*/0
M"GT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %9VLZG)I=O T%K]IEGG6!(_,"#+9Y)/;BM&L[6=&@U
MNWA@N3^ZCF64KC[V,\9[=>H]* ,<^,Y!OSI;_N(B;@>>OR2>8T01>/FRZ]>!
M@Y]J=<>,)+&)A>Z:8[A+@6K1I.&'F.H:+#8'#9P2<;>XQS6O'H.F16[0)90B
M%X1;LA&0T>2<'UY8G\:BB\,Z1#;^0EC'Y>'!#$MG> &)).22 !D\XXI@-M-<
M-SJG]GM;%)T:03#?D(J[=K=.0V]<?CZ56?Q-,INY5T\?8X'DBCF:Y13)(AVE
M=IZ#.0#R>.G2KVGZ.MEJ-Y>M+YLUP$0';C9&F=J^IQD\GKGVJ.?POH]S<SW$
MUA$TMP,2,<\].1SP>!R,'@<T@,N'QI)(HWZ85:,SFYQ-Q$D00LRY4%LB08&!
M_6KFC:O?WVHWJ7ML+58[:&6.(2+)]XR<[@/]D#';'&:NV7A_3-/_ ./6SC3[
M^>ISNVALYZYV+G/7%+INA:=I E&GVJ0>: 'VDG(&<#D]!DX]* ,6Q\6SS/:(
MVGNULYMXGN6F7=OEC5A\@ S]X ]/85->:_>6'B&ZA^S>?8QBV#,'"F(R.RY
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MU*XUCPGIM_>%6N+B$.Y5< D^U;- !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY8@9SG?MZ=LY[8S4EUXN@L9IXY+:[N#&9&(MX/\ 5HBH6+9;MY@^O0#CE/\
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M [Q!=76F6JS:5:"2YGE5)'6V:4A<$[BJD$],#D=:B@URXGGT=$2">VOE82W
M!3Y@C'"QG)'*\Y/'3GM>N])%[8P027=U'+#@K<0R;'R!@GT.<G@C%+#HUI;I
M8K$KJMB2T0W$\E2I)]<[B?K0!0NM=DL/%,6GR1Q+8-:>89,$,DF6('IMVQM^
M(JA;>.8X+-7U:$I.7E9DA Q%$KX#-N(YQC(&3D' K:U+P_9:K)(]T)"9$C0[
M7QPCEQC\20?4'%5KGPE87,WFE[F-R[LS1R8+AVW%3[9],$>M #7\76PDDCBL
MK^=UG:"-8XU)F9<[RF6' QR3CJ,9--_X332UO6MY/.C"Y#2.H"JP3>4(SN!
MSVQGC.>*L7'AFSGA"I+<P2+.]PDT,NUT9\[@#Z'.,5'%X0TR*Y:11/Y;J5>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M' #%?F4J>#CH>W'7O4E%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MLJ^:_&&&(QP>/O>M)8:S?7FHWUK/?-9I;R7;VTTV-EP59AU[)&""1U.<]!R
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>EGT'3+F-TFL8&5U16^0 X3.SGMMR<>F:9HFN1ZY:27$=E?VHC?84O+<Q.>
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M >)/_!8]/A\?V\TR1C0O$2EV"[GTUP!GN3Z4 =7163KOB"/04A:2QU&[\TD
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M.=57)QDGL*T]=\0QZ#Y'F6&I7?G;L?8K9IMN,?>QTZ\?C0!KT5R/_"Q+;_H
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MI>::?MD#JW&Y 25;'56&5/UI/!<$CZ(-6NGWW>KD7DI!)"!@-D8]E7 _,]Z
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MDZK_ ,]X_P#/X4>3JO\ SWC_ ,_A0!J45E^3JO\ SWC_ ,_A1Y.J_P#/>/\
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MQH>F7<-U%<6%O+'=N'G5XP1*PQ@MZD8'Y5%Y.J_\]X_\_A1Y.J_\]X_\_A0
MK>&]';25TQM,M#8*VY;?RAL4YSD#L<D\U<L[*VTZUCM;*"*WMXQA(XE"JOT
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MDZK_ ,]X_P#/X4>3JO\ SWC_ ,_A0!J45E^3JO\ SWC_ ,_A1Y.J_P#/>/\
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MSWW,#]35OP_>:-=2Z@FC>7NMYQ#<A!CYU15'X;5 S_LTD#-FBBB@#%NHYO\
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MM75.N8@I3( Z8.1GC^$5KT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?_B:O?\ "LO"'_0#MOS;_&C_ (5EX0_Z =M^;?XT 4?^%Q>#?^@G)_X#2_\
MQ-'_  N+P;_T$Y/_  &E_P#B:O?\*R\(?] .V_-O\:/^%9>$/^@';?FW^- %
M'_A<7@W_ *"<G_@-+_\ $UTV@^(-/\2Z:+_2IC-;%RFXH5Y'7@@&N/\ %_P^
M\+Z?X/U>[M-'@CGAM)'C<%LJP4X/6CX(_P#)/D_Z^I?Z4 >A4444 9=I_P A
MNZ^G^%:E9=I_R&[KZ?X5J4 %%%% !1110 5F:W_J8?\ KI6G69K?^IA_ZZ4
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ME &G1110!7O[^VTRQEO+V58K>%=SNW;_ .O[4FG7T6J:;;7T <17,2RH'&&
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MKSZ4Z+4[6;[45EC\NU;;))YB[0<9/(/&.^<51BTZ[@NM.G6*SS%$\,R1YC5
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M3((!!ZXP5((R* .@!!&1R#2U#:QO#:0QRLK2(BJS*NT$@<D#L/:IJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** *NH:98ZK (-1L[>[A#;@D\8=0?7![\
MFL[_ (0OPU_T+^E?^ D?^%;=% &)_P (7X:_Z%_2O_ 2/_"C_A"_#7_0OZ5_
MX"1_X5MT4 8G_"%^&O\ H7]*_P# 2/\ PH_X0OPU_P!"_I7_ ("1_P"%;=%
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MT+^E?^ D?^%;=% &)_PA?AK_ *%_2O\ P$C_ ,*/^$+\-?\ 0OZ5_P" D?\
MA6W10!B?\(7X:_Z%_2O_  $C_P */^$+\-?]"_I7_@)'_A6W10!B?\(7X:_Z
M%_2O_ 2/_"C_ (0OPU_T+^E?^ D?^%;=% &)_P (7X:_Z%_2O_ 2/_"C_A"_
M#7_0OZ5_X"1_X5MT4 8G_"%^&O\ H7]*_P# 2/\ PK1L-,LM*MS!IUI!:PEM
MQC@C"*3ZX'?@5:HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#+M/^0W=?3_"M2LNT_P"0W=?3_"M2@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,NT_Y#=U]/
M\*U*R[3_ )#=U]/\*U* "BBB@ HHHH *S-;_ -3#_P!=*TZS-;_U,/\ UTH
MTZ*** ,SQ"^S2CES'$TT22N&VXC,BAN>W!/-8R&5K*Q:*[F6VAU0Q1JKY$L?
MF$*"W4@<@<]AUQ6_JUT;6P9EB25Y&6%$<_*S.P49]N>?:L*X\3?98[:V^SV<
M<Z-()$=RL:^6X7Y2%.,Y!!. O>A =56/K5RMKJ>BM).(8VN7#%GVJ?W,F ?Q
MK7K&\0W(7[/:K:V=Q)+OD_TPXBC5!RQ.#Z@?C0!4G\0RCQ+!:P3Q26SS+ RA
M!U:,OD-NR3TZ+C!ZYZ)#J>K/H-K>O<6AEO9(%0"$[8@[ '^+YNN1TYJY!J>F
M"[MX#;QQW!1%!2,,B,5W+'O QG'(Q_44Z#7;"XL//M[>YD@4KY06U;]YGIL&
M.<8//;%,"";4=0M-6M=,E>*66Y",DHBV@A2?.XR>VW'NU2>,&*^&;DJ0,O$.
M9#&"#(H(+#D ]":8EW'<ZYIE];XEM[R%XT9BP:/ W'"]!G !SSP*EM]9MM8U
M-]/6#S;8P-(7EC.V3#A>,C##KS[4@*'V>&&UT5XDBC9+W8!;W+2H P;(W'&<
MX'44[50+6X\0/"QC+:8)2=YP&_>C=UXZ#IZ5'X@UY/#,J6MII<3QFW>:((-J
MB4$8! ' (W'/^S[U>U+7[>"WU'[-;M/<V\$A&Z,B.1D7/E[\8[_J?>CH!E7/
MB2_MX1#%/;W!\\H+N-4"$>4),89PN<G'WNGO6C9ZGJ5[=/(&MTA@MHIG@1"[
M2,Z$E0V<#! P<'-5K#Q%9WEC=&;3&6TBF"Q1) 7+?('9BH'&&W?E[U<M_$=G
M-JDUL5*HY01W"HVQPT8<9;& <$X^GO38(R/^$GOUMF*W-K<-(+8AH4 \CS=Y
M(.YP#C: ,D=>:T-.U74]4N;.-9;6%3;">7">9O\ G*X!#8 (&>IP?6HM/NM$
ML[:=D6[G^TM&I6>%F:4-N\O (Y4X;GZY-=!8SVUY:Q75JH\MTPIV;2!Z8[8/
M:D!9HHHH **** "BBB@ HHHH RO$3E--0,Y2%[B))F#;<1EP&Y[ ]#[&N>N)
M8);*VMTO9/M+2S)9$W)54C67 F)S\VT8 SG.0.Y-=1J]U]EL?EBCE>9U@1)/
MNDN=OS>W.36%J%S/-8VDL6FZ5+,DQM/*G4G$@?;A#CA< M[ 4(#JZY?QE>7,
M0M(;*.YDFBW7C+;D9Q'C ;)'RDD ]?I745BZ[KEOH=Q:-<B%$N!(IED.,;5W
M ?B: *R:Q=W&IJ89X#92W(MXP(_FPUN)0^<]<]L=*HVD^H7&CZ8/[566[:_9
M&D:,90!9/E90>3QT/]*UM/UNSG2Q1[9HI;B))%VPGRPYCW;0V,$[<_@,>U$6
MNZ5]D-['!,L4LB;'%HP,SL/E*\9;/3-,1G6_B2\GDM&:6UC)6W#0;3NG,C;6
M9>> .3WZ'-,M_$6HI:BZN9('C$"W;A(B-D8DVOWY^7YL^H]ZVEU+3O,C+0F.
M9!&$5X"KKYI(  (R.0<^F#FH_$IM;/0I9)D"P;HXY-K>7^[:158$CM@G([T#
M+NE7$]WIL-Q<!5>8&0*!]U2<J/KMQGWK TR9(_%D@^TBX>>290T=RVY=O.R2
M$\ +C 8>W][G9T/58]8LY9X1'Y*3R11LAR&56P#^E&L3II.F7VIPP0FXBA+%
MF&-V!P&;KBEL!?BECGC62&19(VZ,AR#^-<9=?;(?$LMVU\XL$U$9AW-PXMO0
M?P8YQZ\UI:?XH@CM95N5A8PRF-&L,RQR ('8K@?P@\^GXXJZ-=TUKORE#,=V
M[S1$2A;R]X^;&,E.: ,2S\2ZC=QR1QS6[2&:V5)6B& LN<_*KGIC(R<^M:5Q
MK,]C>BRN+BW:;-JJG;M,GF2%7(7/H/PI]OKND?9?,@MW4;H]D0MBKR;@60JN
M.<X8_@:F_MG3+F[M1'&]Q-*BR1NENS;$8XR3CY1D<^F* ,N+Q#=/8O.U[9;Y
M=G[O8<V8:382_/.,]\<@]NEJ2ZGE32I?ML%PGVPPR-$A"R$;@".>",<]1G-;
M@MH!YN(8_P![_K/E'S_7UJGK%RNDZ-)<101L+?;LC(P!R!QZ=: -&BJ-OJ]O
M=7\MI"L[/"Q5W\I@BL,97=C&<$&KU !1110 4444 9/B)]MC"KN8X)+F-)V#
M;?D+<@GL"< _6N=N[F)-*MIEO7:>WE)@4W# M")RH9!_RT8J HSG(/OSU.L7
M)M[((L,<TEQ(L"))]PECCYO8#)_"L.Z\1B!]-62QM1(69 K-SO601%8N.O?G
M'&/P$!U=<KXPN[FUOK'R3(MN89S=M&^&CA!CWNH[L ?P!)'-=56)KNMII5[9
MP&".6:[21(%9L%Y,H @]CN))[!: *5IKEU+XA^PP");-7\A!N0G:(@X<'?N/
M_?.,<YILTUZGATNFH+;RQZCY<LXC&&7S]IR"< >O:M1-0L;?4$MY(-ET(_+\
MQ+<A"57<45L<X'./;UJ,:]IT^G>:()W@G8+&AM6_TC<-V54CY@1DY]C0!GM?
M7EMXCF>*ZCDMB]K$Z,I._>"-RG.%['IS6KXDF\C25D\SRP+FWRV[;@><F<GT
MJ./7-)>XA@A4L)!$5=83L&X'R\G'&<8'I[5:UJ=+?3LR01SH\T431R#*D-(J
M]/;.?PH!EE+NWD$92>)A(2J$.#N(!) ]> ?RK+\8.T?A/461MK"+KO*]QW'3
MZUJ0VEO;HB0P11HA)540 *3U( Z=34&L3BUTBZF-M]I"1DF$C(?ZC!X_ T <
MSI%W?*BV%E<6\1>]EBW;VN4B41!P$8D%O?/0DCL*LWNOW\%U<+'-;;HY&A%L
M4^?"Q>9YG7H<8QC&".<T6WB."SMK,S6UJT#><5?3P94 4*2P &5X8Y!Z8]ZU
M&UC2QJ#JP&\(4:X,1V<+O*;\8SM^;% &+IWB+4M69(XI((=]P(MYB+85DDE4
M@9Z[/*_,U=LIS>:EHE^X"SW5G)YNQCM; 0],^I-6$U_3%M_-2&56$BHL/V<K
M(S%3MPN,\J#CV!'M6M"(I(HI(T 7;E,IM*@^QY'TIB.=N=3N],L]4=2LTRW\
M<(DV@;0ZQ\D%@O ;U /&:UM"O9K_ $F*>Y">:6=24((;:Q /!(YQT!-7FAC=
M75HT99/O@J,-VY]:5$6-%2-0J*,!5& !2&.HHHH **** "BBB@#(\1,!:VJ2
MR&.VEN42=@Q7Y#G@D= 3M'XUSMQJMREEI$>+]K=;E'\^)&<3+Y^U%+#MM )S
MUROJ:[:2-)HVCE171AAE89!'TI?+0JJ[%VKC QP,=* '5RWC">]AFB^PF/<;
M&[9A)*R# 5.1@'D=OYUU-,>))#ET5C@CD9X/44 <A8^([\W9@Q'Y,4;( Y7=
M\L0</]_<<GMMQ@CGUEN;O4#;Z+<7.IVMO)<R&02>45C0&!FVX+?-ST)(KJ!;
M0"0R"&,.5V%MHR5],^GM1);031B.6&-T'164$#\*&".6MO$^H7.K6<1ABCBD
M6 .C%06\Q-Q89;=QV 4]#D^CI[W5KCP?<:BVH10.ZAT,,/\ J@&P>2W.1SVQ
MS74&")IEF,:&51A7*C<!Z THB01^6$4)C&W'&/I3 ;:L6MHR9EG.T9E4 !_?
MBL>VU.#4/%$1L[D2Q)9R^8JMPC>8@&X=CPW7T-;4<:0QK'$BHBC"JHP /84B
M011L[1QHK2'+E5 +'W]:0"Q2I-$LD3J\;@,K*<AAZ@UR@O8+>[U*]FN)&U6"
M:=8K;SF^9%0E5*=-N,-G'4]>:ZQ$6-%1%"JHP% P *:(8A.9A&GFE=I?:-V/
M3/I0!S4.L:A<3)9PWUI*S3A/M<<65(,+28"[L9!4=^A'>K.F:GJ&IW$,GG6\
M4"VD%S*@B+%S(&R <\ ;>.#6W';0Q*JQPQHJDD!5  )ZG]:<D:1_<15X"\#'
M Z"@#D+7Q1>7 D7[3;A9/L[)<-& L2R%QDKO/'RC&[!RW(K;\+RO/X?@DDF6
M9F>3,BG(;]XW(]JT!96P1T%O"%?.Y=@PWU]:E1%C0+&JJHZ!1@"@!U%%% !1
M110 4444 9'B$IY-G'<2&.UEN52=MY0;=K$ D= 6"C\:YK[0V_3+RXFBNO)C
MB$<$DSB9PTQ574 X8D!3SG..V<UW,L4<T;1RHKHW!5AD'\*1H(F>-VB0O']Q
MBHROT]* )*P?%>I06^D7=H+D17DD!,*!BK/D@#;ZG) P.>16]4<D,4K(TD:.
MT9RA902I]1Z4 <G?>*+N'4[J*WF@:-5G5 T8&QXP/]K<W).> /0^L#>*=46W
MV%H#*TQ7SE1550$+8(=P.2/7IG KL3:VYD:0P1%W^\VP9/;DT/:6\B%'@B9"
M02I0$$CI0!S]MX@NY-<LX9V@2&>./]W%B0AVC+D$[MPZ<':5([YK>N[^UL!&
MUY.D*R/L5G.%W8)QGH. >M2&"(SB8Q(90-H?:-P'IGTI988YXS'-&DB'JKJ"
M#^!H RO#,_\ Q3NF"XE_?30[E$C?,_?(SR>.:/%222^'Y8X9G@E>6%5D1L%2
M95 K6,:%E8JI9?NG'(^E#*KC#*&&<X(H X0ZU?Z'IURKW<<EVDUQ<2[EW*VT
MJ2H+,-J M@ 9;&,"NFM)M0O-1OA]I@2V@D,*((26),:L&+9[%NF.E:+VMO(0
M9((F()8;D!Y/4U(J*N=J@9.3@=: .7AU"_33K"&WN(4EFGNEDE:(MG89#D+N
MXR5'?UI;7Q'=W%Y:$R6P65H8S:A3O821!S(#GH"3VZ*><].F\F,8_=IP21\H
MXSUI!;PK(L@BC#HNQ6"C(7T!]* )**** "BBB@ HHHH **** ,NT_P"0W=?3
M_"M2LNT_Y#=U]/\ "M2@ HHHH **** "LS6_]3#_ -=*TZS-;_U,/_72@#3H
MHHH K:A9"_M&A,C1MN5TD4 E&4AE//N!67+X726%0+R59766.XE"+F9)&W.,
M8^7D<$=/>MVB@!% 50H& !@5G:MI']I^2\=PUO/%N"N$5P58892K<$'C\0*T
MJ* ,"T\(VEEJ,%S _P L*H-K1(S$H@0'?C(& .!W';FK$WA])=%M-/%PX6V*
M$,RA@^T8PRG@CGIZ@>E:]% &58Z#'8PZ=&LSL+#?M) &[<".<?7M2:9H7]FW
MGFB[EEB2(PPQ,H C0MNQD<GTY[8K6HH S=0T9-0DG=I70S6C6I  X#'.?K5>
M;P\91=Q?;YUM;D2'R JX5G'S'/4]R!ZGZ8VJ* ,/4O#,>HSRR&Y=/,D#LA17
M4_N]GW3P3W!/0TL'AF"&%(C/(ZJ\;$$#G9%Y>/Q'-;=% &);>&Q"\3RWLTSP
MM%L+*HPD>[:O Y^\<GO6CIUDNG6,=LCEU0L=S=3DD_UJU10 4444 %%%% !1
M110 4444 5=1LA?VOE>8T3JZR1R* 2C*00<'KR.E5K?14@-FS3O(UO)),Q(
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M*I0C!ZDYZYYXZ5KV5JME906R.[K"@0,YRQ &,D^M3T4 %%%% !1110 4444
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MFM[@_8+=YEEM5BV2NJ.L[%5.64'C'4#!'2M9$\-+KT*QI8#4A"$BVJNX)MX
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M15,.22L:Y^7DC&<]_6MFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,_4TIFC#;3(@;(7&X9R>@H ?1445S#.SK%-'(R8W!6!*YZ9]*;+>1174-LS
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M>N:T:KV%C;Z9916EHFR&,84$DGKDDD\DDDDD^M6* ,/Q(]_"+)K&_:U$ES'
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MS7,J[Y %11-M6< [E! .' /(_P#KTP*\OBJW@@GDEA=?L\<C3 $?(5DV!?\
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M5HR6C$7;#]X'^T_:SYBL%P/GSG[I(^A-7[:WT^PN(XX&BBE>%8HX_,Y*)DC
MSSC<>: &:5K,>K$^3$RA8D=RQ^XS9RA]QCGZBJFIZW<:;K)0V[2V26RRRLI
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M'2CQ-JDNGW-JB7QM5D@G<8C#&21=FQ>0?4\#KTI 4+WPUJ-U=NP6V$>UPI#
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MR&[KZ?X5J5EVG_(;NOI_A6I0 4444 %%%% !69K?^IA_ZZ5IUF:W_J8?^NE
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(VLQ*@^8C'[HST;K@\]3QZ/F\-6UQ=:C+))(4OK?R#&,83(PS#W("?\ ?(H
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MFEO#!-8++<F-YI%@,DB[ 0/E(3J<_P 6!QUJW;ZU)+K\NGS6ZPH ?*9RP:7
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M1-<N7OGGVGS-^Y&$;'?\A!+D'"_W5''7FNGHI#"BBB@ HHHH **** "BBB@
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M(D9Q&0%*NIW#S!&20#E>6!P<$BI9]>N/MMG#:6/FI+=2V\C-(%*[ >0._3-
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MZ#5KN6PTF[NH(1-+#$TBH6V@X&>M95SX@N[3[)+-8.4>TDN)XXW4F,*4YR2
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MN)F^R+MM;4(HC<^4",\9/S'UK(L=5OVLE>\O9A:&<"2XC4LZ?NR<9,:\;\=
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M)+@1M&265D;&596*D<<'D&L(ZG<6-EKTL.G);FVG+*X<.9F(4Y(SU.?Y#M2
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M*1;C[(2T4:8#?+E?,R0H0!1\XP.2.<DT =3:26-G!%%#<Q;)I',>90=[%BS
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M6IMI;W *Q^7/'9RN0J;)%!\U\M\H!;"C/%=CM (.!D#&:"H(((!!ZB@#B/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &7:?\ (;NOI_A6
MI67:?\ANZ^G^%:E !1110 4444 %9FM_ZF'_ *Z5IUF:W_J8?^NE &G1110
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M?X;UFZM).8IT6)1(O]X!G!P>V171WW_'A<?]<F_D:Q_ O/@/0O\ KQB_]!%
M&EH^K6VN:7#?V9?R90<!UVLI!(*D=B""#]*NUS'P]Y\**?6[NO\ T>]=/0 5
M6O=1M=.6%KR81+-,L$9(/+L<*/Q-6:P?%VC/KUA:6BH6C^UH\I5@"B@'YA[@
MX- $\OBO1H)8(Y;]%:=V1 5;J'V'/'RC<-N3@$U ?&NAB2[1KJ56M%+3[K64
M!![DKW[>O:N2@\,>(1I<MM<V:23ZE;"WN)A,H%NPN)'+D=2"LFX8R<C!Q6UK
MNAZA=P^*1!;LYO4MQ;A9%4OM'S8)/!^N* .FT[4K?5;;[1:&0Q[BO[R%XSD>
MS &K1.T$GH/2L#3;=SI5NEQINHLR72L$O;I99$Y!$FX,<@>F<\=*WR< G!..
MPH JZ;J=MJUL;BS9VB#E,O$R'(X/# 'KQ5NN6L=+N+W3[&&_T^2-([V>26*9
ME.5;S"I.UB",NO'K6[I$,T&C6<-R#YT<"+("<G( !Y[T 2-?VRHKF92K2^2"
M.?GSMV\>_%6*Y2/P\!92V"Z6D4?]HB9RNP)-'YI8=#GA2 01[<U4F\/:GYUD
MJ)*(8<I$$9#Y&)F8'+'*C9M'RY.%Q0!V2S(\SQ#.] "WRG'.<<]#TJ2L"]TF
M8C7OLL(0WELHC*,%+R8?)]CRO-:UC8V^GP>3:Q+%&3N*KZGJ: ))+B.*6*.1
ML/,Q5!CJ0"?Y TL4R3*63. Q4Y4CD'!Z_P ZYU=(G/B=;F6R+@7$CF[,@QY3
M1%53;G/!XQC'?N:CO-$G_P"$?^QQ6K82]ED2*+8P"%G*_(Q"LN"/ER,=1R*
M.JHKF;;3;M=4MIKO3Q-*$AV3)/A;;:N'49.X\Y]=V>3Q4#^')X_#>R"$K>R2
MJUSR':5!(3M^8X/!Z$XQQ0!U+3QI,D3.HDD!*J3RP'7'YBA9D>9XEW;XP"V5
M('/3GH>G:N9MM$DMY-%N)]/-S);>:C%O+,D(9LH>N,+Z G';-6;S2+DMK?V.
M((+M(BNUMGFL,[QD="1QGWH Z&BN.D\/3W,3C[ 8K?;<M;VS2#]R61 G . 2
MP=A@\9[5TMK/*LD5K-$^];=7:4D$;NA'UXS3 N45FZQ'<;[&>V@>X,%QO>-&
M"DJ4=>,D#@L*YK3M/N_[2B@-JPNK>*RWW'F@B#:#O7KDY&1P.<\]*0';T5QM
MMH%XT:QR631)FW%R#,&^T.LNYY.O0C/7!.<8XKHM$M9++31!(FS9++L7.<(9
M&*@>VTCCM0!H45Q\NBZ@;K5S#;-B='96D==SMO#*%8')! /WP-O !(I9=-O;
MEGGNM)DGBDGF=;4SJ"I94".2#@8VL."2N[(S0!U45Q%.TJQON,+^6XQT; ./
MR(J6N<AT66/7?M_D 2M>EGD#Y)A^SA<=>F\#CU&:NZ_:27<5K_HIO((YMTUL
M& ,B[6 ZD X8@X)[>U &EY\8G$.]?-*[PF><9QFDMKF*\MH[BW??%(NY6QC(
MKGK#1IK34]+NKJR6XG2T\B2<%6:)L@C))!(QD9&3^=9J>&;ZVTKR;6 Q-);P
M_:%5E;S660EQ@G!)4XYX(XSB@#N*BN;F*TMWGG?9&@RS8SBN<T_P\SO8#4('
M>&&&;Y9&'R,9%9!A3CA<XQG;TS6MXAM);[0+RV@C\V22,JJ;]N[VSV^M &E1
M7'3:7J$5M*UGITBQRBYCBM1,@,(=$"D\X W*QX)QN^M6[32KN'Q.MR;<F%HP
MLDDA4@#RP,*0=WWARI!'4@@F@#HHIDF#%-V%8H<J1R.#U_G4E<U'H+?9[:U>
MU3[*FI2S&($;1$1)MX],LO'Z50M]"U5=1TV283;88H%#!D/E;"=X+$[N1_=!
MW9P<8I@=I17&0:'?)9ZK"UK*(YBC*=\9E=A(2><[7&/[X!(^4^HZ/0H)[;1K
M>&ZB2*1 1L7@ 9..,G!QC@$@=!Q2 T**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH R[3_D-W7T_PK4K+M/^0W=?3_"M2@ HHHH **** "LS
M6_\ 4P_]=*TZS-;_ -3#_P!=* -.BBB@ HHHH *PO$+&2]L;22[FM+>5)G>2
M*4QDLJC:-P^I./\ 9]*W:SM8ETV.WC758HY8V?*1O"9<D G(4 G@ G/84 8V
MF>(+^9;19S;MO,$+K@^87>$.6(SC@]L=,^E20W6IMX.OKF:\@DN(Q.0RQ,N%
M5F&.'R#QP01CWQ4MK=Z0OB:[#(@OG= DK)G(,2G ;&%X!X)YP:FCU30DM[J9
M1'''*R^?FW93*7X4D;<MNZ \YH8(CO-:N+>^V1+!Y,(M_,5\F23S7VC:<]O<
M'/3BG:+K%Y>W:1726X26*26/R@05VR;,')YR,'MCGK4SWVCS75G)(B-.0#"[
MV[;HPQP,DCY,G@9QDU/I]UIMS.Z6*IOA!7*Q%1C<<[3C!&X'..XI@4/$FOS:
M.1]G\EV2)IY$9&8E00.H("CGJ2><<&J\_B2]MI;J1XK9K>-[A$4;@V8EW DY
MQ@\YXXZ^U:6L3Z1%+ NJQ122,&\I6@,K8XW8 !..1FE:_P!(2ZFB<PK)%O=V
M:+"@XR_S8P3@\@'..M(!FASW4MSJ:WD\4SQW"J##G8!Y2' !)QUZ9]^]0W(V
M>+XG$T^!8RR>5YS>66#* 2F<9PQ[5+;:CH]A8B2UC%O"SE?+CM65BP7)^0+N
M^[SG'2FRWNA'5EF9(9+\1 B9("[",J2/G . 1G'//-#!%&#Q!J+PP)(MFL]T
MMNT;@-LC\T.2&&<G&S Y&2PZ4LOB2]2^M[>.""==D3320_,C;Y"GRL6&T#:3
MR#D\>]:$UWHK6KK(D$L)CB4HL._<K9,:A0.>Y '2JU[JFBPBQD2W@GE!B6VQ
M#_JU=P@P=OR=\ X^Z10!4DUS5)M.O"'M87-G//"Z(Q,?EOMYR><C![8/K6A=
MSWD5MI+O/%(7N(TF**R;\],8;CW!R#5Z[^R:;92W36P*0QMD11;FV]2  .YK
M+T_5M-AT:Q>[M8;%),RQ0+$Q$0!^\1L&T#(^8@#GK0@$F\23P3:A$T$;/I\4
MTTRKG)48,6/3<"<_[IJYH&IW6HQ7 O(1')$X (7;N!4'[NYB.OKSP>]2PW^F
MRZI/;0[6NS\DQ$)YP,A6;&,X;(!/0TES):>']/S;VT<,9D "1QE4RQQD[5./
MJ1Z4 8K)J-UXPNOLINA'!<P[I#<XA6/RU+)Y>>2<]<=3G/%30W\NG:?=I%,6
MD_M%K>'SR\QP<':!G+'&< D?45L"_L(M3>U4@74A!DVQG!.WC<P&,[1P"<X%
M5DO=&U" ILBDAFF7Y9("%D=N589'.<<-TXZT 9=OXGO[B""X$=J(A' \JX)+
M%YFC.TYP,;<]_3WK<UR6X@T*^EM)%BGC@=T=EW $ GID556^T2,0Q(D027:J
M[;<[1\Y"Y(&%&_.,XYZ5*/$.ERI-_I(V1*Q?=&P! ;:<9'S?-QQGGCO0P10O
M-:OK&VA426DDD=F]W-(ZE5D"D?*HSP>>N3CCCFN@RSPY3Y69<KN&<'W%8IN?
M#R65KF" 0(S-$GV4_N2I^8E=OR8)Y) QFMJ65887E8,512Q"*6)'L!R:&!SD
M>JZA'I]BD)MS//+<*\DH=E&PN>!NSR5'&>!]*FL-=N;^YB;-G#;XA5XY&/F,
MTD8?Y3T[X QSAN1BF#Q%IBV6F7;6;QP76\KNMV#1DH7;"A<G/.2..IJZESHO
M]HVPC6W-SY:K#(L.=JD$JH?&!D9P,]* ,W^W]331(;^2&W9KN1(X$A1F*9)!
M+98;NG &.3CWIC^*KQ4M'\F%6/E_:(]A8C?*8P=P.%S@D#YB3QCC-:*ZKH=W
MILD:A);-=J>7]G8H^3@!1M^;D=%SR*<)-"F2&3R;5A'''Y9,'W%9]J@<<?,,
M8[$=J8&;-XIN[8:CYL$1>'/V=%4G</-$>[<"0P&02/E(/&.];.AW\^H6+274
M7ERI*T9&,9P>NW)V_0DU434/#^;UU6W!96-PWV<CS0&V-V^?YN,#/)]Z;IVO
MZ7#8_NXQ:6Z321(B1-@!#AF*A?E&3R3C&>32 KWUWJ*-XD!O(_*M[4M B(5>
M,F,D'=GV]*BN/$6IVBBU:&&6[\_RP\4;,NWRA)]TL#GG'7H"?:M?[1I%YJ\D
M!CBEO0AAD)@)PI&2A;&.0<XSSFHM;GTVS-O'J%G%+#=2'=F'S.50D': 2>%Q
M["CH!HV%PUWI]O<.GEM-$KE-P;:2,XR.M6*HQZM8-M2*=#\Z1J%!Y++N7'L5
MYST_*KU !1110 4444 %%%% &/K'A;2]<N8[F]AD%Q&NQ9H9WA?;G.TE""1G
MG!I='\+Z7H5Q+<64,GVB50C333/*^T<[0SDD#/.!6O10 4444 %4]4TJSUJP
M>SU"$30.02I)!!!R"".00>XJY10!SEOX#T."YBG,5U.T+B1%N+R:5 PZ':S$
M$CZ5T=%% !1110 G6N:;X>Z#N;RHKN!&)/E07TT<8SUPJL !["NFHH KV%A;
M:78PV=C"D%M"NV.-.BBK%%% !6?K-^^GV2O$T8EDD6- Z,^23T"CDG&>,CZB
MM"JFIM9K9'^T(UD@+ ;&C\S<V> % ))SZ"@#GX_%5V\.G3-% D,V1.X4MM(D
M\OH&RH..#AAG@^M;NLWDUAIDD]N(S*&15\P';\SA><?6L\W_ (=S9_);Y \R
M _9C^ZR^W/W?D^;@YQS6DM[97Q2#<LID+D(R'K&P#9!'&&Q^- ',-XOO_P"R
MFGV6HN$5Y614=LHL:/ZC ^< L3QQP<UL6VM3SZW_ &=Y4889F8\_Z@H-I^I<
ME?\ @)J34ET6PBC%]:V^SYF5?LV_   9L '  QDGC&*KI?V%KXD\J)WGN;G]
MRWR_+"B(7"J0N#USC)/S?2@"]JU[<6LME%;-;HUS,8R\X)"@(S< $9/R^OK5
M&PUB_P!2GC:*.VCMQ:PW$H8,SMOW9"\@?PY!/7-%W=Z7J=C;76I)NA2XD6.$
MQ,Y=@'7!0KNR!DD8XQZ5?BU+3-X:&2+<_E1AD7[P8$QC..F"<?6@#&B\27SQ
M0Y^Q;[E;>2-ANVQK*^W:W/+#L>,G/ IDOBN]6:&.*UCDVC,S*/E?]\T?RL6&
MT?*3DYZ@>]3RS^&[RSDV+&MO]HC>3R[8A9GW8 ^[\^6&#C/-32ZKX;!LQ+]G
MRBAK;-N?W8R1Q\OR\J>.,;3Z4 3V,][JDUZMQY"622R0 1%UE.TXW;@>._3\
MZSH];N=-\/Z7*P\_[1 8T:0DLT^!Y8)SSNY![]*U3K6E6GVH>:L0AW22MY;!
M20<,0<88@D XS@]:H7NHZ6S:656Y>%+HQI##;MM615)&]=N1CJ!QUSR!0!M7
MERUEIL]RZ^8T$32%5XW$#.!^58XU?4-L$'GZ8US<2 +(FXI&IC+X9<YR<<<\
MCGVK?D=(XW>1@J*"69CP!WS6"+WPW_9;+Y-L+1I@IA-J1ND(ROR;<DD=..>U
M %"'Q;?3WMJ%@MEMYO*W#YBXW>7G!SC_ ):<<=O>M#PWKUUK$C_:;811M"LT
M9QM(#$C;]XD]/O8'?CBM2&WLKE([F.WB(8*R,8L'MCJ,C[J_D/2J%GJNAPPS
MW5EY4:N5=VC@*M+N)"D#&7R<CC/.:8%;6-3N]/UQW@DA,$=JDCPR,<OF0K\H
M!X//7GL.])8Z]?ZA?W,"P+#'B<0R/']TQOLY^;Y\]> ,=.]7)-0T2ZN;.:18
M9IGP89# 69/FVY)Q\GS<<XY]ZCM]4TF.XU6Y^RFV:U;9<W#VQ3>  <[L?-U_
MKZ4@,VRU#4-.T*P'VF"6XGM7O9)KDO@A54E1EC@G=]  >*OQZW?2M>W(A@%E
M:1"1HR&,KYB$F,]!@G'0Y]JDN]0T(V<(NDA:&)BJ1O;DF(H.?EVY4 $<X  (
M]:LIJ^F"^E@65%F+$2-L(4L$#8+8P3LP>O2@"OX<U>ZU6.;[9 L;($92!MW!
MESTW$\>O<8XISSWH\71P+<Q+9FT,AA,7S$[@,[L^X[5';ZSH.G6FZW,=K"\F
M"JV[)EB,Y*[<X(YSTQ4S:EH]W=V;,8Y9B \$C0D[-V<?-CY"<'@X)Q3 P[/Q
M#J=GI$(N%BN)9(8&A9%9F_>.4^;)&X\ \$9)Q[UTFC7LVH:9'/<1"*4LRLH]
M58C.,G&<9QGCI67<:UH7]DW,\<"W,$,"[HTMB=\9)Q@$<KD'V&#6W9B%;.(6
MT7DP[?DC\LQ[1Z;2!CZ4@.;N/%5W'-=B%;:5%BE> [&5<QR*F"Q/S?>Y(  (
MQDTZX\0:G$9H46S,MN+AG<JVUA&J,,#/&=^#R>F?:MX:78B22065OODSO;RE
MRV>N3CGH*D-E;,S,UO$2^[<2@YW8#9^N!GZ"A 8[^(V24A_(1!<-&=S$806_
MFY/X^W2LZ36+K4M#U7SR8IK-8Y8Y(-\)^9<C(W9Q]>HQP*Z?^S;(W/VC[);^
M?MV^9Y8W8QC&>O0XI(=,L;>%XH;.WCBD&'1(P P]QWH!%ECM4GT&:XRW\8ZB
MULS2VUNTCK%Y8A5C@NR#D$\X\SID9QUYX[/K5;^S+$QM']CM]CKL9?+&"O'!
M]N!^0H YN7Q9J""W46(\P(TDP*C! E*==V$Z9YW8) K5TZ749K_6(Y+NW98I
MMD"^2?W>8T89^;D?-[=^>U7SI=BRP*;*W*VYS"#$N(_]WCC\*D%I;K=-=+!&
M+AEV-*%&XKZ$]<4 <V-:OX-&L'MQ;F1[6:>1IM[9\O' YSSGN3CWJU;Z[=7&
MK01@6JVTLY@\LD^:"(?,W=<8]L=,'O6S]CMMBI]GBVJI0+L& IZCZ&J2Z!:K
MK2ZEN8RH/D3:H"_+MX(&[&,\$XYH DU:]GMC:0VIA66YF\L23 E%PK-T!&3\
MN ,CK5#3M8U#5;BV\E+6.$V\<\N[<Q;<S*0N,<?+D$^O2MFYM8+R$PW4,<T1
MY*2*&!_ TY((HVW1QHK;0F54#Y1T'T&30!)1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!EVG_ "&[KZ?X5J5EVG_(;NOI_A6I0 44
M44 %%%% !69K?^IA_P"NE2SZQ9VZ@M(SDNT86*-G8LOWN ">.]5M5FCN+*UF
MA</'(P96'0@CB@#7HHHH **** "L3Q5;6MQIT?VR]MK.-9.)+A01N((&#E2&
M'4$$=.XK;K$\21LRVDJG4%:)W97LHUD96*$#*D'@Y(Z?7 H 5=#$@61+UW#2
MQSB3 +';%Y><]R?O9K*LM,L+*"XN9M;M9$BEM_.ER  T3$_,2Q^9BW.3UZ5N
M17%Q)8PVEP"FHRV>]RH^17P >?\ >-<S965PNF1QW2:FL< M@[QVRB5)$#;@
MHVY:,';T!ZG!/- (U+[3=,U+6[2^%]9EKA8RB. [2A&+ QG/OSP?;!YJW8:0
MNCWM[?S7:+%*"S*$\I!R3O?G:6[;@!QUS6.L&HS!!>6\[7=TMMLE\K[GES,Q
M+D<(=N"1QR2!6WK$OVNRN(HH993:W$+2QA,EU#(YVC^+Y?UXH DFGL7O;"_-
M_ J,CQ0Y<8E+E?NG//W>WK69%H%D-?O&BO+8SN))#%Y:M+&9!@DY)^7DX&WO
M@DBJ%Q9W+17+_8KAEO8KF.W3RCF-GD!4L/X,_>R<8QSS6A9VTRZ\B&VE5H;J
MXGDG*81D<87#=SRO';9]* &-X,5K&*$W$1>*9I(U,+&% RA2JIOR!QN^]C.>
M,<5JZ7IT-C<3B&=7Q'#"8P -FQ>,@=,@@XQ57Q6+LV$)LVN0PDRRPJYW?*<
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M>+2(!=P7&]IFC7.]SC)PQW?,JX_O<CC-)#+UG9"SDNF#[A<2B3&,;?D5<?\
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M%% !1110 4444 %%%% &7:?\ANZ^G^%:E9=I_P ANZ^G^%:E !1110 4444
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MYM_=+(V%SZD^W6N?_L74#8@16RK+/!-;3^=<;FS(03*6"X)X.0,=@.!75T4
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MNXVM0MG;F5/-D#*%9$W;BW3!P1@#(X/-(";Q-9ZG<7-C+I.5D02AY 0-HP'
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MVTEV9&M[@3[CDC 8G8,DG S@9)Z4 2W&MZ3YMQ9W-S$2D;F5'4E=JKE\\8.
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MC(QF@1EQ7_AZWTC$7D1V32;3&(B,OC=RN,] #G'3!Z59>^T<Z@D!>![J4I*
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M5% !/K]>*GHH K?V=9_;6O/LL/VEEVF78-Q'IFFV^E6-K&L=O:01(K^8%1
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M%% !1110 4444 %%%% !1110!EVG_(;NOI_A6I67:?\ (;NOI_A6I0 4444
M%%%% !69K?\ J8?^NE:=9FM_ZF'_ *Z4 :=%%% !532_^0?'_P "_F:MUQ$^
MG^+X=0>VM/$VDPH[LT%O); R!,DCODX'>@#MZ*XA=,\>.S*OB;2F9#A@++E3
MUY_.G?V1X_\ ^ADTO_P!H [6BN*_LCQ__P!#)I?_ ( T?V3X_P#^ADTO_P
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M8%2/L/8UVL8*QJ&(+  $B@!U%%% !1110 4444 %%%% !1110 4444 %%%%
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ML4\R]^TZ@!%':-')&'$N',W1AR,#N67TKOO[4N/^?&3]?\*/[4N/^?&3]?\
M"@#D+B&VO'G_ +%M62.:VM[> I"T82Z5F9'/'!C'+'TX]JT%C0>&]-CDMREU
M;ZG"EQO7DS><-[@GKN)W9'9A6_\ VI<?\^,GZ_X56NI!?/ USICR&"021Y9L
M*PZ''?'O0!N45F?VI<?\^,GZ_P"%']J7'_/C)^O^% &G169_:EQ_SXR?K_A1
M_:EQ_P ^,GZ_X4 <.[K;VZ3:?:7"ZE:7]V]S-!;X986>08+%<')9".O3..*M
M/+=W=HSW5U>?9K/4X666-F;$1126W% 6 8GG''/85UW]J7'_ #XR?K_A1_:E
MQ_SXR?K_ (4 <]'J>J2>)Q&+AEB-PBPQD.1);E02VT)CGD[BPP1CV/:5F?VI
M<?\ /C)^O^%']J7'_/C)^O\ A0!IT5F?VI<?\^,GZ_X4?VI<?\^,GZ_X4 :=
M%9G]J7'_ #XR?K_A1_:EQ_SXR?K_ (4 :=%9G]J7'_/C)^O^%']J7'_/C)^O
M^% &G169_:EQ_P ^,GZ_X4?VI<?\^,GZ_P"% &G169_:EQ_SXR?K_A1_:EQ_
MSXR?K_A0!IT5F?VI<?\ /C)^O^%']J7'_/C)^O\ A0!IT5F?VI<?\^,GZ_X4
M?VI<?\^,GZ_X4 :=%9G]J7'_ #XR?K_A1_:EQ_SXR?K_ (4 :=%9G]J7'_/C
M)^O^%']J7'_/C)^O^% &G169_:EQ_P ^,GZ_X4?VI<?\^,GZ_P"% &G169_:
MEQ_SXR?K_A1_:EQ_SXR?K_A0!S4"0Q>)UBMHVEDDO96DCEM2D]MN5LR+*.&0
MY&,YX(&>,5;,EU:Z3%&\US#;_P!I3)<3QQ_O1$&?:W"]R$!;'0Y]ZVO[4N/^
M?&3]?\*KWDQOXECN=.D958.I#,I5AW!&"#SVH YN&_U>[T^]NH=0OF%I"9(/
MW(!E<3S+\PV\_*B@KQZ]:N)J-[<>*4@6>\2&2YFMY48_<0(VU@H3"#*@ABQ)
MS[\;5K=-96R6]MIK1PQC"JN>/TJ;^U+C_GQD_7_"@#G-'O7TOPYI0^T76+>Y
M6._$J$F(;&&T\9 W;>?UQ4^F2ZEK%["DU[?6]N89I<I&$)(N&"9RO'R8X[C%
M;G]J7'_/C)^O^%']J7'_ #XR?K_A0!@Z?J&K2^*FBGF*C[3*CVY#D"$ ["!L
MP,_*=V[G)'L-K7"3=:1&_P#J)+T"3T.$=D!_X&%_'%2?VI<?\^,GZ_X5%/>2
M7,?ES:<[KN# '/!!R#T[$"@#+U[4WOKRV@TVWG?4+&XEE\J2%@!MAD"MGH5+
M,N.><_7#-/FN;Z.]AAOKZXM?L:R--*FUTGYR@RH[ 97''XUN?VI<?\^,GZ_X
M4?VI<?\ /C)^O^% '/7,FJ-91^1<75N+?1%N52&( -.!P"-OMC:*O60\CQG<
M/<W%TK75M"88VSY;D>9N X[9'&>]:?\ :EQ_SXR?K_A1_:EQ_P ^,GZ_X4 9
M'B06T>N)+JMN9K%K"6*,&(R#S2RY7 !^9EZ>N#6+I5SXDM4L]/N)+DF+99R.
M8\_-@3;]V.<1C9GU]Z['^U+C_GQD_7_"C^U+C_GQD_7_  H Y26]UVTT^V=;
MJZE-U9P37+RICR26 <KA3MX/(P<=<<$U<L9=4U!M.MWO[A;>5[@-+"IRR*%V
M?.R ]<_-@9'KUK?_ +4N/^?&3]?\*/[4N/\ GQD_7_"@#&2^O8/&"VKW%S<1
M%Q&$ VE%\O.YE*;67<,[U8<G&.U:NAY6ZU>-/]0EZ?+] 2B,X'_ RWXDU)_:
MEQ_SXR?K_A4<%Y);1^7#ISHNXL0,\DG)/3U- &O169_:EQ_SXR?K_A1_:EQ_
MSXR?K_A0!IT5F?VI<?\ /C)^O^%']J7'_/C)^O\ A0!IT5F?VI<?\^,GZ_X4
M?VI<?\^,GZ_X4 :=%9G]J7'_ #XR?K_A1_:EQ_SXR?K_ (4 :=%9G]J7'_/C
M)^O^%']J7'_/C)^O^% $?BQ&D\(ZNBH79K.4!5&2?E/&.]<I-<+%K#RZ1'<6
MFFW4<<;RQ(;>.290Y)SL)Z%1D+\Q&,\5U_\ :EQ_SXR?K_A1_:EQ_P ^,GZ_
MX4 <QIT]VVH:5J%]-=K<W&F[ K*51YPP^0C'!/7!Q5SP??ZG=W1%]<-)FW#3
MQL')CFR,CE%"]QM!/0?4[?\ :EQ_SXR?K_A1_:EQ_P ^,GZ_X4 :=%9G]J7'
M_/C)^O\ A1_:EQ_SXR?K_A0!IT5F?VI<?\^,GZ_X4?VI<?\ /C)^O^% &G16
M9_:EQ_SXR?K_ (4?VI<?\^,GZ_X4 :=%9G]J7'_/C)^O^%']J7'_ #XR?K_A
M0!IT5F?VI<?\^,GZ_P"%']J7'_/C)^O^% &G169_:EQ_SXR?K_A1_:EQ_P ^
M,GZ_X4 :=%9G]J7'_/C)^O\ A1_:EQ_SXR?K_A0!IT5F?VI<?\^,GZ_X4?VI
M<?\ /C)^O^% &G169_:EQ_SXR?K_ (4?VI<?\^,GZ_X4 :=%9G]J7'_/C)^O
M^%']J7'_ #XR?K_A0!IT5F?VI<?\^,GZ_P"%(=3N3TL9,_C_ (4 %I_R&[KZ
M?X5J5GZ=:RI)+<7'$DO\/H*T* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g22642bgi002.jpg
<DESCRIPTION>G22642BGI002.JPG
<TEXT>
begin 644 g22642bgi002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" 3: \ # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=0/"7 SMW*1G'XUSFB>$+^PU32;V\O+:0Z?IK6!$4;+O&1M;DGL!GWH L_\
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M)'RG!Y'%9Z>"9Y56VN[J)K1/MT8\M"':.XYYR<9!)_2IKCPQJFK:9-I^L:G
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M7>G^%%TJVEDFNHKE?[(>.)F:$ C8'/0!1N&XXRH]:ZBUTN"TT6+3(MRP1P"
M%3AL;<9R._O0!Q^B:_JMWJ-H+C7+3[;*ZBYT>YM?L[1 _>$;'YF*_B&QVS6K
MI/BJZN+"YFNM+NVF%_+:P0PJI+!68#)W87 7DL0,].U1+X8UNX%G9:GJUK<:
M=9S1RI(+8BYD\M@5#.6(!X&6 R>>F:9=>$+^:"6%;FTE@&H2WB03(_ES"3<2
MD@!YVELC'' R* );GQA+(=,^P6$Y:;43974;[-T1"%BN=V">AR"1@'OBKMOX
MMM+BYA5;>Z6TN)C;P7C*OE22 D8'.X D$ D '\JS;3P=>6-L@@N;,2Q:I_:$
M:K 8X@ICV% H/&,G!^F>]-TOP&-,O[?RTTO[-;3&5)OL0-TPR2%9SQQD?,!D
MX'3K0!;@\<V]P+9HM+U)DNW>*W;8F)9$SE1\W'W6.3@<'FK"^+K:2SMWAM+N
M2ZN)9(5LPJB4/&2) 26V@*1USCD8ZU#8>%YK.UT.)KF-CIMS+.Y"GYPXD  ]
M,>8/RJG=^!FN(TD9K*XGAO+FX2.Z@\R%DF;<589R"/E^8>G3F@#0;QE:G[(D
M%E>SW-U)+$MNBJ'22/[RME@!]<X]^15>'Q;+?:[I%O9V4XM;M;@3^8%#Q/$P
M4J1N_A.<XSG(QGFGZ;X4>PN]+G$EHGV1KAY([>W$2$R  !0.PQU.2:2T\,7=
MEJ=G>1W,#&&ZNY'5D/,<[AL Y^\, >AYIB-74]7.GRQPPV%W>S2*7VP*H"J,
M9+,Q"CKP,Y/I6<OC.VN/L8T^QOKV2\MFN8TB500JL%8-N8 $$XZTOB'PY<:O
MJEK=(]G+#%&8VMKV)I(P20?,"@@%N,<]O2H_#OA2?1)[!Y+J.86EE+:G:FW=
MNE#@XZ#@8Q2&3KXOM+F.T;3[6\O7N8/M/EPH T4><9;<1SG(P,DD''2K'A/4
M)]5\+:=>W;AYYX0[L%VY)]NU96G>%=1T:.SDT^^MOM,=M]EG\Z)F1DWLZLH!
M!##<W!X.>U:-CH][IW@Y-*M[M/ML=L8DN2IVA\'#8^ISB@.IFZ/XDN[OQ*1<
M2(=+U!IH]/ 49#0G#9/??\S#/9*MVOC*VN9X!]AOHK>>Y>S2Y=%\LRJS+MX;
M."5.#C&>*I'X<Z596MI)HMM;VFIVCQ/'=E3N8J1N#8Z[AN!^M6X_"\R:786G
MVB/=:ZF;XMM.&4RN^WZX8#/M3 =9^,K:\FMA]AOHK>YN'M8KF1%\LRJ6&WAL
M\[3@XQ5F#Q-:W%CIUTL4P2_N3;1@@95AOY//3]V?TJG!X7FBTK2[0W,9:RU
MWC-M.&4O(VT>_P X_*H+3PIJ-L^GV[7ULUAI]ZUU$HB(D<-OX8YQQYG8<XI
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MT?R DC;8X6)+%MF"QW'@=@*FOO%5C'<ZPMC/!<1:J!^\E25/);RQ&=PV'<N
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHK*UW6WT2*)TTK4=1\QB-ME$'*>YR1Q0!JT
M5R/_  GLW_0H^)__  $3_P"+K4T+Q%)K4\L;Z+JVG"-0V^]A"*WL,,>: -JB
MN8OO&<ME?36R^&/$%P(G*B:"U5D?W4[N14'_  GLW_0H^)__  $3_P"+H ZZ
MBLRZUE[;04U(:9J$S,B-]CBB!G&['!7.,C///8UB?\)[-_T*/B?_ ,!$_P#B
MZ .NHKG-*\6RZIJ,5JWAS7;,29_?W5NJQK@$\D,>N,5+K7BB31[X6R:#K-^"
M@;S;.!73G/&2PYXH WJ*Y'_A/9O^A1\3_P#@(G_Q=;>G:P]_I$E^VF7]JR!C
M]FN(@LS8]%R1SVYH TZ*Y'_A/9O^A1\3_P#@(G_Q=/@\<333QQ'PIXDC#L%W
MO:*%7)ZD[^E '5T5DZ[KKZ(D+)I.I:CYI((L8@Y3&/O9(QG/Z5C_ /">S?\
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M$-N)7"&6:U543)ZL=W %7M=\0R:)+"B:-JNH^8"=UE"'"8['+#% &S2%0W#
M'!SS7)?\)[-_T*/B?_P$3_XNMC0M<?6TF9])U+3O*( %[$$+Y_NX)SC% &M1
M7*3>.9H9I(QX4\2.$8KO2T4JV.X^?I3/^$]F_P"A1\3_ /@(G_Q= '74U45,
M[5 R<G ZFL[6-8?2=/CNDTV_OB[!?)M(@\BY!.2"1P,8_&L3_A/9O^A1\3_^
M B?_ != '745@Z+XGDUB]-N^@ZS8 (7\V\@5$.".,ACSS^AJ+5/%TNF:C+:K
MX<UV\$>/W]K;*T;9 /!+#UQ^% '1T5R/_">S?]"CXG_\!$_^+K;76';0/[3_
M +,U -L+_8S$/M'7&-N<9[]: -.BN1_X3V;_ *%'Q/\ ^ B?_%U8L/&4M]?0
MVS>&?$%L)6"F:>V58T]V.XX% '345B:YXCDT6>*)-$U;4!(N[?90!U7GH<L.
M:S/^$]F_Z%'Q/_X")_\ %T ==169HFLOK-I).^F:AIY1]OEWD01VX!R ">.<
M?A6(?'DW_0H^)O\ P$3_ .+H ZZBN1_X3R;_ *%'Q-_X")_\76WK>LOHUI'.
MFF:A?EWV^59Q!W7@G)!(XXQ^- &G17(_\)[-_P!"CXG_ / 1/_BZT]#\1R:U
M/+$^B:MIXC7=OO8 BMST!#'F@#;HKF;_ ,92V-]-;+X9\07(B8J)H+96C?W4
M[AD57_X3V;_H4?$__@(G_P 70!UU%9C:PZZ!_:?]F7Y;8'^QB(?:.N,;<XS^
M-8G_  GLW_0H^)__  $3_P"+H ZZBN<TOQ=+J>HQ6K>'-=LQ)G]_<VRK&N 3
MR0Q],?C4NM>)Y-'O1;IH.LWX*!_-LX%=!DGC)8<\?J* -ZBN1_X3V;_H4?$_
M_@(G_P 76WH^L/JVGR73Z9?V)1BODW<021L '( )X.<?A0!IT5R/_">S?]"C
MXG_\!$_^+I\/CF:69(SX4\2('8+O>T4*N>Y^?I0!U=%9.NZX^B)"R:3J6H^:
M2"+*(.4Q_>R1C.:Q_P#A/9O^A1\3_P#@(G_Q= '745C:%XADUN69'T;5=.\L
M [KV$('SV&&.:HWOC26SO9K=?"_B&X$3E!+#:JR/@]5.[D&@#IZ*Y'_A/9O^
MA1\3_P#@(G_Q=;=[K#V>B)J(TV_G9E1OLD,0,XW8X*YQD9YY[4 :=%<C_P )
M[-_T*/B?_P !$_\ BZN:3XLEU748[5O#NN60<$^?=6ZI&N!GDACUZ4 =%16!
MK/BF32+[[,F@:U?#:&\ZSMU>/GMDL.:H?\)[-_T*/B?_ ,!$_P#BZ .NHK,L
M=8>]T5]0;3;^W9%<_99X@LS;>P7.,GMS6)_PGLW_ $*/B?\ \!$_^+H ZZBN
M5M_&\UQ<Q0GPKXCB$CA?,DM5"KDXR3OZ"M/7=>?1! 4TC4]1\W=G[#"'V8Q]
M[)&,YX^AH UZ*Y'_ (3V;_H4?$__ (")_P#%UL:%KKZVDS/I.I:=Y1  OH@A
M?.?NX)SC'ZT :U%<I/XXFAGDB'A3Q)($8KO2T4JV#U!W]*9_PGLW_0H^)_\
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M(G_Q= '745A:)XEDUF[>!]"UC3PJ;_,O8%1#R!@$,>>?T-;M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:?\ ^.__ !J@#U6BO*O["^+7_0P:?_X[_P#&J/["^+7_ $,&G_\ CO\ \:H
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M:?\ ^.__ !J@#U6BO*O["^+7_0P:?_X[_P#&J/["^+7_ $,&G_\ CO\ \:H
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M:?\ ^.__ !J@#U6BO*O["^+7_0P:?_X[_P#&J/["^+7_ $,&G_\ CO\ \:H
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M+'(6$;JQ0[6"G.T^AKR?X>>'YIM*T2\;PMHKP_*_VYIOW_#??V[?O#'K75^
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M10 4444 >6>#_P#DN7BK_K@?_0HZ]3KRSP?_ ,ER\5?]<#_Z%'7J= !1110
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MI<:E;:A+"&N[576&3)^0-@-QTYP*J77A?2+U-12XLE==2*&[!=AYI3&WOQC
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M@?\ T*.O4Z "BBB@ HHHH *\M^.O_(&T;_K^_P#937J5>6_'7_D#:-_U_?\
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M-#K=Y907D(M[NW15=94'IN^X<'&12ZCX)%QJ<%[INIS:>R6/]GR*D:R;X<Y
M&[[I'KS5O0?%<7B!T\C3=2@@EC\V&XGA BE7V8$X/L<&C6/%MOI.JKIL=C?W
M]X8?M#16<0<I'G&XY(SSV&3[4 4]$\#1Z-=:-.M\\ITNTDM0#&!Y@9LYZ\8J
ME_PK2W71-.M$OO\ 2M.EFDAGDMDD4B4DLK1MD$<C\LUL:CXOM;"XM[:.RU"\
MO)X/M'V6V@S+''TW.&(V\\8ZYXQ6>/%IU'Q%X?&EW ;3-1M;F5\Q_,2@&!SR
M"#D$4 ;^B:5_8VEQVAF$SJ26D$*1;B?]E  *KQ^'T3Q7=:V9V+7%HMJ8=N,
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MMW,L1_O)(C CZ=*ZVB@#CO\ A$-5TZ[L[_2-6B>_BL%L+A[Z)G690<A^&!#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/+/!_P#R7+Q5_P!<#_Z%'7J=>6>#_P#DN7BK_K@?_0HZ]3H **** "BBB@ K
MRWXZ_P#(&T;_ *_O_937J5>6_'7_ ) VC?\ 7]_[*: /4J*** "BBB@ HHHH
M *Y2Y\<O:ZA%92>&];,\Y?R0$A_>!?O$?O/<=?6NKKF=:/\ Q7WAC_KG>?\
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M5YC"BC2]6-K=:?+I1EM/MT.C12K D?F?O64Y(R4^\$/0<UT7AC^PO^$]NO\
MA&_L_P!D_LU-WV;_ %6[S#]W'&<8SC^>:: ZO^VK8:W-I;!DEAMTN&=L!-K,
MR@9SURIJ\[K&A>1E51U+' %<9>:+I^M_$R[CU.UCNHH])A*QRC*Y,LG..F?0
M]JY!GFET7PM]NFT[^S5M9U5M6#O;F59,*&P0-P0';NXX/>D![$754+,P"@9R
M3QBD,B!E4NH9ON@GD_2O*]*L(+^;PW9W<UO?:?+?WACCBCD6#RQ%D(H?ED#
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M5?\ 7 _^A1UZG0 4444 %%%% !7EOQU_Y VC?]?W_LIKU*O+?CK_ ,@;1O\
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M$4855"+M0Y48X'TH,498L8U+'&21R<=*X*Q\8:RZW\%LO]L3I9O<6\@TZ:T
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M>,SR7IN'@_M1S=(-@5768MC?QR <8P.:FL?#^N/%I']I&=XX+Z>3$UPLLMO
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M?+@@]^#7HUUIME?1)%>6=O<1QG*)+$K!3[ CBI#;0F6.4PQF2(%8WVC* XR
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M:T2XE>6?1M.DD<EF=[5"6)ZDDBK-QIEC=M"US9VTS0\Q&2)6,?\ NY''X4=
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MLHK=8I+?3M4N#&8@00TA9B=L9/H3RAZ$U+I/CN]NI]2MP-/U:6VL7NX6TT2
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MW=U&B:=:PS.C1R;.%B52,L6Y).<=^!6E>^#6O;JY1]7O!I5W+YUQ884J[<9
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M\TCQ+(5970#*LK!E.#P>0.#P:R['PK>VVK?VG<Z[/=7GV1[4%H$5$#%2"J*
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M1110 4444 %%%% !1110 4WRT\SS-B^9C;NQSCTS3J* "BBB@ HHHH ****
M"J=EI-CILUU-9VL<,MW)YL[J.9&]2:N44 %%%% %/4=)L=7BBBU"VCN(XI!*
MB2#(##H<=^O>KE%% !1110 4444 %%%% !1110 4444 5Q8VPU!KX0K]J:(0
MF7N4!)"_3))JQ110 4444 5[2QM["-X[6)8D>1I6"]V8Y8_B235BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2XOUB=G*Y*0@CYR/7O6E/XWNK[5;*Q\-Z8M\\]DFH2--/Y02)ONCH?F/^?8
M[&BN-^%M[<ZAX4EGO))WE-[./WSEF4;N%R?2MC7_ ! =!N=*#VWF6]]=K:/+
MOQY3,/E.,<@D8[4 ;5%<"GQ2BGL]5DM].+SVE[':6T1EQ]IWN55@<<?=;UZ5
MD>*];E73O%2V4E[;3VNH6D;2?:V8'<1G8.-@]0.M /0]5HKD-$N[B3XG>)[>
M2>5H(H+4QQ,Y*H2AS@=!FL[6=4UFV^*_V;2(3>%M'W"WEN#'"A\TY<]>>,<#
M//I0!Z!17GDOQ50Z98[+."#4[F>6"2*\NEBAMVBQO+2$=.1CUS72>#_%47BS
M2YKA8TBFMIVMYDCE$B;ACE7'#*000: -^BN-NOB MA8^(&N['9>:1.L*VZR9
M\\/CRF!QQNSZ'&*+KQAK$VIW5AHNB17<^G0I)?&2YV*KLN[RT./F.,\\"@#L
MJ*\SNO&^J:OXB\(2Z);DZ=J*2R-$TX0RLH(=6XXV=1V8_2I)?BY#'?R2?9[/
M^RX[O[*S&]47)YQY@AZ[,_CCF@#TBBN"\0>,-4N?^$BM-&TOS;73('CN+K[1
MY<BN4)S&,<[>O4=..U;O@RXEG\!:3/<222RO9(SN[$LQV]23SF@#H**\WT/Q
MQ+!H7AJWTW2Y[J75_M(B6YOB[(T;'[TA7)'4^P' -=/X1\2S^(8;^.^LUM+W
M3[IK:>-)-Z$CNIP.* .AHKS.Y\0:_+XI\8V<D9CL[33V,96X \@>6Q1P ,DM
MP?5:E\)^,=5MK/PO:ZKIV;34XA#%=M<[Y6<+G<RXZ'ZY_E0!Z/17FZ_%R$WX
MD^SV?]EF[^R@_;5^U=<>;Y/79G\<<UUGB_Q)_P (KH1U+[*;K$L<?E!]I.YL
M<'% &Y17 S>.O$$>I:CIG_".V_VZT@^U\WGR"''<[>6[8''7TYMW/CB[E\.:
M5JFG6%HL=]&9));Z]6"*#'\))Y8DYQ@4 =G17 V_Q,EN])T.YM=(\ZXU2XDM
MA"+@ (Z=PV.5)[]AZTK_ !&NK'0M<N=1TE$OM&GCAF@CGRCAR "K8]#TQ0!W
MM%<;;^.;NVUNXLM>TI;&-;!]0B>.?S3Y2]0PP,-]/_KU1\/_ !/&K:QI]K=6
MUE%%J>[[/]GO5FEB(&0LJ 94D?KQ0!Z!17)>$?%NI>*IY)1I"6NFQ-)$T[7
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MNX9Q0!=HKBO%E[=V_P 0/"4-M-*$E^U;X5D*K*1&"H8=#SZ]*H?#"?5M4O\
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M+Y;[4EL[Q;B.08Z@CE?H:WJ "BBB@ HHHH **** "BBB@#RSP?\ \ER\5?\
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M<GI732>)-'BL;>]DU.T2UN 3#*TH"O@9.#[ &J]SXR\/V=E;7=SJUK%!=#=
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MC:/,(/SX&,<=LU2M?AU=6_AFST5M822"RU!+NW8VV"$5BQ0X;DDMU_2N\HH
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M(&,_,=Q_"M'5])U"75]8>.QN623PK]G1A$2&ES]P>K>W6O4**'J!A:';S0^
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MJ&PL[O6+SPI:6OAV\TJ719%>[N)X1&@55PR(P^_N/I^/>O4:* /'KGPY=_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110!Y9X/_ .2Y>*O^N!_]"CKU.O+/!_\
MR7+Q5_UP/_H4=>IT %%%% !1110 5Y;\=?\ D#:-_P!?W_LIKU*O+?CK_P @
M;1O^O[_V4T >I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% 'EG@__DN7BK_K@?\ T*.O4Z\L\'_\ER\5?]<#_P"A1UZG0 44
M44 %%%% !7EOQU_Y VC?]?W_ +*:]2KRWXZ_\@;1O^O[_P!E- 'J5%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y9X/_ .2Y
M>*O^N!_]"CKU.O+/!_\ R7+Q5_UP/_H4=>IT %%%% !1110 5Y;\=?\ D#:-
M_P!?W_LIKU*O+?CK_P @;1O^O[_V4T >I4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'EG@__DN7BK_K@?\ T*.O4Z\L\'_\
MER\5?]<#_P"A1UZG0 4444 %%%% !7EOQU_Y VC?]?W_ +*:]2KRWXZ_\@;1
MO^O[_P!E- 'J5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y9X/_ .2Y>*O^N!_]"CKU.O+/!_\ R7+Q5_UP/_H4=>IT %%%
M% !1110 5Y;\=?\ D#:-_P!?W_LIKU*O+?CK_P @;1O^O[_V4T >I4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EG@__DN7
MBK_K@?\ T*.O4Z\L\'_\ER\5?]<#_P"A1UZG0 4444 %%%% !7EOQU_Y VC?
M]?W_ +*:]$GUBSMU!:1G)=HPL4;.Q9?O< $\=Z\X^-TT=QH&A30N'CDO RL.
MA!7B@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH \L\'_\ER\5?]<#_P"A1UZG7EG@_P#Y+EXJ_P"N!_\ 0HZ]3H ****
M"BBB@#FUGLK/6KB6&UU:66-W5E2-VC#-@D@=.>*XGXRQQQ>%_#Z0I)'&+L;5
MD&&'RGK[UZ3-X@TFWG>&;4;5)4.UU:094^AKSGXUR"7PYH+K,LP:[!$BCA_E
M/(H ]7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** /+/!_P#R7+Q5_P!<#_Z%'7J=>6>#_P#DN7BK_K@?_0HZ]3H **** "BB
MB@#,FU?2["ZE1YE24D&78C-@X_B(& <8Z]J\\^-LAE\/:%(3&=]X&S&VY3\I
MZ'N*]";2KF.64V6HO;Q2N9&0Q*^&/4J3TS[YKSGXRP):^%_#\,:.BI=A0LA!
M8?*>N.,T >M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#RSP?_P ER\5?]<#_ .A1UZG7EG@__DN7BK_K@?\
MT*.O4Z "BBB@ HHHH *\M^.O_(&T;_K^_P#937=?VM>)//*]DIL8I3$S1N3*
MN.KE,<K]"3CGFO.OC#>_VCX3\.W>%'G70<;3D8*GI0!Z[1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /+/!_P#R7+Q5_P!<#_Z%'7J=>6>#_P#DN7BK_K@?
M_0HZ]3H **** "BBB@#DM3\A=3D&JK<O<%R;8PW,: )_#@%EY]<@\UR7QE%P
MOA?P^+Q@UP+H>81Z[?:NON6>"]O$M+>.\CDE8RR-9-(4;NI(/SX]!TZ=JXSX
MO)%%X0\-I!-YT2W*A9,8W#9Z=OIVHZ >O4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'EG@__DN7BK_K@?\ T*.O4Z\L\'_\
MER\5?]<#_P"A1UZG0 4444 %%%% &;+HL;S2/%=7EN)3N=(9<*2>IZ'!/MBO
M._C;!':^']"@A79''>!57T&TUZM7EOQU_P"0-HW_ %_?^RF@#U*BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMWH ])HKB)/&.K:QK&GZ?X;M+17FT]-1G>_+ (C' 0!>=V>]'PHDEE\*W3W
M(E.H3[E+;MIW=,^U ';T5YOXB^(>IZ'K$H!T:2UAN5A-HDCR7)4D#<67Y4//
MW6YJSJGC+Q#]N\20Z59Z=Y.A;9))+AGS(FS>5 '\7!YSB@#OZ*X4^,]7UB_T
MBP\/VEDES>:<NI3O>,Q2-&( 4;>2<]_TI_PJEGFT'5&NAMF.JW&]-^X(?ER
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MHJ* ,?PYX=C\.QWZ13O,+V]DO&W #:7QE1[<5#9^$[6VGUUII&N(M:?=-$P
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M/^A#U#\Y/_C= 'JE%>5_\+8\2?\ 0AZA^<G_ ,;H_P"%L>)/^A#U#\Y/_C=
M'JE%>5_\+8\2?]"'J'YR?_&Z/^%L>)/^A#U#\Y/_ (W0!ZI17E?_  MCQ)_T
M(>H?G)_\;H_X6QXD_P"A#U#\Y/\ XW0!ZI17E?\ PMCQ)_T(>H?G)_\ &Z/^
M%L>)/^A#U#\Y/_C= 'JE%>5_\+8\2?\ 0AZA^<G_ ,;H_P"%L>)/^A#U#\Y/
M_C= 'JE%>5_\+8\2?]"'J'YR?_&Z/^%L>)/^A#U#\Y/_ (W0!ZI17E?_  MC
MQ)_T(>H?G)_\;H_X6QXD_P"A#U#\Y/\ XW0!ZI17E?\ PMCQ)_T(>H?G)_\
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M (W0!ZI17E?_  MCQ)_T(>H?G)_\;H_X6QXD_P"A#U#\Y/\ XW0!ZI17E?\
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MZI17E?\ PMCQ)_T(>H?G)_\ &Z/^%L>)/^A#U#\Y/_C= 'JE%>5_\+8\2?\
M0AZA^<G_ ,;H_P"%L>)/^A#U#\Y/_C= 'JE%>5_\+8\2?]"'J'YR?_&Z/^%L
M>)/^A#U#\Y/_ (W0!ZI17E?_  MCQ)_T(>H?G)_\;H_X6QXD_P"A#U#\Y/\
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MU,\0C_EFF<G/IT&!V KT*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
(B@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
